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ACIP Advisory Committee on Immunization Practices
ACS American Cancer Society
AIDS Acquired immunodeficiency syndrome
ASCUS Atypical squamous cells of undetermined significance
BV Bacterial vaginosis
CMV Cytomegalovirus
CSF Cerebrospinal fluid
DDC Dideoxycytodine
DDI Didanosine
DGI Disseminated gonococcal infection
DTH Delayed-type hypersensitivity
FDA Food and Drug Administration
FTA-ABS Fluorescent treponemal antibody absorbed
HBc Hepatitis B core antigen
HBIG Hepatitis B immune globulin
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
Hib Haemophilus influenzae type b
HIV Human immunodeficiency virus
HPV Human papillomavirus
HSV Herpes simplex virus
IFA Immunofluorescence assay
IM Intramuscularly
IV Intravenous or intravenously
KOH Potassium hydroxide
LET Leukocyte esterase test
LGV Lymphogranuloma venereum
MPC Mucopurulent cervicitis
NIAID National Institute of Allergy and Infectious Diseases
NGU Nongonococcal urethritis
OTC Over-the-counter
Pap Papanicolaou
PCP Pneumocystis carinii pneumonia
PID Pelvic inflammatory disease
PPD Purified protein derivative
PPV Positive predictive value
RPR Rapid plasma reagin
RVVC Recurrent vulvovaginal candidiasis
SIL Squamous intraepithelial lesions
STD Sexually transmitted disease
TB Tuberculosis
TCA Trichloroacetic acid
TMP-SMX Trimethoprim-sulfamethoxazole
VDRL Venereal Disease Research Laboratory
VVC Vulvovaginal candidiasis
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1993 Sexually Transmitted Diseases
Treatment Guidelines
Summary
These guidelines for the treatment of patients with sexually transmitted dis-
eases (STDs) were developed by staff members of CDC after consultation with a
group of invited experts who met in Atlanta on January 19–21, 1993. Included
are new recommendations for single-dose oral therapy for gonococcal infec-
tions, chlamydial infections, and chancroid; new regimens for the treatment of
bacterial vaginosis (BV) and outpatient management of pelvic inflammatory dis-
ease (PID); a new patient-applied medication for treatment of genital warts; and
a revised approach to the management of victims of sexual assault. This report
includes new sections on subclinical human papillomavirus (HPV) infections and
cervical cancer screening for women who attend STD clinics or who have a his-
tory of STDs. These recommendations also include expanded sections on the
management of patients with asymptomatic human immunodeficiency virus
(HIV) infection; vulvovaginal candidiasis (VVC); STDs among patients coinfected
with HIV; and STDs among infants, children, and pregnant women.
INTRODUCTION
Physicians and other health-care providers have a critical role in the effort to pre-
vent and treat sexually transmitted diseases (STDs). These recommendations for the
treatment of STDs are intended to assist with that effort. They were developed by CDC
staff members in consultation with a group of invited experts.*
This report was produced through a multi-stage process. Beginning in the spring of
1992, CDC personnel systematically reviewed literature on each of the major STDs,
focusing on data and reports that have become available since the 1989 STD Treat-
ment Guidelines  were published. Background papers were written and tables of
evidence constructed summarizing the type of study (e.g., randomized controlled trial,
case series), the study population and setting, the treatments or other interventions,
outcome measures assessed, reported findings, and weaknesses and biases in study
design and analysis. For these reviews and tables, published abstracts and peer-
reviewed journal articles were considered. CDC personnel then developed a draft
document based on those reviews.
*Expert Consultants
Alfred O. Berg, M.D., M.P.H. (Chair and Moderator), University of Washington School of
Medicine; H. Hunter Handsfield, M.D. (Moderator), Seattle-King County Department of Public
Health and University of Washington; King K. Holmes, M.D., Ph.D. (Moderator), University
of Washington School of Medicine; Edward W. Hook III, M.D. (Rapporteur), University of
Alabama School of Medicine and Birmingham City Health Department; William M. McCor-
mack, M.D. (Rapporteur), State University of New York Health Science Center at Brooklyn;
A. Eugene Washington, M.D. (Rapporteur), Stanford University School of Medicine; Jonathan
M. Zenilman, M.D. (Rapporteur), Johns Hopkins University School of Medicine and Baltimore
City Health Department; Gail A. Bolan, M.D., San Francisco Department of Public Health and
University of California, San Francisco, School of Medicine; William R. Bowie, M.D., University
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In January 1993, invited consultants assembled in Atlanta for a 3-day meeting. CDC
personnel presented the key questions on STD treatment suggested from their litera-
ture reviews and presented the data available to answer those questions. Where
relevant, the questions focused on four principal outcomes of STD therapy: a) micro-
biologic cure, b) alleviation of signs and symptoms, c) prevention of sequelae, and
d) prevention of transmission. The consultants then assessed whether the questions
identified were the appropriate ones, ranked them in order of priority, and attempted
to arrive at answers using the available evidence. In addition, the consultants evalu-
ated the quality of evidence supporting the answers based on the number and types
of studies and the quality of those studies.
of British Columbia; Virginia A. Caine, M.D., Bellflower Clinic, Indianapolis; John M. Douglas,
Jr., M.D., University of Colorado Health Science Center; Paul R. Gully, M.B., Ch.B., Bureau of
Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Ottawa; Mar-
garet R. Hammerschlag, M.D., State University of New York Health Science Center at
Brooklyn; Carole Jenny, M.D., Children’s Hospital, Denver; Karen Hein, M.D., Montefiore
Medical Center, New York; Franklyn N. Judson, M.D., Denver Department of Health and
University of Colorado Health Science Center; David H. Martin, M.D., Louisiana State Uni-
versity Medical Center, New Orleans; Daniel M. Musher, M.D., Baylor College of Medicine,
Houston; Allan R. Ronald, M.D., University of Manitoba Health Science Center, Winnipeg;
Alfred J. Saah, M.D., Johns Hopkins University School of Hygiene and Public Health; Jack
D. Sobel, M.D., Wayne State University School of Medicine; P. Frederick Sparling, M.D.,
University of North Carolina School of Medicine; Walter E. Stamm, M.D., University of
Washington School of Medicine; Richard L. Sweet, M.D., Magee-Women’s Hospital, Pitts-
burgh; Edwin M. Thorpe, Jr., M.D., University of Tennessee at Memphis; Richard J. Whitley,
M.D., University of Alabama School of Medicine; Constance B. Wofsy, M.D., University of
California, San Francisco, School of Medicine.
Other Expert Consultants (Did not attend meeting )
Judith A. Fortney, Ph.D., Family Health International, Research Triangle Park; Joseph
Kelaghan, M.D., National Institute of Child Health and Development, Bethesda; Louis M.
Mendelson, M.D., University of Connecticut Health Center, West Hartford; Kenneth L. Noller,
M.D., University of Massachusetts Medical Center, Worcester; Martin F. Shapiro, M.D., Ph.D.,
University of California, Los Angeles, School of Medicine, Los Angeles; Gillian M. Shepherd,
M.D., Cornell University Medical Center/New York Hospital, New York; Dorothy D. Sogn, M.D.,
National Institutes of Health, Bethesda; Timothy J. Sullivan, M.D., University of Texas, South-
western Medical Center at Dallas, Dallas; Neil S. Wenger, M.D., M.P.H, University of California,
Los Angeles, School of Medicine, Los Angeles.
Liaison Observers
King K. Holmes, M.D., Ph.D., Infectious Disease Society of America; Claude Betts, M.D.,
Pan-American Health Organization, Washington; Peggy Clarke, American Social Health As-
sociation; Gina Dallabetta, M.D., AIDSCAP/Family Health International; Q.M. Islam, M.D.,
World Health Organization, Geneva; Noni E. MacDonald, M.D., American Academy of Pedi-
atrics; R. Dee Legako, M.D., American Academy of Family Physicians; Norbert P. Raposa,
Ph.D., American Medical Association; Richard L. Sweet, M.D., American College of Obstetri-
cians and Gynecologists and Infectious Disease Society for Obstetrics and Gynecology.
CDC STD Treatment Guidelines 1993 Project
William E. Brady, P.A.-C, M.P.H. (Coordinator); William C. Levine, M.D., M.Sc. (Coordinator);
George P. Schmid, M.D. (Co-chair); Bernard M. Branson, M.D. (Co-moderator); Robert E.
Johnson, M.D., M.P.H (Co-moderator); Robert T. Rolfs, Jr., M.D. (Co-moderator); Katherine M.
Stone, M.D. (Co-moderator); John A. Becher, National Center for Infectious Diseases (NCID);
Stuart M. Berman, M.D.; Stuart T. Brown, M.D.; Paul V. Effler, M.D.; Donna L. Higgins, M.S.;
M. Riduan Joesoef, M.D., Ph.D.; Mary L. Kamb, M.D.; William J. Kassler, M.D., M.P.H.; John
S. Moran, M.D.; H. Trent MacKay, M.D., M.P.H.; Thomas A. Peterman, M.D., M.Sc.; Herbert
B. Peterson, M.D., National Center for Chronic Disease Prevention and Health Promotion;
Robert W. Pinner, M.D., NCID; Susan E. Reef, M.D., NCID; Joann Schulte, D.O.; J. Todd Weber,
M.D.; W. L. Whittington, M.S.; Richard Noegel (Editor); Garrett K. Mallory; Darlene W. Davis;
Diana M. Cronin; Doris C. Ferguson.
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In several areas, the process diverged from that described above. The section on
STD/HIV prevention guidelines was reviewed for comment by experts who had not
been present at the January meeting, as well as by additional experts on STD/HIV
prevention at CDC. The recommendations for STD screening during pregnancy were
developed after CDC staff reviewed the published recommendations of other expert
groups that were convened by CDC and other organizations. The sections on HIV in-
fection and early intervention and hepatitis B virus (HBV) also are principally a
compilation of recommendations developed by other experts and are provided in this
report for the convenience of those who use this document.
Throughout this document the evidence used as the basis for specific recommen-
dations is briefly discussed. More comprehensive, annotated discussions of such
evidence will appear in background papers that will be submitted for publication in
1994.
These recommendations were developed in consultation with experts whose expe-
rience is primarily with the treatment of patients in public STD clinics. These
recommendations also should be applicable to other patient-care settings, including
family planning clinics, private doctor’s offices, and other primary-care facilities.
When using these guidelines, consideration should be given to the disease prevalence
and to other characteristics of the practice setting. These recommendations should
not be construed as standards or as inflexible rules, but as a source of clinical guid-
ance within the United States.
These recommendations focus on the treatment and counseling of individual pa-
tients and do not address other community services and interventions that also play
important roles in STD/HIV prevention. Clinical and laboratory diagnoses are de-
scribed when such information is related to therapy. For a more comprehensive
discussion of diagnosis, refer to CDC’s STD Clinical Practice Guidelines, 1991 (1 ). 
STD/HIV PREVENTION GUIDELINES
Prevention and control of STDs is based on four major concepts: first, education of
those at risk on the means for reducing the risk for transmission; second, detection of
asymptomatically infected individuals and of persons who are symptomatic but
unlikely to seek diagnostic and treatment services; third, effective diagnosis and treat-
ment of those who are infected; fourth, evaluation, treatment, and counseling of sex
partners of persons who have an STD. Although this document deals largely with sec-
ondary prevention, namely clinical aspects of STD control, primary prevention of
STDs is based on changing the sexual behaviors that place patients at risk.
Physicians and other health-care providers have an important role in the preven-
tion of STDs. In addition to interrupting transmission by treating persons who have
bacterial and parasitic STDs, clinicians have the opportunity to provide patient educa-
tion and counseling and to participate in identifying and treating infected sex partners.
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Prevention Methods
Condoms
When used consistently and correctly, condoms are very effective in preventing a
variety of STDs, including HIV infection. Multiple cohort studies, including those of
serodiscordant couples, have demonstrated a strong protective effect of condom use
against HIV infection. Condoms are regulated as medical devices and subject to ran-
dom sampling and testing by the Food and Drug Administration (FDA). Each latex
condom manufactured in the United States is tested electronically for holes before
packaging. Condom breakage rates during use are low in the United States (≤2 per 100
condoms tested). Condom failure usually results from inconsistent or incorrect use
rather than condom breakage.
Patients should be advised that condoms must be used consistently and correctly
to be effective in preventing STDs. Patients should also be instructed in the correct use
of condoms. The following recommendations ensure the proper use of condoms:
• Use a new condom with each act of intercourse.
• Carefully handle the condom to avoid damaging it with fingernails, teeth, or
other sharp objects.
• Put the condom on after the penis is erect and before any genital contact with the
partner.
• Ensure that no air is trapped in the tip of the condom.
• Ensure that there is adequate lubrication during intercourse, possibly requiring
the use of exogenous lubricants.
• Use only water-based lubricants (e.g., K-Y Jelly  or glycerine) with latex con-
doms (oil-based lubricants [e.g., petroleum jelly, shortening, mineral oil,
massage  oils, body lotions, or cooking oil] that can weaken latex should never be
used).
• Hold the condom firmly against the base of the penis during withdrawal, and
withdraw while the penis is still erect to prevent slippage.
Condoms and Spermicides
The effectiveness of spermicides in preventing HIV transmission is unknown. No
data exist to indicate that condoms lubricated with spermicides are more effective
than other lubricated condoms in protecting against the transmission of HIV infection
and other STDs. Therefore, latex condoms with or without spermicides are recom-
mended.
Female Condoms
Laboratory studies indicate that the female condom (Reality )—a lubricated poly-
urethane sheath with a ring on each end that is inserted into the vagina—is an
effective mechanical barrier to viruses, including HIV. Aside from a small study of
trichomoniasis, no clinical studies have been completed to evaluate protection from
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HIV infection or other STDs. However, an evaluation of the female condom’s effective-
ness in pregnancy prevention was conducted during a 6-month period for 147 women
in the United States. The estimated 12-month failure rate for pregnancy prevention
among the 147 women was 26%.
Vaginal Spermicides, Sponges, Diaphragms
As demonstrated in several cohort studies, vaginal spermicides (i.e., film, gel, sup-
positories; contraceptive foam has not been studied) used alone without condoms
reduce the risk for cervical gonorrhea and chlamydia, but protection against HIV infec-
tion has not been established in human studies. The vaginal contraceptive sponge
protects against cervical gonorrhea and chlamydia, but increases the risk for candidi-
asis as evidenced by cohort studies. Diaphragm use has been demonstrated to protect
against cervical gonorrhea, chlamydia, and trichomoniasis, but only in case-control
and cross-sectional studies; no cohort studies have been performed. Gonorrhea and
chlamydia among women usually involve the cervix as a portal of entry, whereas
other STD pathogens (including HIV) may infect women through the vagina or vulva,
as well as the cervix. Protection of women against HIV infection should not be as-
sumed from the use of vaginal spermicides, vaginal sponges, or diaphragms. The role
of spermicides, sponges, and diaphragms for preventing STDs among men has not
been studied.
Nonbarrier Contraception, Surgical Sterilization, Hysterectomy
Women who are not at risk for pregnancy may incorrectly perceive themselves to
be at no risk for STDs, including HIV infection. Nonbarrier contraceptive methods offer
no protection against HIV or other STDs. Women using hormonal contraception (oral
contraceptives, Norplant , Depo-Provera ), who have been surgically sterilized or
who have had hysterectomies should be counseled regarding the use of condoms and
the risk for STDs, including HIV infection.
Prevention Messages
Preventing the spread of STDs requires that persons at risk for transmitting or ac-
quiring infections change their behaviors. When risks have been identified, the
health-care provider has an opportunity to deliver prevention messages. Counseling
skills are essential to the effective delivery of prevention messages (i.e., respect, com-
passion, and a nonjudgmental attitude). Techniques that can be effective in
developing rapport with the patient include using open-ended questions, using lan-
guage that the patient understands, and reassuring the patient that treatment will be
provided regardless of considerations such as ability to pay, citizenship or immigra-
tion status, language spoken, or lifestyle.
Prevention messages should be tailored to the patient, with consideration given to
his or her specific risks. Messages should include a description of measures, such as
the following, that the person can take to avoid acquiring or transmitting STDs:
• The most effective way to prevent sexual transmission of HIV infection and other
STDs is to avoid sexual intercourse with an infected partner. 
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• If a person chooses to have sexual intercourse with a partner whose infection
status is unknown or who is infected with HIV or other STDs, men should use a
new latex condom with each act of intercourse. 
• When a male condom cannot be used, couples should consider using a female
condom. 
Injection Drug Users
Prevention messages appropriate for injection drug users are the following:
• Enroll or continue in a drug treatment program.
• Do not, under any circumstances, use injection equipment (needles, syringes)
that has been used by another person.
• Persons who continue to use injection equipment that has been used by other
persons should first clean the equipment with bleach and water. (Disinfecting
with bleach does not sterilize the equipment and does not guarantee that HIV is
inactivated. However, thoroughly and consistently cleaning injection equipment
with bleach should reduce the rate of HIV transmission when equipment is
shared.)
HIV Prevention Counseling
Knowledge of one’s HIV status and appropriate counseling are thought to play an
important role in initiating behavior change. Counseling associated with HIV testing
has two main components: pretest and posttest counseling.
During pretest counseling, the clinician should conduct a personalized risk assess-
ment, explain the meaning of positive and negative test results, ask for informed
consent for the HIV test, and help the person to develop a realistic, personalized risk
reduction plan.
During posttest counseling, the clinician should inform the patient of the results,
review the meaning of the results, and reinforce prevention messages. If the patient is
HIV positive, posttest counseling should include referral for follow-up medical serv-
ices and for social and psychological services, if needed. HIV- seronegative persons at
continuing risk for HIV infection also may benefit from referral for additional counsel-
ing and prevention services.
HIV counseling is considered to be an important HIV-prevention strategy, although
its efficacy in reducing risk behavior is still under evaluation. By ensuring that counsel-
ing is empathic and “client-centered,” clinicians will be able to develop a realistic
appraisal of the person’s risk and help him or her to develop a specific and realistic
HIV-prevention plan (2 ).
Partner Notification and Management of Sex Partners
Patients with STDs should ensure that their sex partners, including those without
symptoms, are referred for evaluation. Providers should be prepared to assist in that
effort. In most circumstances, partners of patients with STDs should be examined.
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When a diagnosis of a treatable STD is considered likely, appropriate antibiotics
should be administered even though there may be no clinical signs of infection and
before laboratory test results are available. In most states, the local or state health
department can assist in notifying the partners of patients with selected STDs, espe-
cially HIV, syphilis, gonorrhea, and chlamydia.
Breaking the chain of transmission is crucial to STD control. For treatable STDs,
further transmission and reinfection can be prevented by referral of sex partners for
diagnosis, treatment, and counseling. The following two strategies are used for part-
ner notification: a) patient referral (index patients notify their partners), and b)
provider referral (partners named by infected patients are notified and counseled by
health department staff). When a physician refers an infected person to a local or state
health department, trained professionals may interview the patient to obtain names
and locating information about all of his or her sex partners. Every health department
protects the privacy of patients in partner notification activities. Because of the advan-
tage of confidentiality, many patients prefer that public health officials notify partners.
If a patient with HIV infection refuses to notify partners while continuing to place
them at risk, the physician has an ethical and legal responsibility to inform persons
that they are at risk of HIV infection. This duty-to-warn may be most applicable to
primary care physicians, who often have knowledge about a patient’s social and famil-
ial relationships. The decision to invoke the duty-to-warn measure should be a last
resort—applicable only in cases in which all efforts to persuade the patient to disclose
positive test results to those who need to know have failed.
Although compelling ethical, theoretical, and public health reasons exist to under-
take partner notification, the efficacy of partner notification as an STD prevention
strategy is under evaluation, and its effectiveness may be disease-specific.
Clinical guidelines for sex partner management and recommendations for partner
notification for specific STDs are included for each STD addressed in this report.
Reporting and Confidentiality
The accurate identification and timely reporting of STDs form an integral part of
successful disease control. Reporting assists local health authorities in identifying sex
partners who may be infected. Reporting also is important for assessing morbidity
trends. STD/HIV and acquired immunodeficiency syndrome (AIDS) cases should be
reported in accordance with local statutory requirements and in a timely manner.
Syphilis, gonorrhea, and AIDS are reportable diseases in every state. The require-
ments for reporting other STDs and asymptomatic HIV infection differ from state to
state, and clinicians should be familiar with local STD reporting requirements.
Reporting may be provider- and/or laboratory-based. Clinicians who are unsure of
local reporting requirements should seek advice from local health departments or
state STD programs.
STD and HIV reports are held in strictest confidence and in many jurisdictions are
protected by statute from subpoena. Further, before any follow-up of a positive STD
test is conducted by program representatives, these persons consult with the patient’s
health-care provider to verify the diagnosis and treatment.
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SPECIAL POPULATIONS
Pregnant Women
Intrauterine or perinatally transmitted STDs can have fatal or severely debilitating
effects on a fetus. Pregnant women and their sex partners should be questioned about
STDs and should be counseled about the possibility of neonatal infections.
Recommended Screening Tests
The following screening tests are recommended for pregnant women:
• A serologic test for syphilis
All women should be screened serologically for syphilis during the early stages of
pregnancy. In populations in which utilization of  prenatal care is not optimal, rapid
plasma reagin (RPR)-card test screening and treatment, if that test is reactive, should
be performed at the time a pregnancy is diagnosed. For patients at high risk, screening
should be repeated in the third trimester and again at delivery. (Some states mandate
screening all women at delivery.) No infant should be discharged from the hospital
without the syphilis serologic status of its mother having been determined at least
once during pregnancy and, preferably, again at delivery. Any woman who delivers a
stillborn infant after 20 weeks gestation should be tested for syphilis.
• A serologic test for hepatitis B surface antigen (HBsAg)
• A test for Neisseria gonorrhoeae
• A test for Chlamydia trachomatis 
Pregnant women at increased risk (<25 years of age, or with a new or more than
one partner) should be tested and treated, if necessary, during the third trimester to
prevent maternal postnatal complications and chlamydial infection among infants.
Screening during the first trimester might permit prevention of adverse effects of
chlamydia during pregnancy. However, the evidence for adverse effects during preg-
nancy is minimal. If screening is performed only during the first trimester, a longer
period exists for acquiring infection before delivery.
• A test for HIV infection
Patients with risk factors for HIV or with a high-risk sex partner should be tested for
HIV infection. Some authorities recommend offering HIV tests to all pregnant women,
particularly in areas of high HIV seroprevalence. Appropriate counseling should be
provided, and informed consent for HIV testing should be obtained.
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Other Issues
Other STD-related issues to be considered are as follows:
• Pregnant women with primary genital herpes, HBV, primary cytomegalovirus
(CMV) infection, group B streptococcal infection, and women who have syphilis
and who are allergic to penicillin may need to be referred to an expert for man-
agement.
• In the absence of lesions during the third trimester, routine serial cultures for
herpes simplex virus (HSV) are not indicated for women with a history of recur-
rent genital herpes. However, obtaining cultures from such women at the time of
delivery may be useful in guiding neonatal management. “Prophylactic” caesar-
ean section is not indicated for women who do not have active genital lesions at
the time of delivery. 
• The presence of genital warts is not considered an indication for caesarean sec-
tion. 
For a more detailed discussion of these issues, as well as for infections not trans-
mitted sexually, refer to Guidelines for Perinatal Care  (3 ).
NOTE: The sources for these guidelines for screening of pregnant women include
Guide to Clinical Preventive Services  (4 ), Guidelines for Perinatal Care  (3 ), and Rec-
ommendations for the Prevention and Management of Chlamydia trachomatis
Infections, 1993  (5 ). These sources are not entirely consistent in their recommenda-
tions. The Guide to Clinical Preventive Services  recommends routine testing for
gonorrhea at the first prenatal visit, with repeat testing for those at increased risk, and
selective screening for chlamydia at the first prenatal visit. The Guidelines for Peri-
natal Care does not specifically recommend screening for either gonorrhea or
chlamydia, but recommends screening for STDs in the third trimester for women at
risk. The Recommendations for the Prevention and Management of Chlamydia
trachomatis Infections, 1993 recommend screening for chlamydia during the third tri-
mester for all pregnant women <25 years of age or for any woman with a new sex
partner or multiple partners. Recommendations to screen pregnant women for STDs
are based on disease severity and sequelae, prevalence in the population, costs, medi-
cal/legal considerations (including state laws), and other factors. The screening
recommendations in this report are more comprehensive (i.e., if followed, more
women will be screened for more STDs than would be screened by following other
recommendations) and are compatible with other CDC guidelines. Physicians should
select a screening strategy compatible with their practice population and setting.
Adolescents
Health-care providers who provide care for patients with sexually transmitted in-
fections should be aware of several issues that relate specifically to adolescents. The
rates of many STDs are highest among adolescents; e.g., the rate of gonorrhea is high-
est among persons 15–19 years of age. Clinic-based studies have demonstrated that
the prevalence of chlamydial infections, and possibly of HPV infections, also is highest
among adolescents.
Vol. 42 / No. RR-14 MMWR 9
All adolescents in the United States can consent to the confidential diagnosis and
treatment of STDs. Medical care for these conditions can be provided to adolescents
without parental consent or knowledge. Furthermore, in many states adolescents can
consent to HIV counseling and testing.
The style and content of counseling and health education should be adapted for
adolescents. Discussions should be appropriate for the patient’s developmental level
and should identify risky behaviors, such as sex and drug use behaviors. Care and
counseling should be direct and nonjudgmental.
Children
Management of children with STDs requires close cooperation between the clini-
cian, laboratory, and child-protection authorities. Investigations, when indicated,
should be initiated promptly. Some diseases, such as gonorrhea, syphilis, and
chlamydia, if acquired after the neonatal period, are almost 100% indicative of sexual
contact. For other diseases, such as HPV infection and vaginitis, the association with
sexual contact is not as clear (see Sexual Assault and STDs).
Persons with HIV Infection
The management of patients infected with HIV and patients infected with both HIV
and other STDs presents complex clinical and behavioral issues. For that reason,
these issues are addressed throughout this report (see HIV Infection and Early Inter-
vention and specific disease sections). Because of its effects on the immune system,
HIV infection may alter the natural histories of many STDs and the effect of antimicro-
bial therapy. Such effects are likely to occur as the degree of immunosuppression
advances; frequent or severe episodes of some STDs or failure to respond appropri-
ately to therapy should lead the health-care provider to consider HIV infection as a
cause. Close clinical follow-up of patients infected with both HIV and STDs is impera-
tive.
STD infection among patients with or without HIV is a sentinel event, often indicat-
ing unprotected sexual activity. Further patient counseling is needed in such
situations.
HIV INFECTION AND EARLY INTERVENTION
Infection with HIV produces a spectrum that progresses from no apparent illness to
AIDS as a late manifestation. The pace of disease progression is variable. The median
time between infection with HIV and the development of AIDS among adults is
10 years, with a range from a few months to ≥12 years. Most adults and adolescents
infected with HIV remain symptom-free for long periods, but viral replication can be
detected in asymptomatic persons and increases substantially as the immune system
deteriorates. Most people who are infected with HIV will eventually have symptoms
related to the infection. In cohort studies of adults infected with HIV, data indicated
that symptoms developed in 70%–85% of infected adults, and AIDS developed in
55%–62% within 12 years after infection. Additional cases are expected to occur
among those who have remained AIDS-free for >12 years.
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Greater awareness of risky behaviors by both patients and health-care providers
has led to increased testing for HIV and earlier diagnosis of early HIV infection, often
before symptoms develop (though emotional or psychological problems may occur).
Such early identification of HIV infection is important for several reasons. Treatments
are available to slow the decline of immune system function. Persons who are in-
fected with HIV and altered immune function also are at increased risk for infections
such as tuberculosis (TB), bacterial pneumonia, and Pneumocystis carinii  pneumonia
(PCP), for which preventive measures are available. Because of its effect on the im-
mune system, HIV affects the diagnosis, evaluation, treatment,  and follow-up of
many other diseases and may affect the efficacy of antimicrobial therapy for some
STDs. Close clinical follow-up after treatment for STDs is imperative. 
During early infection, persons with HIV and their families can be educated about
the disease and become linked with a support network that addresses their needs and
with care systems effective in maintaining good health and delaying the onset of
symptoms. Early diagnosis also offers the opportunity for counseling and for assis-
tance in preventing the transmission of HIV infection to others.
For the purpose of these recommendations, early intervention for HIV is defined as
care for persons infected with HIV who are without symptoms. However, recently de-
tected HIV infection may not have been recently acquired. Persons newly diagnosed
with HIV may be at many different stages of the infection. Therefore, early interven-
tion also involves assuming the responsibility for coordinating care and for arranging
access to resources necessary to meet the medical, psychological, and social needs of
persons with more advanced HIV infection.
Diagnostic Testing for HIV-1 and HIV-2
HIV infection is most often diagnosed by using HIV-1 antibody tests. Antibody test-
ing begins with a sensitive screening test such as the enzyme-linked immunosorbent
assay (ELISA) or a rapid assay. If confirmed by Western blot or other supplemental
test, a positive antibody test means that a person is infected with HIV and is capable
of transmitting the virus to others. HIV antibody is detectable in ≥95% of patients
within 6 months of infection. Although a negative antibody test usually means a per-
son is not infected, antibody tests cannot rule out infection that  occurred <6 months
before the test.
Since there is transplacental passage of maternal HIV antibody, antibody tests for
HIV are expected to be positive in the serum of both infected and uninfected infants
born to a seropositive mother. Passively acquired HIV antibody falls to undetectable
levels among most infants by 15 months of age. A definitive determination of HIV
infection for an infant <15 months of age should be based either on the presence of
antibody to HIV in conjunction with a compatible immunologic profile and clinical
course or on laboratory evidence of HIV in blood or tissues by culture, nucleic acid, or
antigen detection.
Specific recommendations for the diagnostic testing of HIV are listed below:
• Informed consent must be obtained before an HIV test is performed. Some states
require written consent. See HIV Prevention Counseling for a discussion of pre-
test and posttest counseling.
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• Positive screening tests for HIV antibody must be confirmed by a more specific
confirmatory test (either the Western blot assay or indirect immunofluorescence
assay [IFA]) before being considered definitive for confirming HIV infection.
• Persons with positive HIV tests must receive medical and psychosocial evalu-
ation and monitoring services, or be referred for these services.
The prevalence of HIV-2 in the United States is extremely low, and CDC does not
recommend routine testing for HIV-2 in settings other than blood centers, unless
demographic or behavioral information suggests that HIV-2 infection might be pres-
ent. Those at risk for HIV-2 infection include persons from a country in which HIV-2 is
endemic or the sex partners of such persons. (As of July 1992, HIV-2 was endemic in
parts of West Africa and an increased prevalence of HIV-2 had been reported in An-
gola, France, Mozambique, and Portugal.) Additionally, testing for HIV-2 should be
conducted when there is clinical evidence or suspicion of HIV disease in the absence
of a positive test for antibodies to HIV-1 (6 ).
Counseling for Patients with HIV Infection
Behavioral and psychosocial services are an integral part of HIV early intervention.
Patients usually experience emotional distress when first being informed of a positive
HIV test result, and also later when notified of changes in immunologic markers, when
antiviral or prophylactic therapy is initiated, and when symptoms develop. Patients
face several major adaptive challenges: a) accepting the possibility of a curtailed life
span, b) coping with others’ reactions to a stigmatizing illness, c) developing strate-
gies for maintaining physical and emotional health, and d) initiating changes in
behavior to prevent HIV transmission. Many patients also require assistance with
making reproductive choices, gaining access to health services and health insurance,
and confronting employment discrimination.
Interrupting HIV transmission depends upon changes in behavior by those persons
at risk for transmitting or acquiring infection. Though some viral culture studies sug-
gest that antiviral treatment reduces viral burden, clinical data are insufficient to
determine whether therapy might reduce the probability of transmission. Infected per-
sons, as potential sources of new infections, must receive extra attention and support
to help break chains of transmission and to prevent infection of others. Targeting
behavior change programs toward HIV-infected persons and their sex partners, or
those with whom they share needles, is an important adjunct to current AIDS preven-
tion efforts.
Specific recommendations for counseling patients with HIV infection are listed be-
low:
• Persons who test positive for HIV antibody should be counseled by a person who
is able to discuss the medical, psychological, and social implications of HIV infec-
tion. 
• Appropriate social support and psychological resources should be available,
either on site or through referral, to assist patients in coping with emotional dis-
tress.
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• Persons who continue to be at risk for transmitting HIV should receive assistance
in changing or avoiding behaviors that can transmit infection to others.
Initial Evaluation and Planning for Care
Practice settings for offering early HIV care are variable, depending upon local re-
sources and needs. Primary-care providers and outpatient facilities must ensure that
appropriate resources are available for each patient and must avoid fragmentation of
care; it is preferable for persons with HIV infection to receive care from a single source
that is able to provide comprehensive care for all stages of HIV infection. But the lim-
ited availability of such resources often results in the need to coordinate care among
outpatient, inpatient, and specialist providers in different locations. Because of the
progressive nature of HIV and the increased risk for bacterial infections, including
TB—even before HIV infection becomes advanced—it is essential to establish specific
provisions for handling the medical, psychological, and social problems likely to arise
at any stage of infection. An important component of early intervention is effective
linkage with referral settings where off-hours care and specialty services are available.
Development of an appropriate plan for care involves the following:
• Identification of patients in need of immediate medical care (e.g., patients with
symptomatic HIV infection or emotional crisis) and of those in need of anti-
retroviral therapy or prophylaxis for opportunistic infections (e.g., PCP).
• Evaluation for the presence of diseases associated with HIV, such as TB and
STDs.
• Administration of recommended vaccinations.
• Case management or referral for case management.
• Counseling (see Counseling for Patients with HIV Infection).
The CD4+ T-lymphocyte count is the best laboratory indicator of clinical progres-
sion, and comprehensive management strategies for HIV infection are typically
stratified by CD4 count. Either the absolute number or the percentage of CD4+ T cells
may be determined. CD4+ percentage is more consistent than absolute CD4+ count
with successive measurements for the same person and less variable with delays in
specimen processing. However, most clinical trials have used absolute CD4+ count to
evaluate the need for and timing of therapeutic interventions. Patients with CD4+
counts >500/µL usually do not demonstrate evidence of clinical immunosuppression.
Patients with 200–500 CD4+ cells/µL are more likely to develop HIV-related symptoms
and to require medical intervention. Patients with CD4+ counts <200 cells/µL, and
those with higher CD4+ counts who develop thrush or unexplained fever (temperature
>37.8 C for ≥2 weeks) are at increased risk for developing complicated HIV disease.
Such patients should be managed in a comprehensive treatment setting with access
to specialty resources and hospitalization.
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Providers unable to offer therapeutic management of HIV may use the initial evalu-
ation to identify the need for prompt referral to appropriate resources. The initial
evaluation of HIV-positive patients should include the following essential compo-
nents:
• A detailed history, including sexual history, substance abuse history, and a re-
view of systems for specific HIV-related symptoms.
• A physical examination; for females, this examination should include a gyne-
cologic examination.
• For females, testing for N. gonorrhoeae, C. trachomatis, a Papanicolaou (Pap)
smear, and wet mount examination of vaginal secretions.
• A syphilis serology.
• A CD4+ T-lymphocyte analysis.
• Complete blood and platelet counts.
• A purified protein derivative (PPD) tuberculin skin test by the Mantoux method
and anergy testing with two delayed-type hypersensitivity (DTH) antigens (Can-
dida, mumps, or tetanus toxoid) administered by the Mantoux method or a
multipuncture device.
• A thorough psychosocial evaluation, including ascertainment of behavioral fac-
tors indicating risk for transmitting HIV and elucidation of information about any
partners who should be notified about possible exposure to HIV.
Preventive Therapy for TB
Studies conducted among persons with and without HIV infection have suggested
that HIV infection can depress tuberculin reactions before signs and symptoms of HIV
infection develop. Cutaneous anergy (defined as skin test response of ≤3 mm to all
DTH antigens) may be present among ≥10% of asymptomatic persons with CD4+
counts >500 cells/µL, and among >60% of persons with CD4+ counts <200.
HIV-positive persons with a PPD reaction ≥5 mm induration are considered to be
infected with M. tuberculosis  and should be evaluated for preventive treatment with
isoniazid after active TB has been excluded. Anergic persons whose risk for tubercu-
lous infection is estimated to be ≥10%, based on available prevalence data, also
should be considered for preventive therapy. For further details regarding evaluation
of patients for TB, refer to Purified Protein Derivative (PPD-tuberculin anergy) and HIV
Infection: Guidelines for Anergy Testing and Management of Anergic Persons at Risk
of Tuberculosis (7 ).
The preliminary results from a randomized clinical trial suggest that treatment with
isoniazid is effective for preventing active TB among HIV-infected persons. The usual
regimen is isoniazid 10 mg/kg daily, up to a maximum adult dose of 300 mg daily.
Twelve months of isoniazid preventive treatment is recommended for persons with
HIV infection. For further details regarding preventive therapy for TB, refer to The Use
of Preventive Therapy for Tuberculous Infection in the United States (8 ) and Manage-
ment of Persons Exposed to Multidrug-Resistant Tuberculosis (9 ). 
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Recommended Immunizations for Adults and Adolescents
Specific recommendations for immunization of persons infected with HIV are listed
below:
• Pneumococcal vaccination and an annual influenza vaccination should be admin-
istered.
• Persons at increased risk for acquiring HBV and who lack evidence of immunity
may receive a three-dose schedule of hepatitis B vaccine, with postvaccination
serologic testing between 1 and 6 months after the vaccination series.
Recommendations for vaccinating HIV-infected persons are based on expert opin-
ions and consensus of the Advisory Committee on Immunization Practices (ACIP). No
clinical data exist to document the efficacy of inactivated vaccines among HIV-infected
persons, and pneumococcal vaccine failures have been reported. However, the use of
inactivated vaccines may be beneficial for persons with HIV infection and there is no
evidence that they are harmful. Immunogenicity studies have suggested a generally
poorer response among HIV-infected persons, with higher response rates among as-
ymptomatic persons than among those with advanced HIV disease.
Current evidence indicates that HIV infection does not increase susceptibility to
HBV, nor does it increase the severity of clinical disease. The presence of HIV infection
is not an indication for hepatitis B vaccine, but HIV-infected persons are at increased
risk for becoming chronic carriers after hepatitis B infection. Because the routes of
transmission of HBV parallel those of HIV, efforts to modify risky behaviors must be
the primary focus of prevention efforts. However, vaccine should be administered to
HIV-infected patients who continue to have a high likelihood for HBV exposure.
Persons with HIV infection also are at increased risk for invasive Haemophilus influ-
enzae  type B (Hib) disease and for complications from measles. Immunization against
Hib and measles should be considered for asymptomatic HIV-infected persons who
may have an increased risk for exposure to these infections. For further details on
immunization of HIV-infected patients, refer to Recommendations of the Advisory
Committee on Immunization Practices (ACIP): Use of Vaccines and Immune Globulins
in Persons with Altered Immunocompetence (10 ). 
Follow-Up Evaluation
There have been no controlled studies to serve as the basis for recommending spe-
cific follow-up tests or follow-up intervals. The suggested frequency of monitoring is
based on the slow decrease in CD4+ counts observed among patients in cohort stud-
ies, but should be modified depending on the patient’s psychological status, the
presence of symptoms, or both. Repeat evaluation for STDs also is important in the
follow-up of HIV-infected persons and should be performed on all persons who con-
tinue to be sexually active. Follow-up evaluation should be performed every 6 months
and should include the following:
• An interim history and physical examination;
• A complete blood count, platelet count, and lymphocyte subset analysis;
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• Re-evaluation of psychosocial status and behavioral factors indicating risk for
transmitting HIV.
To follow CD4+ measurements, providers should use the same laboratory and, op-
timally, obtain each specimen at the same time each day. When unexpected or
discrepant results are obtained or when major treatment decisions are to be made,
health-care providers should consider repeating the CD4+ measurement after at least
1 week.
More frequent laboratory monitoring, every 3–4 months, is indicated if CD4+ re-
sults indicate a patient is close to a point when a clinical intervention may be
indicated.
Continuing Management of Patients with Early HIV Infection
Providing comprehensive, continuing management of patients with early HIV infec-
tion can include additional diagnostic studies (e.g., chest x-ray, serum chemistry,
antibody testing for toxoplasmosis and hepatitis B), antiretroviral therapy and moni-
toring, and PCP prophylaxis. Treatment of HIV infection and prophylaxis against
opportunistic infections continue to evolve rapidly. This treatment should be under-
taken in consultation with physicians who are familiar with the care of persons with
HIV infection. The complete therapeutic management of HIV infection is beyond the
scope of this document.
Antiretroviral Therapy
The optimal time for initiating antiretroviral therapy has not yet been established.
Zidovudine (ZDV) at a dose of 500 mg/day (100 mg orally every 4 hours while the
patient is awake) has been recommended for symptomatic persons with <500 CD4+
T-cells/µL, and for asymptomatic persons with <300 CD4+ T-cells/µL. This recommen-
dation is based on results of short-term follow-up in three randomized clinical trials
demonstrating that the initiation of ZDV therapy delays progression to advanced
disease. Evidence for improved long-term survival after early treatment is less conclu-
sive. The effects of ZDV may be transient, possibly because of the development of
viral resistance or other factors. Sequential or combination therapy with other an-
tiretroviral agents could be more efficacious.
Whether other daily dosages, dose schedules, or dosages based on body weight
would result in greater therapeutic benefit or few side effects is not known. Providers
should work with patients to design a treatment strategy that is both clinically sound
and appropriate for each individual patient’s needs, priorities, and circumstances. An
initial dose of 600 mg in divided doses has been recommended by a panel of experts
convened by the National Institute of Allergy and Infectious Diseases (NIAID). Prelimi-
nary data suggest ZDV can yield therapeutic results when the dosing interval is
increased to 8 hours, and at doses of 200 mg three times daily. Antiretroviral efficacy
is diminished at doses <300 mg/day, and it has been suggested that higher oral doses
may be required to achieve effective levels in the central nervous system.
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There are no data to support the use of antiretroviral drugs other than ZDV as initial
therapy. Didanosine (DDI) is recommended for persons who are intolerant of ZDV or
who experience progression of symptoms despite ZDV. Two 100 mg tablets of DDI are
recommended every 12 hours for persons who weigh ≥ 60 kg; the recommended dose
for adults <60 kg is one 100 mg tablet and one 25 mg tablet every 12 hours. Two tablets
are recommended at each dose so that adequate buffering is provided to prevent gas-
tric acid degradation of the drug.
Benefits have been reported from other antiretroviral regimens, including treat-
ment with combinations of ZDV, DDC (dideoxycytidine [zalcitabine]), and DDI, or
switching therapy to DDI after long-term therapy with ZDV. Experience with these al-
ternatives is insufficient to serve as a basis for recommendations. Providers managing
patients who are taking antiretroviral therapy should be familiar with evidence being
developed in several clinical trials. Current information is available from the NIAID
AIDS Clinical Trials Information Service, 1-800-TRIALS-A.
Side effects that are serious (e.g., anemia, cytopenia, pancreatitis, and peripheral
neuropathy) and uncomfortable (e.g., nausea, vomiting, headaches, and insomnia)
are common during antiretroviral therapy. Although hematologic toxicity from ZDV is
less common with the lower doses recommended, approximately 2% of patients who
receive 500 mg/day manifest severe anemia by the 18th month of treatment—most
within the 3rd through 8th month of treatment. Careful hematologic monitoring of
patients receiving ZDV is recommended.
PCP Prophylaxis
Adults and adolescents with <200 CD4+ T-cells/µL or with constitutional symptoms,
such as thrush or unexplained fever >100 F for ≥2 weeks, and any patient with a pre-
vious episode of PCP should receive PCP prophylaxis. Prophylaxis should be
continued for the lifetime of the patient.
Based upon evidence from randomized controlled clinical trials, the Public Health
Service Task Force on Antipneumocystis Prophylaxis has recommended the following
regimens for PCP prophylaxis among adults and adolescents:
• Oral trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of one double-
strength tablet (800 mg SMX and 160 mg TMP) orally once a day.
• For patients unable to tolerate TMP-SMX: aerosol pentamidine administered by
either the Respirgard II nebulizer regimen (300 mg once a month) or the Fisoneb
nebulizer (initial loading regimen of five 60 mg doses during a 2-week period,
followed by a 60 mg dose every 2 weeks).
The efficacy of alternatives for patients unable to tolerate TMP-SMX, including dap-
sone 100 mg orally once a day and sulfa desensitization, has not been studied
extensively. For further details on PCP prophylaxis, refer to Recommendations for Pro-
phylaxis Against  Pneumocystis carinii pneumonia for adults and adolescents infected
with human immunodeficiency virus  (11 ).
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Management of Sex Partners
The rationale for implementing partner notification is that early diagnosis and treat-
ment of HIV infection may reduce morbidity and offers the opportunity to encourage
risk-reducing behaviors. Two complementary notification processes, patient referral
and provider referral, can be used to identify partners. With patient referral, patients
inform their own partners directly of their exposure to HIV infection. With provider
referral, trained health department personnel locate partners on the basis of the
names, descriptions, and addresses provided by the patient. During the notification
process, the anonymity of patients is protected; their names are not revealed to sex or
needle-sharing partners who are notified. Many state health departments provide as-
sistance with provider referral partner notification upon request. 
One randomized trial suggested that provider referral is more effective in notifying
partners than patient referral. In that trial, 50% of partners in the provider referral
group were notified, yet only 7% of partners were notified by subjects in the patient
referral group. However, few data demonstrate whether behavioral change takes
place as a result of partner notification and many patients are reluctant to disclose the
names of partners because of concern about discrimination, disruption of relation-
ships, and loss of confidentiality for the partners.
When referring to those persons infected with HIV, the term “partner” includes not
only sex partners but also injecting drug users who share needles or other injecting
equipment. Partner notification is a means of identifying and concentrating risk-
reduction efforts on persons at high risk for contracting or transmitting HIV infection.
Partner notification for HIV infection must be confidential and should depend upon the
voluntary cooperation of the patient. 
Specific recommendations for implementing partner notification procedures are
listed below:
• Persons who are HIV-positive should be encouraged to notify their partners and
to refer them for counseling and testing. Providers should assist in this process,
if desired by the patient, either directly or through referral to health department
partner notification programs.
• If patients are unwilling to notify their partners or if it cannot be assured that their
partners will seek counseling, physicians or health department personnel should
use confidential procedures to assure that the partners are notified.
Special Considerations
Pregnancy
Women who are HIV-infected should be specifically informed about the risk for
perinatal infection. Current evidence indicates that 15%–39% of infants born to HIV-
infected mothers are infected with HIV, and the virus also can be transmitted from an
infected mother by breastfeeding. Pregnancy among HIV-infected patients does not
appear to increase maternal morbidity or mortality.
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Women should be counseled about their options regarding pregnancy. The objec-
tive of counseling is to provide HIV-infected women with current information for
making reproductive decisions, analogous to the model used in genetic counseling.
Contraceptive, prenatal, and abortion services should be available on site or by refer-
ral.
Minimal information is available on the use of ZDV or other antiretroviral drugs
during pregnancy. Trials to evaluate its efficacy in preventing perinatal transmission
and its safety during pregnancy are being conducted. A case series of 43 pregnant
women has been published; dosages of ZDV ranged from 300 to 1,200 mg/day. ZDV
was well tolerated and there were no malformations among the newborns in this se-
ries. Although this observation is encouraging, this series of negative case reports
cannot be used to infer that ZDV is not teratogenic.
Burroughs Wellcome Co. and Hoffmann-LaRoche, Inc., in cooperation with CDC,
maintain a registry to assess the effects of the use of ZDV and DDC during pregnancy.
Women who receive either ZDV or DDC during pregnancy should be reported to this
registry (1-800-722-9292, ext. 58465).
HIV Infection Among Infants and Children
Infants and young children with HIV infection differ from adults and adolescents
with respect to the diagnosis, clinical presentation, and management of HIV disease.
For example, total lymphocytes and absolute CD4+ cell counts are much higher in
infants and children than in healthy adults and are age dependent. Specific indications
and dosages for both antiretroviral and prophylactic therapy have been developed for
children (12 ). Other modifications must be made in health services that are recom-
mended for infants and children, such as avoiding vaccination with live oral polio
vaccine when a child (or close household contact) is infected with HIV.
State laws differ regarding consent of minor persons (<18 years of age) for HIV
counseling and testing, evaluation, treatment services, and participation in clinical tri-
als. Although most adolescents receive adult doses of antiretroviral and prophylactic
therapy, there are no data on modification of these dosages during puberty. Manage-
ment of infants, children, and adolescents—who are known or suspected to be
infected with HIV—requires referral to, or close consultation with, physicians familiar
with the manifestations and treatment of pediatric HIV infection.
DISEASES CHARACTERIZED BY GENITAL ULCERS 
Management of the Patient with Genital Ulcers
In the United States, most patients with genital ulcers have genital herpes, syphilis,
or chancroid. The relative frequency of each varies by geographic area and patient
population, but in most areas of the United States genital herpes is the most common
of these diseases. More than one of these diseases may be present among at least
3%–10% of patients with genital ulcers. Each disease has been associated with an in-
creased risk for HIV infection.
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A diagnosis based only on history and physical examination is often inaccurate.
Therefore, evaluation of all persons with genital ulcers should include a serologic test
for syphilis and possibly other tests. Although ideally all of these tests should be con-
ducted for each patient with a genital ulcer, use of such tests (other than a serologic
test for syphilis) may be based on test availability and clinical or epidemiologic suspi-
cion. Specific tests for the evaluation of genital ulcers are listed below:
• Darkfield examination or direct immunofluorescence test for Treponema
pallidum,
• Culture or antigen test for HSV, and
• Culture for Haemophilus ducreyi.
HIV testing should be considered in the management of patients with genital ul-
cers, especially for those with syphilis or chancroid.
A health-care provider often must treat a patient before test results are available
(even after complete testing, at least one quarter of patients with genital ulcers have
no laboratory-confirmed diagnosis). In that circumstance, the clinician should treat for
the diagnosis considered most likely. Many experts recommend treatment for both
chancroid and syphilis if the diagnosis is unclear or if the patient resides in a commu-
nity in which chancroid morbidity is notable (especially when diagnostic capabilities
for chancroid and syphilis are not ideal).
Chancroid
Chancroid is endemic in many areas of the United States and also occurs in dis-
crete outbreaks. Chancroid has been well established as a co-factor for HIV
transmission and a high rate of HIV infection among patients with chancroid has been
reported in the United States and in other countries. As many as 10% of patients with
chancroid may be coinfected with T. pallidum  or HSV.
Definitive diagnosis of chancroid requires identification of H. ducreyi on special cul-
ture media that are not commercially available; even using these media, sensitivity is
no higher than 80% and is usually lower. A probable diagnosis, for both clinical and
surveillance purposes, may be made if the person has one or more painful genital
ulcers, and a) no evidence of T. pallidum  infection by darkfield examination of ulcer
exudate or by a serologic test for syphilis performed at least 7 days after onset of
ulcers, and b) either the clinical presentation of the ulcer(s) is not typical of disease
caused by HSV or the HSV test results are negative. The combination of a painful ulcer
with tender inguinal adenopathy (which occurs among one-third of patients) is sug-
gestive of chancroid, and when accompanied by suppurative inguinal adenopathy is
almost pathognomonic.
Treatment
Successful treatment cures infection, resolves clinical symptoms, and prevents
transmission to others. In extensive cases, scarring may result despite successful ther-
apy.
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Recommended Regimens
Azithromycin 1 g orally in a single dose
or
Ceftriaxone 250 mg intramuscularly (IM) in a single dose
or
Erythromycin base 500 mg orally 4 times a day for 7 days.
All three regimens are effective for the treatment of chancroid among patients
without HIV infection. Azithromycin and ceftriaxone offer the advantage of single-
dose therapy. Antimicrobial resistance to ceftriaxone and azithromycin has not been
reported. Although two isolates resistant to erythromycin were reported from Asia a
decade ago, similar isolates have not been reported.
Alternative Regimens
Amoxicillin 500 mg plus clavulanic acid 125 mg orally 3 times a
day for 7 days,
or
Ciprofloxacin 500 mg orally 2 times a day for 3 days.
NOTE: Ciprofloxacin is contraindicated for pregnant and lactating women, children,
and adolescents ≤17 years of age.
These regimens have not been evaluated as extensively as the recommended regi-
mens; neither has been studied in the United States.
Other Management Considerations
Patients should be tested for HIV infection at the time of diagnosis. Patients also
should be tested 3 months later for both syphilis and HIV, if initial results are negative.
Follow-Up
Patients should be re-examined 3–7 days after initiation of therapy. If treatment is
successful, ulcers improve symptomatically within 3 days and improve objectively
within 7 days after therapy. If no clinical improvement is evident, the clinician must
consider whether a) the diagnosis is correct, b) coinfection with another STD agent
exists, c) the patient is infected with HIV, d) treatment was not taken as instructed, or
e) the H. ducreyi  strain causing infection is resistant to the prescribed antimicrobial.
The time required for complete healing is related to the size of the ulcer; large ulcers
may require ≥2 weeks. Clinical resolution of fluctuant lymphadenopathy is slower than
that of ulcers and may require needle aspiration through adjacent intact skin—even
during successful therapy.
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Management of Sex Partners
Persons who had sexual contact with a patient who has chancroid within the 10
days before onset of the patient’s symptoms should be examined and treated. The
examination and treatment should be administered even in the absence of symptoms.
Special Considerations
Pregnancy
The safety of azithromycin for pregnant and lactating women has not been estab-
lished. Ciprofloxacin is contraindicated during pregnancy. No adverse effects of
chancroid on pregnancy outcome or on the fetus have been reported.
HIV Infection
Patients coinfected with HIV should be closely monitored. These patients may re-
quire courses of therapy longer than those recommended in this report. Healing may
be slower among HIV-infected persons and treatment failures do occur, especially af-
ter shorter-course treatment regimens. Since data on therapeutic efficacy with the
recommended ceftriaxone and azithromycin regimens among patients infected with
HIV are limited, those regimens should be used among persons known to be infected
with HIV only if follow-up can be assured. Some experts suggest using the erythromy-
cin 7-day regimen for treating HIV-infected persons.
Genital Herpes Simplex Virus Infections
Genital herpes is a viral disease that may be recurrent and has no cure. Two sero-
types of HSV have been identified: HSV-1 and HSV-2; most cases of genital herpes are
caused by HSV-2. On the basis of serologic studies, approximately 30 million persons
in the United States may have genital HSV infection.
Most infected persons never recognize signs suggestive of genital herpes; some
will have symptoms shortly after infection and then never again. A minority of the
total infected U.S. population will have recurrent episodes of genital lesions. Some
cases of first clinical episode genital herpes are manifested by extensive disease that
requires hospitalization. Many cases of genital herpes are acquired from persons who
do not know that they have a genital infection with HSV or who were asymptomatic at
the time of the sexual contact.
Randomized trials show that systemic acyclovir provides partial control of the
symptoms and signs of herpes episodes when used to treat first clinical episodes, or
when used as suppressive therapy. However, acyclovir neither eradicates latent virus
nor affects subsequent risk, frequency, or severity of recurrences after administration
of the drug is discontinued. Topical therapy with acyclovir is substantially less effec-
tive than the oral drug and its use is discouraged. Episodes of HSV infection among
HIV-infected patients may require more aggressive therapy. Immunocompromised
persons may have prolonged episodes with extensive disease. For these persons, in-
fections caused by acyclovir-resistant strains require selection of alternate antiviral
agents. 
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First Clinical Episode of Genital Herpes
Recommended Regimen
Acyclovir 200 mg orally 5 times a day for 7–10 days or until
clinical resolution is attained.
First Clinical Episode of Herpes Proctitis
Recommended Regimen
Acyclovir 400 mg orally 5 times a day for 10 days or until clini-
cal resolution is attained.
Recurrent Episodes
When treatment is instituted during the prodrome or within 2 days of onset of le-
sions, some patients with recurrent disease experience limited benefit from therapy.
However, since early treatment can seldom be administered, most immunocompetent
patients with recurrent disease do not benefit from acyclovir treatment, and it is not
generally recommended. 
Recommended Regimen
Acyclovir 200 mg orally 5 times a day for 5 days,
or
Acyclovir 400 mg orally 3 times a day for 5 days,
or
Acyclovir 800 mg orally 2 times a day for 5 days.
Daily Suppressive Therapy
Daily suppressive therapy reduces the frequency of HSV recurrences by at least
75% among patients with frequent recurrences (i.e., six or more recurrences per year).
Suppressive treatment with oral acyclovir does not totally eliminate symptomatic or
asymptomatic viral shedding or the potential for transmission. Safety and efficacy
have been documented among persons receiving daily therapy for as long as 5 years.
Acyclovir-resistant strains of HSV have been isolated from some persons receiving
suppressive therapy, but these strains have not been associated with treatment failure
among immunocompetent patients. After 1 year of continuous suppressive therapy,
acyclovir should be discontinued to allow assessment of the patient’s rate of recurrent
episodes.
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Recommended Regimen
Acyclovir 400 mg orally 2 times a day.
Alternative Regimen
Acyclovir 200 mg orally 3–5 times a day.
The goal of the alternative regimen is to identify for each patient the lowest dose
that provides relief from frequently recurring symptoms.
Severe Disease
Intravenous (IV) therapy should be provided for patients with severe disease or
complications necessitating hospitalization (e.g., disseminated infection that includes
encephalitis, pneumonitis, or hepatitis).
Recommended Regimen
Acyclovir 5–10 mg/kg body weight IV every 8 hours for
5–7 days or until clinical resolution is attained.
Other Management Considerations
Other considerations for managing patients with genital HSV infection are as fol-
lows:
• Patients should be advised to abstain from sexual activity while lesions are pre-
sent. 
• Patients with genital herpes should be told about the natural history of the dis-
ease, with emphasis on the potential for recurrent episodes, asymptomatic viral
shedding,  and sexual transmission. Sexual transmission of HSV has been docu-
mented to occur during periods without evidence of lesions. Many cases are
transmitted during such asymptomatic periods.
The use of condoms should be encouraged during all sexual exposures. The risk for
neonatal infection should be explained to all patients—male and female—with genital
herpes. Women of childbearing age who have genital herpes should be advised to
inform health-care providers who care for them during pregnancy about their HSV
infection.
Management of Sex Partners
Sex partners of patients who have genital herpes are likely to benefit from evalu-
ation and counseling. Symptomatic sex partners should be managed in the same
manner as any patient with genital lesions. However, the majority of persons with
genital HSV infection do not have a history of typical genital lesions. These asympto-
matic persons may benefit from evaluation and counseling; thus, even asymptomatic
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partners should be queried about histories of typical and atypical genital lesions and
encouraged to examine themselves for lesions in the future.
Commercially available HSV type-specific antibody tests have not demonstrated
adequate performance characteristics; their use is not currently recommended. Sensi-
tive and specific type-specific serum antibody assays now utilized in research settings
might contribute to future intervention strategies. Should tests with adequate sensi-
tivity and specificity become commercially available, it might be possible to accurately
identify asymptomatic persons infected with HSV-2, to focus counseling on how to
detect lesions by self-examination, and to reduce the risk for transmission to sex part-
ners.
Special Considerations
Allergy, Intolerance, or Adverse Reactions
Effective alternatives to therapy with acyclovir are not available.
HIV Infection
Lesions caused by HSV are relatively common among patients infected with HIV.
Intermittent or suppressive therapy with oral acyclovir may be needed.
The acyclovir dosage for HIV-infected persons is controversial, but experience
strongly suggests that immunocompromised patients benefit from increased dosage.
Regimens such as 400 mg orally 3 to 5 times a day, as used for other immunocom-
promised persons, have been found useful. Therapy should be continued until clinical
resolution is attained.
For severe disease, IV acyclovir therapy may be required. If lesions persist among
patients undergoing acyclovir treatment, resistance to acyclovir should be suspected.
These patients should be managed in consultation with an expert. For severe disease
because of proven or suspected acyclovir-resistant strains, hospitalization should be
considered. Foscarnet, 40 mg/kg body weight IV every 8 hours until clinical resolution
is attained, appears to be the best available treatment.
Pregnancy
The safety of systemic acyclovir therapy among pregnant women has not been
established. Burroughs Wellcome Co., in cooperation with CDC, maintains a registry
to assess the effects of the use of acyclovir during pregnancy. Women who receive
acyclovir during pregnancy should be reported to this registry (1-800-722-9292, ext.
58465).
Current registry findings do not indicate an increase in the number of birth defects
identified among the prospective reports when compared with those expected in the
general population. Moreover, no consistent pattern of abnormalities emerges among
retrospective reports. These findings provide some assurance in counseling women
who have had inadvertent prenatal exposure to acyclovir. However, accumulated case
histories comprise a sample of insufficient size for reaching reliable and definitive con-
clusions regarding the risks of acyclovir treatment to pregnant women and to their
fetuses.
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In the presence of life-threatening maternal HSV infection (e.g., disseminated infec-
tion that includes encephalitis, pneumonitis, or hepatitis), acyclovir administered IV is
indicated. Among pregnant women without life-threatening disease, systemic
acyclovir should not be used to treat recurrences nor should it be used as suppressive
therapy near-term (or at other times during pregnancy) to prevent reactivation.
Perinatal Infections
Most mothers of infants who acquire neonatal herpes lack histories of clinically
evident genital herpes. The risk for transmission to the neonate from an infected
mother appears highest among women with first episode genital herpes near the time
of delivery, and is low (≤3%) among women with recurrent herpes. The results of viral
cultures during pregnancy do not predict viral shedding at the time of delivery, and
such cultures are not routinely indicated.
At the onset of labor, all women should be carefully questioned about symptoms of
genital herpes and should be examined. Women without symptoms or signs of genital
herpes infection (or prodrome) may deliver their babies vaginally. Among women
who have a history of genital herpes, or who have a sex partner with genital herpes,
cultures of the birth canal at delivery may aid in decisions relating to neonatal man-
agement.
Infants delivered through an infected birth canal (proven by virus isolation or pre-
sumed by observation of lesions) should be followed carefully, including virus
cultures obtained 24–48 hours after birth. Available data do not support the routine
use of acyclovir as anticipatory treatment for asymptomatic infants delivered through
an infected birth canal. Treatment should be reserved for infants who develop evi-
dence of clinical disease and for those with positive postpartum cultures.
All infants with evidence of neonatal herpes should be treated with systemic acy-
clovir or vidarabine; refer to the Report of the Committee on Infectious Diseases,
American Academy of Pediatrics (13 ). For ease of administration and to lower toxicity,
acyclovir (30 mg/kg/day for 10-–14 days) is the preferred drug. The care of these in-
fants should be managed in consultation with an expert.
Lymphogranuloma Venereum
Lymphogranuloma venereum (LGV), a rare disease in the United States, is caused
by serovars L1, L2, or L3 of C. trachomatis. The most common clinical manifestation of
LGV among heterosexuals is tender inguinal lymphadenopathy that is most com-
monly unilateral. Women and homosexually active men may have proctocolitis or
inflammatory involvement of perirectal or perianal lymphatic tissues resulting in fistu-
las and strictures. When patients seek care, most no longer have the self-limited
genital ulcer that sometimes occurs at the site of inoculation. The diagnosis is usually
made serologically and by exclusion of other causes of inguinal lymphadenopathy or
genital ulcers. 
Treatment
Treatment cures infection and prevents ongoing tissue damage, although tissue
reaction can result in scarring. Buboes may require aspiration or incision and drainage
through intact skin. Doxycycline is the preferred treatment.
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Recommended Regimen
Doxycycline 100 mg orally 2 times a day for 21 days.
Alternative Regimens
Erythromycin 500 mg orally 4 times a day for 21 days
or
Sulfisoxazole 500 mg orally 4 times a day for 21 days or
equivalent sulfonamide course.
Follow-Up
Patients should be followed clinically until signs and symptoms have resolved.
Management of Sex Partners
Persons who have had sexual contact with a patient who has LGV within the 30
days before onset of the patient’s symptoms should be examined, tested for urethral
or cervical chlamydial infection, and treated.
Special Considerations
Pregnancy
Pregnant and lactating women should be treated with the erythromycin regimen.
HIV infection
Persons with HIV infection and LGV should be treated following the regimens pre-
viously cited.
Syphilis
General Principles
Background
Syphilis is a systemic disease caused by T. pallidum. Patients with syphilis may
seek treatment for signs or symptoms of primary infection (ulcer or chancre at site of
infection), secondary infection (manifestations that include rash, mucocutaneous le-
sions, and adenopathy), or tertiary infection (cardiac, neurologic, ophthalmic,
auditory, or gummatous lesions). Infections also may be detected during the latent
stage by serologic testing. Patients with latent syphilis who are known to have been
infected within the preceding year are considered to have early latent syphilis; others
have late latent syphilis or syphilis of unknown duration. Theoretically, treatment for
late latent syphilis (as well as tertiary syphilis) requires therapy of longer duration
because organisms are dividing more slowly; however, the validity of this division and
its timing are unproven.
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Diagnostic Considerations and Use of Serologic Tests
Darkfield examinations and direct fluorescent antibody tests of lesion exudate or
tissue are the definitive methods for diagnosing early syphilis. Presumptive diagnosis
is possible with the use of two types of serologic tests for syphilis: a) nontreponemal
(e.g., Venereal Disease Research Laboratory [VDRL] and RPR, and b) treponemal (e.g.,
fluorescent treponemal antibody absorbed [FTA-ABS] and microhemagglutination as-
say for antibody to T. pallidum  [MHA-TP]). The use of one type of test alone is not
sufficient for diagnosis. Nontreponemal test antibody titers usually correlate with dis-
ease activity, and results should be reported quantitatively. A fourfold change in titer,
equivalent to a change of two dilutions (e.g., from 1:16 to 1:4, or from 1:8 to 1:32), is
necessary to demonstrate a substantial difference between two nontreponemal test
results that were obtained using the same serologic test. A patient who has a reactive
treponemal test usually will have a reactive test for a lifetime, regardless of treatment
or disease activity (15%–25% of patients treated during the primary stage may revert
to being serologically nonreactive after 2–3 years). Treponemal test antibody titers
correlate poorly with disease activity and should not be used to assess response to
treatment.
Sequential serologic tests should be performed using the same testing method
(e.g., VDRL or RPR) by the same laboratory. The VDRL and RPR are equally valid, but
quantitative results from the two tests cannot be directly compared because RPR titers
are often slightly higher than VDRL titers.
Abnormal results of serologic testing (unusually high, unusually low, and fluctuat-
ing titers) have been observed among HIV-infected patients. For such patients, use of
other tests (e.g., biopsy and direct microscopy) should be considered. However, sero-
logic tests appear to be accurate and reliable for the diagnosis of syphilis and for
evaluation of treatment response for the vast majority of HIV-infected patients.
No single test can be used to diagnose neurosyphilis among all patients. The diag-
nosis of neurosyphilis can be made based on various combinations of reactive
serologic test results, abnormalities of cerebrospinal fluid (CSF) cell count or protein,
or a reactive VDRL-CSF (RPR is not performed on CSF) with or without clinical mani-
festations. The CSF leukocyte count is usually elevated (>5 WBC/mm3) when active
neurosyphilis is present, and it is also a sensitive measure of the effectiveness of ther-
apy. The VDRL-CSF is the standard serologic test for CSF; when reactive in the
absence of substantial contamination of the CSF with blood, it is considered diagnos-
tic of neurosyphilis. However, the VDRL-CSF may be nonreactive when neurosyphilis
is present. Some experts recommend performing an FTA-ABS test on CSF. The CSF
FTA-ABS is less specific (i.e., yields more false positives) for neurosyphilis than the
VDRL-CSF; however, the test is believed to be highly sensitive. 
Treatment
Parenteral penicillin G is the preferred drug for treatment of all stages of syphilis.
The preparation(s) used (i.e., benzathine, aqueous procaine, or aqueous crystalline),
the dosage, and the length of treatment depend on the stage and clinical manifesta-
tions of disease.
The efficacy of penicillin for the treatment of syphilis was well established through
clinical experience before the value of randomized controlled clinical trials was recog-
nized. Therefore, nearly all the recommendations for the treatment of syphilis are
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based on expert opinion reinforced by case series, open clinical trials, and 50 years of
clinical experience.
Parenteral penicillin G is the only therapy with documented efficacy for neuro-
syphilis or for syphilis during pregnancy. Patients with neurosyphilis and pregnant
women with syphilis in any stage who report penicillin allergy should almost always
be treated with penicillin, after desensitization, if necessary. Skin testing for penicillin
allergy may be useful for some patients and in some settings (see Management of the
Patient With a History of Penicillin Allergy). However, minor determinants needed for
penicillin skin testing are not available commercially.
The Jarisch-Herxheimer reaction is an acute febrile reaction—accompanied by
headache, myalgia, and other symptoms—that may occur within the first 24 hours
after any therapy for syphilis; patients should be advised of this possible adverse re-
action. The Jarisch-Herxheimer reaction is common among patients with early
syphilis. Antipyretics may be recommended, but there are no proven methods for pre-
venting this reaction. The Jarisch-Herxheimer reaction may induce early labor or
cause fetal distress among pregnant women. This concern should not prevent or de-
lay therapy (see Syphilis During Pregnancy).
Management of Sex Partners
Sexual transmission of T. pallidum  occurs only when mucocutaneous syphilitic le-
sions are present; such manifestations are uncommon after the first year of infection.
However, persons sexually exposed to a patient with syphilis in any stage should be
evaluated clinically and serologically according to the following recommendations:
• Persons who were exposed to a patient with primary, secondary, or latent (dura-
tion <1 year) syphilis within the preceding 90 days might be infected even if
seronegative, and therefore should be treated presumptively.
• Persons who were sexually exposed to a patient with primary, secondary, or la-
tent (duration <1 year) syphilis >90 days before examination should be treated
presumptively if serologic test results are not available immediately, and the op-
portunity for follow-up is uncertain.
• For purposes of partner notification and presumptive treatment of exposed sex
partners, patients who have syphilis of unknown duration and who have high
nontreponemal serologic test titers (≥1:32) may be considered to be infected with
early syphilis.
• Long-term sex partners of patients with late syphilis should be evaluated clini-
cally and serologically for syphilis.
The time periods before treatment used for identifying at-risk sex partners are
3 months plus duration of symptoms for primary syphilis, 6 months plus duration of
symptoms for secondary syphilis, and 1 year for early latent syphilis.
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Primary and Secondary Syphilis
Treatment
Four decades of experience indicate that parenteral penicillin G is effective in
achieving local cure (healing of lesions and prevention of sexual transmission) and in
preventing late sequelae. However, no adequately conducted comparative trials have
been performed to guide the selection of an optimal penicillin regimen (i.e., dose, du-
ration, and preparation). Substantially fewer data on nonpenicillin regimens are
available.
Recommended Regimen for Adults
Nonallergic patients with primary or secondary syphilis should be treated with the
following regimen:
Benzathine penicillin G, 2.4 million units IM in a single dose.
NOTE: Recommendations for treating pregnant women and HIV-infected persons for
syphilis are discussed in separate sections.
Recommended Regimen for Children
After the newborn period, children diagnosed with syphilis should have a CSF ex-
amination to exclude a diagnosis of neurosyphilis, and birth and maternal medical
records should be reviewed to assess whether the child has congenital or acquired
syphilis (see Congenital Syphilis). Children with acquired primary or secondary syphi-
lis should be evaluated (including consultation with child-protection services) and
treated using the following pediatric regimen (see Sexual Assault or Abuse of Chil-
dren).
Benzathine penicillin G, 50,000 units/kg IM, up to the adult dose
of 2.4 million units in a single dose.
Other Management Considerations
All patients with syphilis should be tested for HIV. In areas with high HIV preva-
lence, patients with primary syphilis should be retested for HIV after 3 months.
Patients who have syphilis and who also have symptoms or signs suggesting
neurologic disease (e.g., meningitis) or ophthalmic disease (e.g., uveitis) should be
fully evaluated for neurosyphilis and syphilitic eye disease (including CSF analysis
and ocular slit-lamp examination). Such patients should be treated appropriately ac-
cording to the results of this evaluation.
Invasion of CSF by T. pallidum  with accompanying CSF abnormalities is common
among adults who have primary or secondary syphilis. However, few patients develop
neurosyphilis after treatment with the regimens described in this report. Therefore,
unless clinical signs or symptoms of neurologic involvement are present (e.g., audi-
tory, cranial nerve, meningeal, or ophthalmic manifestations), lumbar puncture is not
recommended for routine evaluation of patients with primary or secondary syphilis.
30 MMWR September 24, 1993
Follow-Up
Treatment failures can occur with any regimen. However, assessing response to
treatment is often difficult, and no definitive criteria for cure or failure exist. Serologic
test titers may decline more slowly among patients with a prior syphilis infection. Pa-
tients should be re-examined clinically and serologically at 3 months and again at
6 months.
Patients with signs or symptoms that persist or recur or who have a sustained four-
fold increase in nontreponemal test titer compared with either the baseline titer or to
a subsequent result, can be considered to have failed treatment or to be reinfected.
These patients should be re-treated after evaluation for HIV infection. Unless reinfec-
tion is likely, lumbar puncture also should be performed.
Failure of nontreponemal test titers to decline fourfold by 3 months after therapy
for primary or secondary syphilis identifies persons at risk for treatment failure. Those
persons should be evaluated for HIV infection. Optimal management of such patients
is unclear if they are HIV negative. At a minimum, these patients should have addi-
tional clinical and serologic follow-up. If further follow-up cannot be assured,
re-treatment is recommended. Some experts recommend CSF examination in such
situations.
When patients are re-treated, most experts recommend re-treatment with three
weekly injections of benzathine penicillin G 2.4 million units IM, unless CSF examina-
tion indicates that neurosyphilis is present.
Management of Sex Partners
Refer to General Principles, Management of Sex Partners.
Special Considerations
Penicillin Allergy
Nonpregnant penicillin-allergic patients who have primary or secondary syphilis
should be treated with the following regimen.
Doxycycline 100 mg orally 2 times a day for 2 weeks
or
Tetracycline 500 mg orally 4 times a day for 2 weeks.
There is less clinical experience with doxycycline than with tetracycline, but com-
pliance is likely to be better with doxycycline. Therapy for a patient who cannot
tolerate either doxycycline or tetracycline should be based upon whether the patient’s
compliance with the therapy regimen and with follow-up examinations can be as-
sured.
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For nonpregnant patients whose compliance with therapy and follow-up can be
assured, an alternative regimen is erythromycin 500 mg orally 4 times a day for 2
weeks. Various ceftriaxone regimens also may be considered.
Patients whose compliance with therapy or follow-up cannot be assured should be
desensitized, if necessary, and treated with penicillin. Skin testing for penicillin allergy
may be useful in some situations (see Management of the Patient With a History of
Penicillin Allergy).
Erythromycin is less effective than other recommended regimens. Data on ceftriax-
one are limited, and experience has been too brief to permit identification of late
failures. Optimal dose and duration have not been established for ceftriaxone, but
regimens that provide 8–10 days of treponemicidal levels in the blood should be used.
Single dose ceftriaxone therapy is not effective for treating syphilis.
Pregnancy
Pregnant patients who are allergic to penicillin should be treated with penicillin,
after desensitization, if necessary (see Management of the Patient With a History of
Penicillin Allergy and Syphilis During Pregnancy).
HIV Infection
Refer to Syphilis Among HIV-Infected Patients.
Latent Syphilis
Latent syphilis is defined as those periods after infection with T. pallidum  when
patients are seroreactive, but show no other evidence of disease. Patients who have
latent syphilis and who have acquired syphilis within the preceding year are classified
as having early latent syphilis. Patients can be demonstrated to have acquired syphilis
within the preceding year on the basis of documented seroconversion, a fourfold or
greater increase in titer of a nontreponemal serologic test, history of symptoms of
primary or secondary syphilis, or if they had a sex partner with primary, secondary, or
latent syphilis (documented independently as duration <1 year). Nearly all others have
latent syphilis of unknown duration and should be managed as if they had late latent
syphilis.
Treatment
Treatment of latent syphilis is intended to prevent occurrence or progression of late
complications. Although clinical experience supports belief in the effectiveness of
penicillin in achieving those goals, limited evidence is available for guidance in choos-
ing specific regimens. There is very little evidence to support the use of nonpenicillin
regimens.
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Recommended Regimens for Adults
These regimens are for nonallergic patients with normal CSF examination (if per-
formed).
Early Latent Syphilis
Benzathine penicillin G, 2.4 million units IM in a single dose.
Late Latent Syphilis or Latent Syphilis of Unknown Duration
Benzathine penicillin G, 7.2 million units total, administered as
3 doses of 2.4 million units IM each, at 1-week intervals.
Recommended Regimens for Children
After the newborn period, children diagnosed with syphilis should have a CSF ex-
amination to exclude neurosyphilis, and birth and maternal medical records should be
reviewed to assess whether the child has congenital or acquired syphilis (see Con-
genital Syphilis). Older children with acquired latent syphilis should be evaluated as
described for adults and treated using the following pediatric regimens (see Sexual
Assault or Abuse of Children). These regimens are for nonallergic children who have
acquired syphilis and who have had a normal CSF examination.
Early Latent Syphilis
Benzathine penicillin G, 50,000 units/kg IM, up to the adult dose
of 2.4 million units in a single dose.
Late Latent Syphilis or Latent Syphilis of Unknown Duration
Benzathine penicillin G, 50,000 units/kg IM, up to the adult dose
of 2.4 million units, for three total doses (total 150,000 units/kg
up to adult total dose of 7.2 million units).
Other Management Considerations
All patients with latent syphilis should be evaluated clinically for evidence of terti-
ary disease (e.g., aortitis, neurosyphilis, gumma, and iritis). Recommended therapy
for patients with latent syphilis may not be optimal therapy for the persons with as-
ymptomatic neurosyphilis. However, the yield from CSF examination, in terms of
newly diagnosed cases of neurosyphilis, is low.
Patients with any one of the criteria listed below should have a CSF examination
before treatment:
• Neurologic or ophthalmic signs or symptoms;
• Other evidence of active syphilis (e.g., aortitis, gumma, iritis);
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• Treatment failure;
• HIV infection;
• Serum nontreponemal titer ≥1:32, unless duration of infection is known to be
<1 year; or
• Nonpenicillin therapy planned, unless duration of infection is known to be
<1 year.
If dictated by circumstances and patient preferences, CSF examination may be per-
formed for persons who do not meet the criteria listed above. If a CSF examination is
performed and the results show abnormalities consistent with CNS syphilis, the pa-
tient should be treated for neurosyphilis (see Neurosyphilis). 
• All syphilis patients should be tested for HIV.
Follow-Up
Quantitative nontreponemal serologic tests should be repeated at 6 months and
again at 12 months. Limited data are available to guide evaluation of the response to
therapy for a patient with latent syphilis. If titers increase fourfold, or if an initially high
titer (≥1:32) fails to decline at least fourfold (two dilutions) within 12–24 months, or if
the patient develops signs or symptoms attributable to syphilis, the patient should be
evaluated for neurosyphilis and re-treated appropriately.
Management of Sex Partners
Refer to General Principles, Management of Sex Partners.
Special Considerations
Penicillin Allergy
For patients who have latent syphilis and who are allergic to penicillin, non-
penicillin therapy should be used only after CSF examination has excluded
neurosyphilis. Nonpregnant, penicillin-allergic patients should be treated with the fol-
lowing regimens.
Doxycycline 100 mg orally 2 times a day
or
Tetracycline 500 mg orally 4 times a day.
Both drugs are administered for 2 weeks if duration of infection is known to have
been <1 year; otherwise, for 4 weeks.
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Pregnancy
Pregnant patients who are allergic to penicillin should be treated with penicillin,
after desensitization, if necessary (see Management of the Patient With a History of
Penicillin Allergy and Syphilis During Pregnancy).
HIV Infection
Refer to Syphilis Among HIV-Infected Patients.
Late Syphilis
Late (tertiary) syphilis refers to patients with gumma and patients with cardiovas-
cular syphilis, but not to neurosyphilis. Nonallergic patients without evidence of
neurosyphilis should be treated with the following regimen.
Recommended Regimen
Benzathine penicillin G, 7.2 million units total, administered as
3 doses of 2.4 million units IM, at 1-week intervals.
Other Management Considerations
Patients with symptomatic late syphilis should undergo CSF examination before
therapy. Some experts treat all patients who have cardiovascular syphilis with a
neurosyphilis regimen. The complete management of patients with cardiovascular or
gummatous syphilis is beyond the scope of these guidelines. These patients should
be managed in consultation with experts.
Follow-Up
There is minimal evidence regarding follow-up of patients infected with late syphi-
lis. Clinical response depends partly on the nature of the lesions.
Management of Sex Partners
Refer to General Principles, Management of Sex Partners.
Special Considerations
Penicillin Allergy
Patients allergic to penicillin should be treated according to treatment regimens
recommended for late latent syphilis.
Pregnancy
Pregnant patients who are allergic to penicillin should be treated with penicillin,
after desensitization, if necessary (see Management of the Patient With a History of
Penicillin Allergy and Syphilis During Pregnancy).
HIV Infection
Refer to Syphilis Among HIV-Infected Patients.
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Neurosyphilis
Treatment
Central nervous system disease can occur during any stage of syphilis. A patient
with clinical evidence of neurologic involvement (e.g., ophthalmic or auditory symp-
toms, cranial nerve palsies) with syphilis warrants a CSF examination. Although four
decades of experience have confirmed the effectiveness of penicillin, the evidence to
guide the choice of the best regimen is limited.
Syphilitic eye disease is frequently associated with neurosyphilis, and patients with
this disease should be treated according to neurosyphilis treatment recommenda-
tions. CSF examination should be performed on all such patients to identify those
patients with CSF abnormalities who should have follow-up CSF examinations to as-
sess response to treatment.
Patients who have neurosyphilis or syphilitic eye disease (e.g., uveitis, neuroretini-
tis, or optic neuritis) and who are not allergic to penicillin should be treated with the
following regimen.
Recommended Regimen
12–24 million units aqueous crystalline penicillin G daily, ad-
ministered as 2–4 million units IV every 4 hours, for 10–14 days.
If compliance with therapy can be assured, patients may be treated with the follow-
ing alternative regimen.
Alternative Regimen
2.4 million units procaine penicillin IM daily, plus probenecid
500 mg orally 4 times a day, both for 10–14 days.
The durations of these regimens are shorter than that of the regimen used for late
syphilis in the absence of neurosyphilis. Therefore, some experts administer ben-
zathine penicillin, 2.4 million units IM after completion of these neurosyphilis
treatment regimens to provide a comparable total duration of therapy.
Other Management Considerations
Other considerations in the management of the patient with neurosyphilis are the
following:
• All patients with syphilis should be tested for HIV. 
• Many experts recommend treating patients with evidence of auditory disease
caused by syphilis in the same manner as for neurosyphilis, regardless of the
findings on CSF examination.
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Follow-Up
If CSF pleocytosis was present initially, CSF examination should be repeated every
6 months until the cell count is normal. Follow-up CSF examinations also may be used
to evaluate changes in the VDRL-CSF or CSF protein in response to therapy, though
changes in these two parameters are slower and persistent abnormalities are of less
certain importance. If the cell count has not decreased at 6 months, or if the CSF is not
entirely normal by 2 years, re-treatment should be considered.
Management of Sex Partners
Refer to General Principles, Management of Sex Partners.
Special Considerations
Penicillin Allergy
No data have been collected systematically for evaluation of therapeutic alterna-
tives to penicillin for treatment of neurosyphilis. Therefore, patients who report being
allergic to penicillin should be treated with penicillin, after desensitization if necessary,
or should be managed in consultation with an expert. In some situations, skin testing
to confirm penicillin allergy may be useful (see Management of the Patient With a
History of Penicillin Allergy).
Pregnancy
Pregnant patients who are allergic to penicillin should be treated with penicillin,
after desensitization if necessary (see Syphilis During Pregnancy).
HIV Infection
Refer to Syphilis Among HIV-Infected Patients.
Syphilis Among HIV-Infected Patients
Diagnostic Considerations
Unusual serologic responses have been observed among HIV-infected persons
who also have syphilis. Most reports involved serologic titers that were higher than
expected, but false-negative serologic test results or delayed appearance of seroreac-
tivity have also been reported. Nevertheless, both treponemal and nontreponemal
serologic tests for syphilis are accurate for the majority of patients with syphilis and
HIV coinfection.
When clinical findings suggest that syphilis is present, but serologic tests are non-
reactive or confusing, it may be helpful to perform such alternative tests as biopsy of
a lesion, darkfield examination, or direct fluorescent antibody staining of lesion mate-
rial. 
Neurosyphilis should be considered in the differential diagnosis of neurologic dis-
ease among HIV-infected persons.
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Treatment
Although adequate research-based evidence is not available, published case re-
ports and expert opinion suggest that HIV-infected patients with early syphilis are at
increased risk for neurologic complications and have higher rates of treatment failure
with currently recommended regimens. The magnitude of these risks, although not
precisely defined, is probably small. No treatment regimens have been demonstrated
to be more effective in preventing development of neurosyphilis than those recom-
mended for patients without HIV infection. Careful follow-up after therapy is essential.
Primary and Secondary Syphilis Among HIV-Infected Patients
Treatment
Treatment with benzathine penicillin G 2.4 million units IM, as for patients without
HIV infection, is recommended. Some experts recommend additional treatments,
such as multiple doses of benzathine penicillin G as suggested for late syphilis, or
other supplemental antibiotics in addition to benzathine penicillin G 2.4 million units
IM.
Other Management Considerations
CSF abnormalities are common among HIV-infected patients who have primary or
secondary syphilis, but these abnormalities are of unknown prognostic significance.
Most HIV-infected patients respond appropriately to currently recommended penicillin
therapy; however, some experts recommend CSF examination before therapy and
modification of treatment accordingly.
Follow-Up
Patients should be evaluated clinically and serologically for treatment failure at
1 month and at 2, 3, 6, 9, and 12 months after therapy. Although of unproven benefit,
some experts recommend performing CSF examination after therapy (i.e., at
6 months).
HIV-infected patients who meet the criteria for treatment failure should undergo
CSF examination and be retreated just as for patients without HIV infection. CSF ex-
amination and re-treatment also should be strongly considered for patients in whom
the suggested fourfold decrease in nontreponemal test titer does not occur within
3 months for primary or secondary syphilis. Most experts would re-treat patients with
benzathine penicillin G 7.2 million units (as 3 weekly doses of 2.4 million units each) if
the CSF examination is normal.
Special Considerations
Penicillin Allergy
Penicillin regimens should be used to treat HIV-infected patients in all stages of
syphilis. Skin testing to confirm penicillin allergy may be used (see Management of
the Patient With a History of Penicillin Allergy), but data on the utility of that approach
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among immunocompromised patients are inadequate. Patients may be desensitized,
then treated with penicillin.
Latent Syphilis Among HIV-Infected Patients
Diagnostic Considerations
Patients who have both latent syphilis (regardless of apparent duration) and HIV
infection should undergo CSF examination before treatment.
Treatment
A patient with latent syphilis, HIV infection, and a normal CSF examination can be
treated with benzathine penicillin G 7.2 million units (as 3 weekly doses of 2.4 million
units each).
Special Considerations
Penicillin Allergy
Penicillin regimens should be used to treat all stages of syphilis among HIV-
infected patients. Skin testing to confirm penicillin allergy may be used (see Manage-
ment of the Patient With a History of Penicillin Allergy), but data on the utility of that
approach in immunocompromised patients are inadequate. Patients may be desensi-
tized, then treated with penicillin.
Syphilis During Pregnancy
All women should be screened serologically for syphilis during the early stages of
pregnancy. In populations in which utilization of prenatal care is not optimal, RPR-card
test screening and treatment, if that test is reactive, should be performed at the time a
pregnancy is diagnosed. In communities and populations with high syphilis preva-
lence or for patients at high risk, serologic testing should be repeated during the third
trimester and again at delivery. (Some states mandate screening at delivery for all
women.) Any woman who delivers a stillborn infant after 20 weeks gestation should
be tested for syphilis. No infant should leave the hospital without the serologic status
of the infant’s mother having been determined at least once during pregnancy.
Diagnostic Considerations
Seropositive pregnant women should be considered infected unless treatment his-
tory is clearly documented in a medical or health department record and sequential
serologic antibody titers have appropriately declined.
Treatment
Penicillin is effective for preventing transmission to fetuses and for treating estab-
lished infection among fetuses. Evidence is insufficient, however, to determine
whether the specific, recommended penicillin regimens are optimal. 
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Recommended Regimens
Treatment during pregnancy should be the penicillin regimen
appropriate for the woman’s stage of syphilis. Some experts
recommend additional therapy (e.g., a second dose of ben-
zathine penicillin 2.4 million units IM) 1 week after the initial
dose, particularly for those women in the third trimester of
pregnancy and for women who have secondary syphilis during
pregnancy.
Other Management Considerations
Women who are treated for syphilis during the second half of pregnancy are at risk
for premature labor or fetal distress, or both, if their treatment precipitates the Jarisch-
Herxheimer reaction. These women should be advised to seek medical attention
following treatment if they notice any change in fetal movements or if they have con-
tractions. Stillbirth is a rare complication of treatment; however, since therapy is
necessary to prevent further fetal damage, that concern should not delay treatment.
All patients with syphilis should be tested for HIV.
Follow-Up
Serologic titers should be checked monthly until adequacy of treatment has been
assured. The antibody response should be appropriate for the stage of disease.
Management of Sex Partners
Refer to General Principles, Management of Sex Partners.
Special Considerations
Penicillin Allergy
There are no proven alternatives to penicillin. A pregnant woman with a history of
penicillin allergy should be treated with penicillin, after desensitization, if necessary.
Skin testing may be helpful for some patients and in some settings (see Management
of the Patient With a History of Penicillin Allergy).
Tetracycline and doxycycline are contraindicated during pregnancy. Erythromycin
should not be used because it cannot be relied upon to cure an infected fetus.
Congenital Syphilis
Diagnostic Considerations
Who Should Be Evaluated
Infants should be evaluated for congenital syphilis if they were born to seropositive
(nontreponemal test confirmed by treponemal test) women who meet the following
criteria:
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• Have untreated syphilis;* or
• Were treated for syphilis during pregnancy with erythromycin; or
• Were treated for syphilis <1 month before delivery; or
• Were treated for syphilis during pregnancy with the appropriate penicillin regi-
men, but nontreponemal antibody titers did not decrease sufficiently after
therapy to indicate an adequate response (≥ fourfold decrease); or
• Do not have a well-documented history of treatment for syphilis; or
• Were treated appropriately before pregnancy but had insufficient serologic fol-
low-up to assure that they had responded appropriately to treatment and are not
currently infected (≥ fourfold decrease for patients treated for early syphilis; sta-
ble or declining titers ≤1:4 for other patients).
No infant should leave the hospital without the serologic status of the infant’s
mother having been documented at least once during pregnancy. Serologic testing
also should be performed at delivery in communities and populations at risk for con-
genital syphilis. Serologic tests can be nonreactive among infants infected late during
their mother’s pregnancy.
Evaluation of the Infant
The clinical and laboratory evaluation of infants born to women described above
should include the following:
• A thorough physical examination for evidence of congenital syphilis;
• A quantitative nontreponemal serologic test for syphilis performed on the in-
fant’s sera (not on cord blood);
• CSF analysis for cells, protein, and VDRL;
• Long bone x-rays;
• Other tests as clinically indicated (e.g., chest x-ray, complete blood count, differ-
ential and platelet count, liver function tests);
• For infants who have no evidence of congenital syphilis on the above evaluation,
determination of presence of specific antitreponemal IgM antibody by a testing
method recognized by CDC as having either provisional or standard status;
• Pathologic examination of the placenta or amniotic cord using specific fluores-
cent antitreponemal antibody staining.
*A woman treated with a regimen other than those recommended for treatment of syphilis (for
pregnant women or otherwise) in these guidelines should be considered untreated.
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Treatment
Therapy Decisions
Infants should be treated for presumed congenital syphilis if they were born to
mothers who, at delivery, had untreated syphilis or who had evidence of relapse or
reinfection after treatment (see Congenital Syphilis, Diagnostic Considerations). Addi-
tional criteria for presumptively treating infants with congenital syphilis are as
follows:
• Physical evidence of active disease;
• X-ray evidence of active disease;
• A reactive VDRL-CSF or, for infants born to seroreactive mothers, an abnormal*
CSF white blood cell count or protein, regardless of CSF serology;
• A serum quantitative nontreponemal serologic titer that is at least fourfold
greater than the mother’s titer†;
• Specific antitreponemal IgM antibody detected by a testing method that has
been given provisional or standard status by CDC;
• If they meet the previously cited criteria for “Who Should Be Evaluated,” but
have not been fully evaluated (see Congenital Syphilis, Diagnostic Considera-
tions).
NOTE: Infants with clinically evident congenital syphilis should have an ophthalmo-
logic examination.
Recommended Regimens
Aqueous crystalline penicillin G, 100,000–150,000 units/kg/day
(administered as 50,000 units/kg IV every 12 hours during the
first 7 days of life and every 8 hours thereafter) for 10–14 days,
or
Procaine penicillin G, 50,000 units/kg IM daily in a single dose
for 10–14 days.
If more than 1 day of therapy is missed, the entire course should be restarted. An
infant whose complete evaluation was normal and whose mother was a) treated for
syphilis during pregnancy with erythromycin, or b) treated for syphilis <1 month be-
fore delivery, or c) treated with an appropriate regimen before or during pregnancy
*In the immediate newborn period, interpretation of CSF test results may be difficult; normal
values vary with gestational age and are higher in preterm infants.  Other causes of elevated
values also should be considered when an infant is being evaluated for congenital syphilis.
Though values as high as 25 white blood cells(WBC)/mm3 and 150 mg protein/dL occur among
normal neonates, some experts recommend that lower values (5 WBC/mm3 and 40 mg/dL) be
considered the upper limits of normal.  The infant should be treated if test results cannot
exclude infection.
†The absence of a fourfold greater titer for an infant cannot be used as evidence against
congenital syphilis.
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but did not yet have an adequate serologic response should be treated with ben-
zathine penicillin G, 50,000 units/kg IM in a single dose. In some cases, infants with a
normal complete evaluation for whom follow-up can be assured can be followed
closely without treatment.
Treatment of Older Infants and Children with Congenital Syphilis
After the newborn period, children diagnosed with syphilis should have a CSF ex-
amination to exclude neurosyphilis and records should be reviewed to assess
whether the child has congenital or acquired syphilis (see Primary and Secondary
Syphilis and Latent Syphilis). Any child who is thought to have congenital syphilis (or
who has neurologic involvement) should be treated with aqueous crystalline penicillin
G, 200,000–300,000 units/kg/day IV or IM (administered as 50,000 units/kg every
4–6 hours) for 10–14 days.
Follow-Up
A seroreactive infant (or an infant whose mother was seroreactive at delivery) who
is not treated for congenital syphilis during the perinatal period should receive careful
follow-up examinations at 1 month and at 2, 3, 6, and 12 months after therapy. Nontre-
ponemal antibody titers should decline by 3 months of age and should be nonreactive
by 6 months of age if the infant was not infected and the titers were the result of
passive transfer of antibody from the mother. If these titers are found to be stable or
increasing, the child should be re-evaluated, including CSF examination, and fully
treated. Passively transferred treponemal antibodies may be present for as long as 1
year. If they are present >1 year, the infant should be re-evaluated and treated for con-
genital syphilis.
Treated infants also should be followed every 2–3 months to assure that nontre-
ponemal antibody titers decline; these infants should have become nonreactive by
6 months of age (response may be slower for infants treated after the neonatal pe-
riod). Treponemal tests should not be used to evaluate response to treatment because
test results can remain positive despite effective therapy if the child was infected. In-
fants with CSF pleocytosis should undergo CSF examination every 6 months, or until
the cell count is normal. If the cell count is still abnormal after 2 years, or if a down-
ward trend is not present at each examination, the child should be re-treated. The
VDRL-CSF also should be checked at 6 months; if still reactive, the infant should be
re-treated.
Follow-up of children treated for congenital syphilis after the newborn period
should be the same as that prescribed for congenital syphilis among neonates.
Special Considerations
Penicillin Allergy
Children who require treatment for syphilis after the newborn period, but who have
a history of penicillin allergy, should be treated with penicillin after desensitization, if
necessary. Skin testing may be helpful in some patients and settings (see Manage-
ment of the Patient With a History of Penicillin Allergy).
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HIV Infection
Mothers of infants with congenital syphilis should be tested for HIV. Infants born to
mothers who have HIV infection should be referred for evaluation and appropriate
follow-up.
No data exist to suggest that infants with congenital syphilis whose mothers are
coinfected with HIV require different evaluation, therapy, or follow-up for syphilis than
is recommended for all infants.
Management of the Patient With a
History of Penicillin Allergy
No proven alternatives to penicillin are available for treating neurosyphilis, con-
genital syphilis, or syphilis among pregnant women. Penicillin also is recommended
for use, whenever possible, with HIV-infected patients. Unfortunately, 3%–10% of the
adult population in the United States have experienced urticaria, angioedema, or ana-
phylaxis (upper airway obstruction, bronchospasm, or hypotension) with penicillin
therapy. Re-administration of penicillin can cause severe immediate reactions among
these patients. Because anaphylactic reactions to penicillin can be fatal, every effort
should be made to avoid administering penicillin to penicillin-allergic patients, unless
the anaphylactic sensitivity has been removed by acute desensitization.
However, only approximately 10% of persons who report a history of severe aller-
gic reactions to penicillin are still allergic. With the passage of time after an allergic
reaction to penicillin, most persons who have experienced a severe reaction stop ex-
pressing penicillin-specific IgE. These persons can be treated safely with penicillin.
Many studies have found that skin testing with the major and minor determinants can
reliably identify persons at high risk for penicillin reactions. Although these reagents
are easily generated and have been available in academic centers for >30 years, cur-
rently only penicilloyl-poly-L-lysine (Pre-Pen, the major determinant) and penicillin G
are available commercially. Experts estimate that testing with only the major determi-
nant and penicillin G detects 90%–97% of the currently allergic patients. However,
because skin testing without the minor determinants would still miss 3%–10% of aller-
gic patients, and serious or fatal reactions can occur among these minor determinant
positive patients, experts suggest caution when the full battery of skin test reagents
listed in the table is not available.
Recommendations
If the full battery of skin-test reagents is available, including the major and minor
determinants (see Penicillin Allergy Skin Testing), patients who report a history of
penicillin reaction and are skin-test negative can receive conventional penicillin ther-
apy. Skin-test positive patients should be desensitized.
If the full battery of skin-test reagents, including the minor determinants, is not
available, the patient should be skin tested using penicilloyl (the major determinant,
Pre-Pen) and penicillin G. Those with positive tests should be desensitized. Some ex-
perts believe that persons with negative tests, in that situation, should be regarded as
probably allergic and should be desensitized. Others suggest that those with negative
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skin tests can be test-dosed gradually with oral penicillin in a monitored setting in
which treatment for anaphylactic reaction is possible.
Penicillin Allergy Skin Testing
Patients at high risk for anaphylaxis (i.e., a history of penicillin-related anaphylaxis,
asthma or other diseases that would make anaphylaxis more dangerous, or therapy
with beta-adrenergic blocking agents) should be tested with 100-fold dilutions of the
full-strength skin-test reagents before testing with full-strength reagents. In these situ-
ations, patients should be tested in a monitored setting in which treatment for an
anaphylactic reaction is possible. If possible, the patient should not have taken antihis-
tamines (e.g., chlorpheniramine maleate or terfenadine during the past 24 hours,
diphenhydramine HCl or hydroxyzine during the past 4 days, or astemizole during the
past 3 weeks).
Reagents (Adapted from Beall [14 ])*
Major Determinant
• Benzylpenicilloyl poly-L-lysine (Pre-Pen [Taylor Pharmacal Company, Decatur, Il-
linois]) (6 x 10-5M).
Minor Determinant Precursors†
• Benzylpenicillin G (10-2M, 3.3 mg/mL, 6000 U/mL),
• Benzylpenicilloate (10-2M, 3.3 mg/mL),
• Benzylpenilloate (or penicilloyl propylamine)(10-2M, 3.3 mg/mL).
Positive Control
• Commercial histamine for epicutaneous skin testing (1 mg/mL).
Negative Control
• Diluent used to dissolve other reagents, usually phenol saline.
Procedures
Dilute the antigens 100-fold for preliminary testing if the patient has had a life-
threatening reaction, or 10-fold if the patient has had another type of immediate,
generalized reaction within the past year.
Epicutaneous (prick) tests. Duplicate drops of skin-test reagent are placed on the
volar surface of the forearm. The underlying epidermis is pierced with a 26-gauge
needle without drawing blood.
*Reprinted with permission from G.N. Beall in Annals of Internal Medicine.
†Aged penicillin is not an adequate source of minor determinants. Penicillin G should be freshly
prepared or should come from a fresh-frozen source.
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An epicutaneous test is positive if the average wheal diameter after 15 minutes is
4 mm larger than that of negative controls; otherwise, the test is negative. The hista-
mine controls should be positive to assure that results are not falsely negative
because of the effect of antihistaminic drugs.
Intradermal test. If epicutaneous tests are negative, duplicate 0.02 mL intradermal
injections of negative control and antigen solutions are made into the volar surface of
the forearm using a 26- or 27-gauge needle on a syringe. The crossed diameters of the
wheals induced by the injections should be recorded.
An intradermal test is positive if the average wheal diameter 15 minutes after injec-
tion is 2 mm or larger than the initial wheal size and also is at least 2 mm larger than
the negative controls. Otherwise, the tests are negative.
Desensitization
Patients who have a positive skin test to one of the penicillin determinants can be
desensitized. This is a straightforward, relatively safe procedure that can be done
orally or IV. Although the two approaches have not been compared, oral desensitiza-
tion is thought to be safer, simpler, and easier. Patients should be desensitized in a
hospital setting because serious IgE-mediated allergic reactions, although unlikely,
can occur. Desensitization can usually be completed in about 4 hours, after which the
first dose of penicillin is given (Table 1). STD programs should have a referral center
where patients with positive skin tests can be desensitized. After desensitization, pa-
tients must be maintained on penicillin continuously for the duration of the course of
therapy.
TABLE 1. Oral desensitization protocol for patients with a positive skin test (15 )*
Penicillin V
suspension
dose†
Amount§
(units/mL) mL Units 
Cumulative
dose (units)
   1  1,000 0.1     100      100
   2  1,000 0.2     200      300
   3  1,000 0.4     400      700
   4  1,000 0.8     800    1,500
   5  1,000 1.6   1,600    3,100
   6  1,000 3.2   3,200    6,300
   7  1,000 6.4   6,400   12,700
   8 10,000 1.2  12,000   24,700
   9 10,000 2.4  24,000   48,700
  10 10,000 4.8  48,000   96,700
  11 80,000 1.0  80,000  176,700
  12 80,000 2.0 160,000  336,700
  13 80,000 4.0 320,000  656,700
  14 80,000 8.0 640,000 1,296,700
Observation period: 30 minutes before parenteral administration of penicillin.
*Reprinted with permission from the New England Journal of Medicine.
†Interval between doses, 15 minutes; elapsed time, 3 hours and 45 minutes; cumulative dose,
1.3 million units.
§The specific amount of drug was diluted in approximately 30 mL of water and then adminis-
tered orally.
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DISEASES CHARACTERIZED BY URETHRITIS AND CERVICITIS
Management of the Patient with Urethritis
Urethritis, or inflammation of the urethra, is caused by an infection characterized by
the discharge of mucoid or purulent material and by burning during urination. How-
ever, asymptomatic infections are common. The two bacterial agents primarily
responsible for urethritis among men are N. gonorrhoeae  and C. trachomatis. Testing
to determine the specific diagnosis is recommended because both of these infections
are reportable to state health departments and because with a specific diagnosis,
treatment compliance may be better and the likelihood of partner notification may be
improved. If diagnostic tools (e.g., Gram stain and microscope) are unavailable,
health-care providers should treat patients for both infections. The added expense of
treating a person with nongonococcal urethritis (NGU) for both infections also should
encourage the health-care provider to make a specific diagnosis. (See Nongonococcal
Urethritis, Chlamydial Infections, and Gonococcal Infections.)
Nongonococcal Urethritis
NGU, or inflammation of the urethra not caused by gonococcal infection, is charac-
terized by a mucoid or purulent urethral discharge. In the presence or absence of a
discharge, NGU may be diagnosed by ≥5 polymorphonuclear leukocytes per oil im-
mersion field on a smear of an intraurethral swab specimen. Increasingly, the
leukocyte esterase test (LET) is being used to screen urine from asymptomatic males
for evidence of urethritis (either gonococcal or nongonococcal). The diagnosis of ure-
thritis among males tested with LET should be confirmed with a Gram-stained smear
of a urethral swab specimen. C. trachomatis  is the most frequent cause of NGU (23%–
55% of cases); however, prevalence varies among age groups, with lower prevalence
found among older men. Ureaplasma urealyticum  causes 20%–40% of cases, and
Trichomonas vaginalis  2%–5%. HSV is occasionally responsible for cases of NGU. The
etiology of the remaining cases of NGU is unknown.
Complications of NGU among men infected with C. trachomatis  include epididymi-
tis and Reiter’s syndrome. Female sex partners of men who have NGU are at risk for
chlamydial infection and associated complications.
Recommended Regimen
Doxycycline 100 mg orally 2 times a day for 7 days.*
Alternative Regimens
Erythromycin base 500 mg orally 4 times a day for 7 days
or
*Azithromycin 1 g in a single dose, according to manufacturer’s data, is equivalent to doxycy-
cline. However, this study has not been published in a peer-reviewed journal. For a discussion
comparing azithromycin and doxycyline, refer to Chlamydial Infections.
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Erythromycin ethylsuccinate 800 mg orally 4 times a day for
7 days.
If a patient cannot tolerate high-dose erythromycin schedules, one of the following
regimens may be used:
Erythromycin base 250 mg orally 4 times a day for 14 days
or
Erythromycin ethylsuccinate 400 mg orally 4 times a day for
14 days.
Treatment with the recommended regimen has been demonstrated in most cases
to result in alleviation of symptoms and in microbiologic cure of infection. If the etio-
logic organism is susceptible to the antimicrobial agent used, sequelae specific to that
organism will be prevented, as will further transmission; this is especially important
for cases of NGU caused by C. trachomatis.
Follow-Up
Patients should be instructed to return for evaluation if symptoms persist or recur
after completion of therapy. Patients with persistent or recurrent urethritis should be
re-treated with the initial regimen if they failed to comply with the treatment regimen
or if they were re-exposed to an untreated sex partner. Otherwise, a wet mount exami-
nation and culture of an intraurethral swab specimen for T. vaginalis  should be
performed; if negative, the patient should be retreated with an alternative regimen
extended to 14 days (e.g., erythromycin base 500 mg orally 4 times a day for 14 days).
The use of alternative regimens ensures treatment of possible tetracycline-resistant
U. urealyticum. 
Effective regimens have not been identified for treating patients who experience
persistent symptoms or frequent recurrences following treatment with doxycycline
and erythromycin. Urologic examinations do not usually reveal a specific etiology.
Such patients should be assured that, although they have persistent or frequently re-
curring urethritis, the condition is not known to cause complications among them or
their sex partners and is not known to be sexually transmitted. However, men exposed
to a new sex partner should be re-evaluated. Symptoms alone, without documenta-
tion of signs or laboratory evidence of urethral inflammation, are not a sufficient basis
for re-treatment.
Management of Sex Partners
Patients should be instructed to refer sex partners for evaluation and treatment.
Since exposure intervals have received limited evaluation, the following recommen-
dations are somewhat arbitrary. Sex partners of symptomatic patients should be
evaluated and treated if their last sexual contact with the index patient was within
30 days of onset of symptoms. If the index patient is asymptomatic, sex partners
whose last sexual contact with the index patient was within 60 days of diagnosis
should be evaluated and treated. If the patient’s last sexual intercourse preceded the
time intervals previously described, the most recent sex partner should be treated. A
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specific diagnosis may facilitate partner referral and partner cooperation. Therefore,
testing for both gonorrhea and chlamydia is encouraged.
Patients should be instructed to abstain from sexual intercourse until patient and
partners are cured. In the absence of microbiologic test-of-cure, this means when ther-
apy is completed and patient and partners are without symptoms or signs.
Special Considerations
HIV Infection
Persons with HIV infection and NGU should receive the same treatment as patients
without HIV infection.
Management of the Patient With Mucopurulent Cervicitis
Mucopurulent cervicitis (MPC) is characterized by a yellow endocervical exudate
visible in the endocervical canal or in an endocervical swab specimen. Some experts
also make the diagnosis on the basis of an increased number of polymorphonuclear
leukocytes on cervical Gram stain. The condition is asymptomatic among many
women, but some may experience an abnormal vaginal discharge and abnormal
vaginal bleeding (e.g., following intercourse). The condition can be caused by
C. trachomatis  or N. gonorrhoeae, although in most cases neither organism can be
isolated. Patients with MPC should have cervical specimens tested for C. trachomatis
and cultured for N. gonorrhoeae. MPC is not a sensitive predictor of infection; how-
ever, most women with C. trachomatis  or N. gonorrhoeae  do not have MPC.
Treatment
The results of tests for C. trachomatis  or N. gonorrhoeae  should determine the
need for treatment, unless the likelihood of infection with either organism is high or
unless the patient is unlikely to return for treatment. Treatment for MPC should include
the following:
• Treatment for gonorrhea and chlamydia in patient populations with high preva-
lence of both infections, such as patients seen at many STD clinics. 
• Treatment for chlamydia only, if the prevalence of N. gonorrhoeae  is low but the
likelihood of chlamydia is substantial. 
• Await test results if the prevalence of both infections are low and if compliance
with a recommendation for a return visit is likely.
Follow-Up
Follow-up should be as recommended for the infections for which the woman is
being treated.
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Management of Sex Partners
Management of sex partners of women with MPC should be appropriate for the
STD (C. trachomatis  or N. gonorrhoeae ) identified. Partners should be notified, ex-
amined, and treated on the basis of test results. However, partners of patients who are
treated presumptively should receive the same treatment as the index patient.
Special Considerations
HIV Infection
Persons with HIV infection and MPC should receive the same treatment as patients
without HIV infection.
Chlamydial Infections
Chlamydial genital infection is common among adolescents and young adults in
the United States. Asymptomatic infection is common among both men and women.
Testing sexually active adolescent girls for chlamydial infection should be routine dur-
ing gynecologic examination, even if symptoms are not present. Screening of young
adult women 20–24 years of age also is suggested, particularly for those who do not
consistently use barrier contraceptives and who have new or multiple partners.
Periodic surveys of chlamydial prevalence among these groups should be conducted
to confirm the validity of using these recommendations in specific clinical settings.
Chlamydial Infections Among Adolescents and Adults
The following recommended treatment regimens or the alternative regimens re-
lieve symptoms and cure infection. Among women, several important sequelae may
result from C. trachomatis  infection, the most serious among them being PID, ectopic
pregnancy, and infertility. Some women with apparently uncomplicated cervical infec-
tion already have subclinical upper reproductive tract infection. Treatment of cervical
infection is believed to reduce the likelihood of sequelae, although few studies have
demonstrated that antimicrobial therapy reduces the risk of subsequent ascending
infections or decreases the incidence of long-term complications of tubal infertility
and ectopic pregnancy.
Treatment of infected patients prevents transmission to sex partners, and for in-
fected pregnant women may prevent transmission of C. trachomatis  to infants during
birth. Treatment of sex partners will help to prevent re-infection of the index patient
and infection of other partners.
Because of the high prevalence of coinfection with C. trachomatis  among patients
with gonococcal infection, presumptive treatment for chlamydia of patients being
treated for gonorrhea is appropriate, particularly if no diagnostic test for C. trachoma-
tis  infection will be performed (see Gonococcal Infections).
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Recommended Regimens
Doxycycline 100 mg orally 2 times a day for 7 days,
or
Azithromycin 1 g orally in a single dose.
Alternative Regimens
Ofloxacin 300 mg orally 2 times a day for 7 days
or
Erythromycin base 500 mg orally 4 times a day for 7 days
or
Erythromycin ethylsuccinate 800 mg orally 4 times a day for
7 days
or
Sulfisoxazole 500 mg orally 4 times a day for 10 days (inferior
efficacy to other regimens).
Doxycycline and azithromycin appear similar in efficacy and toxicity; however, the
safety and efficacy of azithromycin for persons ≤15 years of age have not been estab-
lished. Doxycycline has a longer history of extensive use, safety, efficacy, and the
advantage of low cost. Azithromycin has the advantage of single-dose administration.
Ofloxacin is similar in efficacy to doxycycline and azithromycin, but is more expensive
than doxycycline, cannot be used during pregnancy or with persons ≤17 years of age,
and offers no advantage in dosing. Ofloxacin is the only quinolone with proven effi-
cacy against chlamydial infection. Sulfisoxazole is the least desirable treatment
because of inferior efficacy.
Follow-Up
Patients do not need to be retested for chlamydia after completing treatment with
doxycycline or azithromycin unless symptoms persist or re-infection is suspected. Re-
testing may be considered 3 weeks after completion of treatment with erythromycin,
sulfisoxazole, or amoxicillin. This is usually unnecessary if the patient was treated
with doxycycline, azithromycin, or ofloxacin. The validity of chlamydial culture testing
performed at <3 weeks following completion of therapy among patients failing ther-
apy has not been established. False-negative results may occur because of small
numbers of chlamydial organisms. In addition, nonculture tests conducted at
<3 weeks following completion of therapy for patients successfully treated may some-
times be false-positive because of the continued excretion of dead organisms.
Some studies have demonstrated high rates of infection among women retested
several months following treatment, presumably because of reinfection. Rescreening
women several months following treatment may be an effective strategy for detecting
further morbidity in some populations.
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Management of Sex Partners
Patients should be instructed to refer their sex partners for evaluation and treat-
ment. Because exposure intervals have received limited evaluation, the following
recommendations are somewhat arbitrary. Sex partners of symptomatic patients with
C. trachomatis  should be evaluated and treated for chlamydia if their last sexual con-
tact with the index patient was within 30 days of onset of the index patient’s
symptoms. If the index patient is asymptomatic, sex partners whose last sexual con-
tact with the index patient was within 60 days of diagnosis should be evaluated and
treated. Health-care providers should treat the last sex partner even if last sexual inter-
course took place before the foregoing time intervals.
Patients should be instructed to avoid sex until they and their partners are cured. In
the absence of microbiologic test-of-cure, this means until therapy is completed and
patient and partner(s) are without symptoms.
Special Considerations
Pregnancy
Doxycycline and ofloxacin are contraindicated for pregnant women, and sulfisoxa-
zole is contraindicated for women during pregnancy near-term and for women who
are nursing. The safety and efficacy of azithromycin among pregnant and lactating
women have not been established. Repeat testing, preferably by culture, after com-
pleting therapy with the following regimens is recommended because there are few
data regarding the effectiveness of these regimens, and the frequent gastrointestinal
side effects of erythromycin may discourage a patient from complying with the pre-
scribed treatment.
Recommended Regimen for Pregnant Women
Erythromycin base 500 mg orally 4 times a day for 7 days.
Alternative Regimens for Pregnant Women 
Erythromycin base 250 mg orally 4 times a day for 14 days
or
Erythromycin ethylsuccinate 800 mg orally 4 times a day for
7 days
or
Erythromycin ethylsuccinate 400 mg orally 4 times a day for
14 days
or 
If erythromycin cannot be tolerated:
Amoxicillin 500 mg orally 3 times a day for 7–10 days.
NOTE: Erythromycin estolate is contraindicated during pregnancy because of
drug-related  hepatotoxicity. Few data exist concerning the efficacy of amoxicillin.
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HIV Infection
Persons with HIV infection and chlamydial infection should receive the same treat-
ment as patients without HIV infection.
Chlamydial Infections Among Infants
Prenatal screening of pregnant women can prevent chlamydial infection among
neonates. Pregnant women <25 years of age and those with new or multiple sex part-
ners should, in particular, be targeted for screening. Periodic surveys of chlamydial
prevalence can be conducted to confirm the validity of using these recommendations
in specific clinical settings.
C. trachomatis  infection of neonates results from perinatal exposure to the
mother’s infected cervix. The prevalence of C. trachomatis  infection generally ex-
ceeds 5% among pregnant women, regardless of race/ethnicity or socioeconomic
status. Neonatal ocular prophylaxis with silver nitrate solution or antibiotic ointments
is ineffective in preventing perinatal transmission of chlamydial infection from mother
to infant. However, ocular prophylaxis with those agents does prevent gonococcal
ophthalmia and should be continued for that reason (see Prevention of Ophthalmia
Neonatorum).
Initial C. trachomatis  perinatal infection involves mucous membranes of the eye,
oropharynx, urogenital tract, and rectum. C. trachomatis  infection among neonates
can most often be recognized because of conjunctivitis developing 5–12 days after
birth. Chlamydia is the most frequent identifiable infectious cause of ophthalmia neo-
natorum. C. trachomatis  also is a common cause of subacute, afebrile pneumonia
with onset from 1 to 3 months of age. Asymptomatic infections of the oropharynx,
genital tract, and rectum among neonates also occur.
Ophthalmia Neonatorum Caused by C. trachomatis
A chlamydial etiology should be considered for all infants with conjunctivitis
through 30 days of age.
Diagnostic Considerations
Sensitive and specific methods to diagnose chlamydial ophthalmia for the neonate
include isolation by tissue culture and nonculture tests, direct fluorescent antibody
tests, and immunoassays. Giemsa-stained smears are specific for C. trachomatis, but
are not sensitive. Specimens must contain conjunctival cells, not exudate alone.
Specimens for culture isolation and nonculture tests should be obtained from the
everted eyelid using a dacron-tipped swab or the swab specified by the
manufacturer’s test kit. A specific diagnosis of C. trachomatis  infection confirms the
need for chlamydial treatment not only for the neonate, but also for the mother and
her sex partner(s). Ocular exudate from infants being evaluated for chlamydial con-
junctivitis should also be tested for N. gonorrhoeae.
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Recommended Regimen
Erythromycin 50 mg/kg/day orally divided into 4 doses for 10–
14 days. 
Topical antibiotic therapy alone is inadequate for treatment of chlamydial infection
and is unnecessary when systemic treatment is undertaken.
Follow-Up 
The possibility of chlamydial pneumonia should be considered. The efficacy of
erythromycin treatment is approximately 80%; a second course of therapy may be
required. Follow-up of infants to determine resolution is recommended.
Management of Mothers and Their Sex Partners
The mothers of infants who have chlamydial infection and the mother’s sex part-
ners should be evaluated and treated following the treatment recommendations for
adults with chlamydial infections (see Chlamydial Infections Among Adolescents and
Adults).
Infant Pneumonia Caused by C. trachomatis
Characteristic signs of chlamydial pneumonia among infants include a repetitive
staccato cough with tachypnea, and hyperinflation and bilateral diffuse infiltrates on a
chest roentgenogram. Wheezing is rare, and infants are typically afebrile. Peripheral
eosinophilia, documented in a complete blood count, is sometimes observed among
infants with chlamydial pneumonia. Because variation from this clinical presentation
is common, initial treatment and diagnostic tests should encompass C. trachomatis 
for all infants 1–3 months of age who have possible pneumonia. 
Diagnostic Considerations
Specimens should be collected from the nasopharynx for chlamydial testing. Tis-
sue culture remains the definitive standard for chlamydial pneumonia; nonculture
tests can be used with the knowledge that nonculture tests of nasopharyngeal speci-
mens produce lower sensitivity and specificity than nonculture tests of ocular
specimens. Tracheal aspirates and lung biopsy specimens, if collected, should be
tested for C. trachomatis.
The microimmunofluorescence test for C. trachomatis  antibody is useful but not
widely available. An acute IgM antibody titer ≥1:32 is strongly suggestive of
C. trachomatis  pneumonia. 
Because of the delay in obtaining test results for chlamydia, inclusion of an agent
active against C. trachomatis in the antibiotic regimen must frequently be decided on
the basis of the clinical and radiologic findings. Conducting tests for chlamydial infec-
tion is worthwhile, not only to assist in the management of an infant’s illness, but also
to determine the need for treatment of the mother and her sex partners.
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Recommended Regimen
Erythromycin 50 mg/kg/day orally divided into 4 doses for 10–
14 days.
Follow-Up
The effectiveness of erythromycin treatment is approximately 80%; a second
course of therapy may be required. Follow-up of infants is recommended to determine
that the pneumonia has resolved. Some infants with chlamydial pneumonia have had
abnormal pulmonary function tests later in childhood.
Management of Mothers and Their Sex Partners
Mothers of infants who have chlamydial infection and the mother’s sex partners
should be evaluated and treated according to the recommended treatment of adults
with chlamydial infections (see Chlamydial Infections Among Adolescents and
Adults).
Infants Born to Mothers Who Have Chlamydial Infection
Infants born to mothers who have untreated chlamydia are at high risk for infection
and should be evaluated and treated as for infants with ophthalmia neonatorum
caused by  C. trachomatis.
Chlamydial Infections Among Children
Sexual abuse must be considered a cause of chlamydial infection among preado-
lescent children, although perinatally transmitted C. trachomatis  infection of the
nasopharynx, urogenital tract, and rectum may persist beyond 1 year (see Sexual
Assault or Abuse of Children). Because of the potential for a criminal investigation and
legal proceedings for sexual abuse, diagnosis of C. trachomatis  among preadolescent
children requires the high specificity provided by isolation in cell culture. The cultures
should be confirmed by microscopic identification of the characteristic
intracytoplasmic inclusions, preferably by fluorescein-conjugated monoclonal anti-
bodies specific for C. trachomatis.
Diagnostic Considerations
Nonculture chlamydia tests should not be used because of the possibility of false-
positive test results. With respiratory tract specimens, false-positive test results can
occur because of cross-reaction of test reagents with Chlamydia pneumoniae; with
genital and anal specimens, false-positive test results occur because of cross-reaction
with fecal flora. 
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Recommended Regimen 
Children who weigh <45 kg
Erythromycin 50 mg/kg/day divided into four doses for 10–
14 days.
NOTE: The effectiveness of erythromycin treatment is approximately 80%; a second
course of therapy may be required.
Children who weigh ≥45 kg but who are <8 years of age
Use the same treatment regimens for these children as the
adult regimens of erythromycin (see Chlamydial Infections
Among Adolescents and Adults).
Children ≥8 years of age
Use the same treatment regimens for these children as the
adult regimens of doxycycline or tetracycline (see Chlamydial
Infections Among Adolescents and Adults). Adult regimens of
azithromycin also may be considered for adolescents.
Other Management Considerations
See Sexual Assault or Abuse of Children.
Follow-Up
Follow-up cultures are necessary to ensure that treatment has been effective.
Gonococcal Infections
Gonococcal Infections Among Adolescents and Adults
An estimated 1 million new infections with N. gonorrhoeae  occur in the United
States each year. Most infections among men produce symptoms that cause the per-
son to seek curative treatment soon enough to prevent serious sequelae—but not
soon enough to prevent transmission to others. Many infections among women do
not produce recognizable symptoms until complications such as PID have occurred.
PID, whether symptomatic or asymptomatic, can cause tubal scarring leading to infer-
tility or ectopic pregnancy. Because gonococcal infections among women are often
asymptomatic, a primary measure for controlling gonorrhea in the United States has
been the screening of high-risk women.
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Uncomplicated Gonococcal Infections
Recommended Regimens
Ceftriaxone 125 mg IM in a single dose
or
Cefixime 400 mg orally in a single dose
or
Ciprofloxacin 500 mg orally in a single dose
or
Ofloxacin 400 mg orally in a single dose
PLUS
A regimen effective against possible coinfection with
C. trachomatis , such as doxycycline 100 mg orally 2 times a
day for 7 days.
Many antibiotics are safe and effective for treating gonorrhea, eradicating N. gon-
orrhoeae, ending the possibility of further transmission, relieving symptoms, and
reducing the chances of sequelae.
Selection of a treatment regimen for N. gonorrhoeae  infection requires considera-
tion of the anatomic site of infection, resistance of N. gonorrhoeae  strains to
antimicrobials, the possibility of concurrent infection with C. trachomatis, and the side
effects and costs of the various treatment regimens. 
Because coinfection with C. trachomatis  is common, persons treated for gonor-
rhea should be treated presumptively with a regimen that is effective against
C. trachomatis  (see Chlamydial Infections).
Most experts agree that other regimens recommended for the treatment of
C. trachomatis  infection are also likely to be satisfactory for the treatment of co-
infection (see Chlamydial Infections). However, studies have not been conducted to
investigate possible interactions between other treatments for N. gonorrhoeae  and
C. trachomatis, including interactions influencing the effectiveness and side effects of
cotreatment.
In clinical trials, these recommended regimens cured >95% of anal and genital in-
fections; any of the regimens may be used for uncomplicated anal or genital infection.
Published studies indicate that ceftriaxone 125 mg and ciprofloxacin 500 mg can cure
≥90% of pharyngeal infections. If pharyngeal infection is a concern, one of these two
regimens should be used.
Ceftriaxone in a single dose of either 125 mg or 250 mg provides sustained, high
bactericidal levels in the blood. Extensive clinical experience indicates that both doses
are safe and effective for the treatment of uncomplicated gonorrhea at all sites. In the
past, the 250 mg dose has been recommended on the supposition that the routine use
of a higher dose may forestall the development of resistance. However, on the basis of
ceftriaxone’s activity against N. gonorrhoeae, its pharmacokinetics, and the results in
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clinical trials of doses as low as 62.5 mg, the 125 mg dose appears to have a
therapeutic reserve at least as large as that of other accepted treatment regimens. No
ceftriaxone-resistant strains of N. gonorrhoeae  have been reported. The drawbacks of
ceftriaxone are that it is expensive, currently unavailable in vials of <250 mg, and must
be administered by injection. Some health-care providers believe that the discomfort
of the injection may be reduced by using 1% lidocaine solution as a diluent. Ceftriax-
one also may abort incubating syphilis, a concern when gonorrhea treatment is not
accompanied by a 7–day course of doxycycline or erythromycin for the presumptive
treatment of chlamydia.
Cefixime has an antimicrobial spectrum similar to that of ceftriaxone, but the
400 mg oral dose does not provide as high nor as sustained a bactericidal level as
does 125 mg of ceftriaxone. Cefixime appears to be effective against pharyngeal
gonococcal infection, but few patients with pharyngeal infection have been included
in studies. No gonococcal strains resistant to cefixime have been reported. The
advantage of cefixime is that it can be administered orally. It is not known if the 400
mg dose can cure incubating syphilis.
Ciprofloxacin at a dose of 500 mg provides sustained bactericidal levels in the
blood. Clinical trials have demonstrated that both 250 mg and 500 mg doses are safe
and effective for the treatment of uncomplicated gonorrhea at all sites. Most clinical
experience in the United States has been with the 500 mg dose. Ciprofloxacin can be
administered orally and is less expensive than ceftriaxone. No resistance has been
reported in the United States, but strains with decreased susceptibility to some qui-
nolones are becoming common in Asia and have been reported in North America. The
500 mg dose is recommended, rather than the 250 mg dose, because of the trend
toward decreasing susceptibility to quinolones and because of rare reports of treat-
ment failure. Quinolones are contraindicated for pregnant or nursing women and for
persons ≤17 years of age on the basis of information from animal studies. Quinolones
are not active against T. pallidum .
Ofloxacin is active against N. gonorrhoeae,  has favorable pharmacokinetics, and
the 400 mg dose has been effective for the treatment of uncomplicated anal and geni-
tal gonorrhea. In published studies a 400 mg dose cured 22 (88%) of 25 pharyngeal
infections.
Alternative Regimens
• Spectinomycin 2 g IM in a single dose. Spectinomycin has the disadvantages of
being injectable, expensive, inactive against T. pallidum , and relatively ineffec-
tive against pharyngeal gonorrhea. In addition, resistant strains have been
reported in the United States. However, spectinomycin remains useful for the
treatment of patients who can tolerate neither cephalosporins nor quinolones.
• Injectable cephalosporin regimens other than ceftriaxone 125 mg that have dem-
onstrated efficacy against uncomplicated anal or genital gonococcal infections
include these injectable cephalosporins: ceftizoxime 500 mg IM in a single dose;
cefotaxime 500 mg IM in a single dose; cefotetan 1 g IM in a single dose; and
cefoxitin 2 g IM in a single dose.
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None of these injectable cephalosporins offers any advantage compared with
ceftriaxone, and there is less clinical experience with them for the treatment of
uncomplicated gonorrhea. Of these four regimens, ceftizoxime 500 mg appears
to be the most effective according to cumulative experience in published clinical
trials. 
• Oral cephalosporin regimens other than cefixime 400 mg include cefuroxime
axetil 1 g orally in a single dose and cefpodoxime proxetil 200 mg orally in a
single dose. These two regimens have anti-gonococcal activity and pharmacoki-
netics less favorable than the 400 mg cefixime regimen, and there is less clinical
experience with them in the treatment of gonorrhea. They have not been very
effective against pharyngeal infections among the few patients studied.
• Quinolone regimens other than ciprofloxacin 500 mg and ofloxacin 400 mg in-
clude enoxacin 400 mg orally in a single dose; lomefloxacin 400 mg orally in a
single dose; and norfloxacin 800 mg orally in a single dose. They appear to be
safe and effective for the treatment of uncomplicated gonorrhea, but none
appears to offer any advantage over ciprofloxacin at a dose of 500 mg or oflox-
acin at 400 mg. 
Enoxacin and norfloxacin are active against N. gonorrhoeae , have favorable
pharmacokinetics, and have been effective in clinical trials, but there is minimal
experience with their use in the United States. Lomefloxacin is effective against
N. gonorrhoeae  and has very favorable pharmacokinetics, but there are few
published clinical studies to support its use for the treatment of gonorrhea, and
there is little experience with its use in the United States.
Many other antimicrobials are active against N. gonorrhoeae. These guidelines are
not intended to be a comprehensive list of all effective treatment regimens.
Other Management Considerations
Persons treated for gonorrhea should be screened for syphilis by serology when
gonorrhea is first detected. Gonorrhea treatment regimens that include ceftriaxone or
a 7-day course of either doxycycline or erythromycin may cure incubating syphilis, but
few data relevant to this topic are available.
Follow-Up
Persons who have uncomplicated gonorrhea and who are treated with any of the
regimens in these guidelines need not return for a test-of-cure. Those persons with
symptoms persisting after treatment should be evaluated by culture for N. gonor-
rhoeae, and any gonococci isolated should be tested for antimicrobial susceptibility.
Infections detected after treatment with one of the recommended regimens more
commonly occur because of reinfection rather than treatment failure, indicating a
need for improved sex partner referral and patient education. Persistent urethritis,
cervicitis, or proctitis also may be caused by C. trachomatis  and other organisms.
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Management of Sex Partners
Patients should be instructed to refer sex partners for evaluation and treatment.
Sex partners of symptomatic patients who have N. gonorrhoeae  infection should be
evaluated and treated for N. gonorrhoeae  and C. trachomatis  infections, if their last
sexual contact with the patient was within 30 days of onset of the patient’s symptoms.
If the index patient is asymptomatic, sex partners whose last sexual contact with the
patient was within 60 days of diagnosis should be evaluated and treated. Health-care
providers should treat the most recent sex partner, if last sexual intercourse took place
before those time periods.
Patients should be instructed to avoid sexual intercourse until patient and part-
ner(s) are cured. In the absence of microbiologic test-of-cure, this means until therapy
is completed and patient and partner(s) are without symptoms.
Special Considerations
Allergy, Intolerance, or Adverse Reactions
Persons who cannot tolerate cephalosporins should, in general, be treated with
quinolones. Those who can take neither cephalosporins nor quinolones should be
treated with spectinomycin, except for those patients who are suspected or known to
have pharyngeal infection. For pharyngeal infections among persons who can tolerate
neither a cephalosporin nor quinolones, some studies suggest that trimethoprim/
sulfamethoxazole may be effective at a dose of 720 mg trimethoprim/3,600 mg sul-
famethoxazole orally once a day for 5 days.
Pregnancy
Pregnant women should not be treated with quinolones or tetracyclines. Those in-
fected with N. gonorrhoeae  should be treated with a recommended or alternate
cephalosporin. Women who cannot tolerate a cephalosporin should be administered
a single dose of 2 g of spectinomycin IM. Erythromycin is the recommended treatment
for presumptive or diagnosed C. trachomatis  infection during pregnancy (see
Chlamydial Infections).
HIV Infection
Persons with HIV infection and gonococcal infection should receive the same treat-
ment as persons not infected with HIV.
Gonococcal Conjunctivitis
Only one North American study of the treatment of gonococcal conjunctivitis
among adults has been published in recent years. In that study, 12 of 12 patients re-
sponded favorably to a single 1 g IM injection of ceftriaxone. The recommendations
that follow reflect the opinions of expert consultants.
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Treatment
Recommended Regimen
A single, 1 g dose of ceftriaxone should be administered IM,
and the infected eye should be lavaged with saline solution
once.
Management of Sex Partners
As for uncomplicated infections, patients should be instructed to refer sex part-
ner(s) for evaluation and treatment (see Uncomplicated Gonococcal Infections,
Management of Sex Partners).
Disseminated Gonococcal Infection
Disseminated gonococcal infection (DGI) results from gonococcal bacteremia,
often resulting in petechial or pustular acral skin lesions, asymmetrical arthalgias,
tenosynovitis or septic arthritis—and is occasionally complicated by hepatitis and,
rarely, by endocarditis or meningitis. Strains of N. gonorrhoeae  that cause DGI tend
to cause little genital inflammation. These strains have become uncommon in the
United States during the past decade.
No North American studies of the treatment of DGI have been published recently.
The recommendations that follow reflect the opinions of expert consultants.
Treatment
Hospitalization is recommended for initial therapy, especially for patients who can-
not be relied on to comply with treatment, for those for whom the diagnosis is
uncertain, and for those who have purulent synovial effusions or other complications.
Patients should be examined for clinical evidence of endocarditis and meningitis. Pa-
tients treated for DGI should be treated presumptively for concurrent C. trachomatis 
infection.
Recommended Initial Regimen
Ceftriaxone 1 g IM or IV every 24 hours.
Alternative Initial Regimens
Cefotaxime 1 g IV every 8 hours
or
Ceftizoxime 1 g IV every 8 hours
or
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For persons allergic to ß-lactam drugs:
Spectinomycin 2 g IM every 12 hours.
All regimens should be continued for 24–48 hours after improvement begins; then
therapy may be switched to one of the following regimens to complete a full week of
antimicrobial therapy:
Cefixime 400 mg orally 2 times a day
or
Ciprofloxacin 500 mg orally 2 times a day.
NOTE: Ciprofloxacin is contraindicated for children, adolescents ≤17 years of age, and
pregnant and lactating women.
Management of Sex Partners
Gonococcal infection is often asymptomatic in sex partners of patients with DGI. As
for uncomplicated infections, patients should be instructed to refer sex partner(s) for
evaluation and treatment (see Uncomplicated Gonococcal Infections, Management of
Sex Partners).
Gonococcal Meningitis and Endocarditis
Recommended Initial Regimen
1–2 g of ceftriaxone IV every 12 hours.
Therapy for meningitis should be continued for 10–14 days and for endocarditis for
at least 4 weeks. Treatment of complicated DGI should be undertaken in consultation
with an expert.
Management of Sex Partners
As for uncomplicated infections, patients should be instructed to refer sex partners
for evaluation and treatment (see Uncomplicated Gonococcal Infections, Manage-
ment of Sex Partners).
Gonococcal Infections Among Infants
Gonococcal infection among neonates usually results from peripartum exposure to
infected cervical exudate of the mother. Gonococcal infection among neonates is usu-
ally an acute illness beginning 2–5 days after birth. The incidence of N. gonorrhoeae 
among neonates varies in U.S. communities, depends on the prevalence of infection
among pregnant women, on whether pregnant women are screened for gonorrhea,
and on whether newborns receive ophthalmia prophylaxis. The prevalence of infec-
tion is <1% in most prenatal patient populations, but may be higher in some settings.
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Of greatest concern are complications of ophthalmia neonatorum and sepsis, in-
cluding arthritis and meningitis. Less serious manifestations at sites of infection
include rhinitis, vaginitis, urethritis, and inflammation at sites of intrauterine fetal
monitoring.
Ophthalmia Neonatorum Caused by N. gonorrhoeae
In most patient populations in the United States, C. trachomatis  and nonsexually
transmitted agents are more common causes of neonatal conjunctivitis than N. gon-
orrhoeae. However, N. gonorrhoeae  is especially important because gonococcal
ophthalmia may result in perforation of the globe and in blindness.
Diagnostic Considerations
Infants at high risk for gonococcal ophthalmia in the United States are those who
do not receive ophthalmia prophylaxis, whose mothers have had no prenatal care, or
whose mothers have a history of STDs or substance abuse. The presence of typical
Gram-negative diplococci in a Gram-stained smear of conjunctival exudate suggests
a diagnosis of N. gonorrhoeae  conjunctivitis. Such patients should be treated pre-
sumptively for gonorrhea after obtaining appropriate cultures for N. gonorrhoeae;
appropriate chlamydial testing should be done simultaneously. The decision not to
treat presumptively for N. gonorrhoeae  among patients without evidence of gono-
cocci on a Gram-stained smear of conjunctival exudate, or among patients for whom
a Gram-stained smear cannot be performed, must be made on a case-by-case basis
after considering the previously described risk factors.
A specimen of conjunctival exudate also should be cultured for isolation of N. gon-
orrhoeae, since culture is needed for definitive microbiologic identification and for
antibiotic susceptibility testing. Such definitive testing is required because of the pub-
lic health and social consequences for the infant and mother that may result from the
diagnosis of gonococcal ophthalmia. Moraxella catarrhalis  and other Neisseria  spe-
cies are uncommon causes of neonatal conjunctivitis that can mimic N. gonorrhoeae
on Gram-stained smear. To differentiate N. gonorrhoeae  from M. catarrhalis  and
other Neisseria  species, the laboratory should be instructed to perform confirmatory
tests on any colonies that meet presumptive criteria for N. gonorrhoeae. 
Recommended Regimen
Ceftriaxone 25–50 mg/kg IV or IM in a single dose, not to ex-
ceed 125 mg.
NOTE: Topical antibiotic therapy alone is inadequate and is unnecessary if systemic
treatment is administered.
Other Management Considerations
Simultaneous infection with C. trachomatis  has been reported and should be con-
sidered for patients who do not respond satisfactorily. The mother and infant should
be tested for chlamydial infection at the same time that gonorrhea testing is done (see
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Ophthalmia Neonatorum Caused by C. trachomatis ). Ceftriaxone should be adminis-
tered cautiously among infants with elevated bilirubin levels, especially premature
infants.
Follow-Up
Infants should be admitted to the hospital and evaluated for signs of disseminated
infection (e.g., sepsis, arthritis, and meningitis). One dose of ceftriaxone is adequate
for gonococcal conjunctivitis, but many pediatricians prefer to maintain infants on
antibiotics until cultures are negative at 48–72 hours. The decision on duration of ther-
apy should be made with input from experienced physicians.
Management of Mothers and Their Sex Partners
The mothers of infants with gonococcal infection and their sex partners should be
evaluated and treated following the recommendations for treatment of gonococcal
infections in adults (see Gonococcal Infections Among Adolescents and Adults).
Disseminated Gonococcal Infection Among Infants
Sepsis, arthritis, meningitis, or any combination thereof are rare complications of
neonatal gonococcal infection. Gonococcal scalp abscesses also may develop as a
result of fetal monitoring. Detection of gonococcal infection among neonates who
have sepsis, arthritis, meningitis, or scalp abscesses requires cultures of blood, CSF,
and joint aspirate on chocolate agar. Cultures of specimens from the conjunctiva, va-
gina, oropharynx, and rectum onto gonococcal selective medium are useful to identify
sites of primary infection, especially if inflammation is present. Positive Gram-stained
smears of exudate, CSF, or joint aspirate provide a presumptive basis for initiating
treatment for N. gonorrhoeae. Diagnoses based on positive Gram-stained smears or
presumptive isolation by cultures should be confirmed with definitive tests on culture
isolates.
Recommended Regimen
Ceftriaxone 25–50 mg/kg/day IV or IM in a single daily dose for
7 days, with a duration of 10–14 days, if meningitis is docu-
mented;
or
Cefotaxime 25 mg/kg IV or IM every 12 hours for 7 days, with a
duration of 10–14 days, if meningitis is documented.
Prophylactic Treatment for Infants Whose Mothers Have
Gonococcal Infection
Infants born to mothers who have untreated gonorrhea are at high risk for
infection.
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Recommended Regimen in the Absence of Signs of Gonococcal Infection
Ceftriaxone 25–50 mg/kg IV or IM, not to exceed 125 mg, in a
single dose.
Other Management Considerations
If simultaneous infection with C. trachomatis  has been reported, mother and infant
should be tested for chlamydial infection.
Follow-Up
Follow-up examination is not required.
Management of Mothers and Their Sex Partners
The mothers of infants with gonococcal infection and the mother’s sex partners
should be evaluated and treated following the recommendations for treatment of
gonococcal infections among adults (see Gonococcal Infections).
Gonococcal Infections Among Children
After the neonatal period, sexual abuse is the most common cause of gonococcal
infection among preadolescent children (see Sexual Assault or Abuse of Children).
Vaginitis is the most common manifestation of gonococcal infection among preado-
lescent children. PID following vaginal infection appears to be less common than
among adults. Among sexually-abused children, anorectal and pharyngeal infections
with N. gonorrhoeae  are common and are frequently asymptomatic.
Diagnostic Considerations
Because of the potential medical/legal use of the test results for N. gonorrhoeae
among children, only standard culture systems for the isolation of N. gonorrhoeae 
should be used to diagnose N. gonorrhoeae  for these children. Nonculture gonococ-
cal tests, including Gram-stained smear, DNA probes, or EIA tests should not be used;
none of these tests have been approved by the FDA for use in the oropharynx, rectum,
or genital tract of children. Specimens from the vagina, urethra, pharynx, or rectum
should be streaked onto selective media for isolation of N. gonorrhoeae. All presump-
tive isolates of N. gonorrhoeae  should be confirmed by at least two tests that involve
different principles, e.g., biochemical, enzyme substrate, or serologic. Isolates should
be preserved to permit additional or repeated analysis.
Recommended Regimen for Children
Children Who Weigh >45 kg
Children who weigh ≥45 kg should be administered the same treatment regimens
as those recommended for adults (see Gonococcal Infections).
Children Who Weigh <45 kg
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The following treatment recommendations are for children with uncomplicated
gonococcal vulvovaginitis, cervicitis, urethritis, pharyngitis, or proctitis.
Ceftriaxone 125 mg IM in a single dose.
Alternative Regimen
Spectinomycin 40 mg/kg (maximum 2 g) IM in a single dose.
Children Who Weigh <45 kg and Who Have Bacteremia, Arthritis, or
Meningitis
Recommended Regimen
Ceftriaxone 50 mg/kg (maximum 1 g) IM or IV in a single dose
daily for 7 days.
NOTE: For meningitis, increase the duration of treatment to 10–14 days and the maxi-
mum dose to 2 g.
Follow-Up
Follow-up cultures of specimens from infected sites are necessary to ensure that
treatment has been effective.
Other Management Considerations
Only parenteral cephalosporins are recommended for use among children.
Ceftriaxone is approved for all gonococcal indications among children; cefotaxime is
approved for gonococcal ophthalmia only. Oral cephalosporins (cefixime, cefuroxime
axetil, cefpodoxime) have not received adequate evaluation in the treatment of gono-
coccal infections among pediatric patients to recommend their use. The
pharmacokinetic activity of these drugs among adults cannot be extrapolated to chil-
dren. 
All children with gonococcal infections should be evaluated for coinfection with
syphilis and C. trachomatis. For a discussion of issues regarding sexual assault, refer
to Sexual Assault or Abuse of Children.
Ophthalmia Neonatorum Prophylaxis
Instillation of a prophylactic agent into the eyes of all newborn infants is recom-
mended to prevent gonococcal ophthalmia neonatorum and is required by law in
most states. Although all the regimens that follow effectively prevent gonococcal eye
disease, their efficacy in preventing chlamydial eye disease is not clear. Furthermore,
they do not eliminate nasopharyngeal colonization with C. trachomatis. Treatment of
gonococcal and chlamydial infections among pregnant women is the best method for
preventing neonatal gonococcal and chlamydial disease. However, ocular prophylaxis
66 MMWR September 24, 1993
should continue because it can prevent gonococcal ophthalmia and, in some popula-
tions, >10% of pregnant women may receive no prenatal care.
Prophylaxis
Recommended Preparations
Silver nitrate (1%) aqueous solution in a single application
or
Erythromycin (0.5%) ophthalmic ointment in a single applica-
tion
or
Tetracycline ophthalmic ointment (1%) in a single application.
One of the above preparations should be instilled into the eyes of every neonate as
soon as possible after delivery. If prophylaxis is delayed (i.e., not administered in the
delivery room), hospitals should establish a monitoring system to see that all infants
receive prophylaxis. All infants should be administered ocular prophylaxis, whether
delivery is vaginal or caesarian. Single-use tubes or ampules are preferable to
multiple-use tubes. Bacitracin is not  effective.
DISEASES CHARACTERIZED BY VAGINAL DISCHARGE
Management of the Patient with Vaginitis
Vaginitis is characterized by a vaginal discharge (usually) or vulvar itching and irri-
tation; a vaginal odor may be present. The three common diseases characterized by
vaginitis include trichomoniasis (caused by T. vaginalis ), BV (caused by a replacement
of the normal vaginal flora by an overgrowth of anaerobic microorganisms and Gard-
nerella vaginalis ), and candidiasis (usually caused by Candida albicans ). MPC caused
by C. trachomatis  or N. gonorrhoeae  may uncommonly cause a vaginal discharge.
Although vulvovaginal candidiasis is not usually transmitted sexually, it is included
here because it is a common infection among women being evaluated for STDs.
The diagnosis of vaginitis is made by pH and microscopic examination of fresh
samples of the discharge. The pH of the vaginal secretions can be determined by
narrow-range pH paper for the elevated pH (>4.5) typical of BV or trichomoniasis. One
way to examine the discharge is to dilute a sample in 1–2 drops of 0.9% normal saline
solution on one slide and 10% potassium hydroxide (KOH) solution on a second slide.
An amine odor detected immediately after applying KOH suggests either BV or tricho-
moniasis. A cover slip is placed on each slide and they are examined under a
microscope at low- and high-dry power. The motile T. vaginalis or the clue cells of BV
are usually easily identified in the saline specimen. The yeast or pseudohyphae of
Candida  species are more easily identified in the KOH specimen. The presence of
objective signs of vulvar inflammation in the absence of vaginal pathogens, along
with a minimal amount of discharge, suggests the possibility of mechanical or
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chemical irritation of the vulva. Culture for T. vaginalis  or Candida  species is more
sensitive than microscopic examination, but the specificity of culture for Candida  spe-
cies to diagnose vaginitis is less clear. Laboratory testing fails to identify a cause
among a substantial minority of women.
Bacterial Vaginosis
BV is a clinical syndrome resulting from replacement of the normal H2O2-producing
Lactobacillus  spp in the vagina with high concentrations of anaerobic bacteria (e.g.,
Bacteroides  spp, Mobiluncus  spp), G. vaginalis, and Mycoplasma hominis. This con-
dition is the most prevalent cause of vaginal discharge or malodor. However, half the
women who meet clinical criteria for BV have no symptoms. The cause of the micro-
bial alteration is not fully understood. Although BV is associated with sexual activity in
that women who have never been sexually active are rarely affected and acquisition
of BV is associated with having multiple sex partners, BV is not considered exclusively
an STD. Treatment of the male sex partner has not been found beneficial in preventing
the recurrence of BV.
Diagnostic Considerations
BV may be diagnosed by the use of clinical or Gram stain criteria. Clinical criteria
require three of the following symptoms or signs:
• A homogeneous, white, noninflammatory discharge that adheres to the vaginal
walls;
• The presence of clue cells on microscopic examination;
• pH of vaginal fluid >4.5;
• A fishy odor of vaginal discharge before or after addition of 10% KOH (whiff test).
When Gram stain is used, determining the relative concentration of the bacterial
morphotypes characteristic of the altered flora of BV is an acceptable laboratory
method for diagnosing BV. Culture of G. vaginalis  is not recommended as a diagnos-
tic tool because it is not specific. G. vaginalis  can be isolated from vaginal cultures
among half of normal women.
Treatment
The principal goal of therapy is to relieve vaginal symptoms and signs. Therefore,
only women with symptomatic disease require treatment. Because male sex partners
of women with BV are not symptomatic, and because treatment of male partners has
not been shown to alter either the clinical course of BV in women during treatment or
the relapse/reinfection rate, preventing transmission to men is not a goal of therapy.
Many bacterial flora characterizing BV have been recovered from the endometrium
or salpinx of women with PID. BV has been associated with endometritis, PID, or vagi-
nal cuff cellulitis following invasive procedures such as endometrial biopsy,
hysterectomy, hysterosalpingography, placement of IUD, caesarian section, or uterine
curettage. A randomized controlled trial found that treatment of BV with
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metronidazole substantially reduced post-abortion PID. Based on these data, it may be
reasonable to consider treatment of BV (symptomatic or asymptomatic) before per-
forming surgical abortion procedures. However, more data are needed to consider
treatment of asymptomatic patients with BV when performing other invasive proce-
dures.
Recommended Regimen
Metronidazole 500 mg orally 2 times a day for 7 days.
NOTE: Patients should be advised to avoid using alcohol during treatment with
metronidazole and for 24 hours thereafter.
Alternative Regimens
Metronidazole 2 g orally in a single dose.
The following alternative regimens have been effective in clinical trials, although
experience with these regimens is limited.
Clindamycin cream, 2%, one full applicator (5 g) intravaginally
at bedtime for 7 days;
or
Metronidazole gel, 0.75%, one full applicator (5 g) intravagi-
nally, 2 times a day for 5 days;
or
Clindamycin 300 mg orally 2 times a day for 7 days.
Oral metronidazole has been shown in numerous studies to be efficacious for the
treatment of BV, resulting in relief of symptoms and improvement in clinical course
and flora disturbances. Based on efficacy data from four randomized-controlled trials,
the overall cure rates are 95% for the 7-day regimen and 84% for the 2 g single-dose
regimen.
Some health-care providers remain concerned about the possibility of metronida-
zole mutagenicity, which has been suggested by  experiments on animals using
extremely high and prolonged doses. However, there is no evidence for mutagenicity
in humans. Some health-care providers prefer the intravaginal route because of lack
of systemic side effects such as mild-to-moderate gastrointestinal upset and unpleas-
ant taste (mean peak serum concentrations of metronidazole following intravaginal
administration are <2% those of standard 500 mg oral doses and mean bioavailability
of clindamycin cream is about 4%).
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Follow-Up
Follow-up visits are not necessary if symptoms resolve. Recurrence of BV is com-
mon. The alternative treatment regimens suitable for BV treatment may be used for
treatment of recurrent disease. No long-term maintenance regimen with any thera-
peutic agent is currently available.
Management of Sex Partners
Treatment of sex partners in clinical trials has not influenced the woman’s response
to therapy, nor has it influenced the relapse or recurrence rate. Therefore, routine
treatment of sex partners is not recommended .
Special Considerations
Allergy or Intolerance to the Recommended Therapy
Clindamycin cream is preferred in case of allergy or intolerance to metronidazole.
Metronidazole gel can be considered for patients who do not tolerate systemic
metronidazole, but patients allergic to oral metronidazole should not be administered
metronidazole vaginally.
Pregnancy
Because metronidazole is contraindicated during the first trimester of pregnancy,
clindamycin vaginal cream is the preferred treatment for BV during the first trimester
of pregnancy (clindamycin cream is recommended instead of oral clindamycin be-
cause of the general desire to limit the exposure of the fetus to medication). During the
second and third trimesters of pregnancy, oral metronidazole can be used, although
the vaginal metronidazole gel or clindamycin cream may be preferable.
BV has been associated with adverse outcomes of pregnancy (e.g., premature rup-
ture of the membranes, preterm labor, preterm delivery), and the organisms found in
increased concentration in BV are also commonly present in postpartum or post-cae-
sarean endometritis. Whether treatment of BV among pregnant women would reduce
the risk of adverse pregnancy outcomes is unknown; randomized controlled trials
have not been conducted.
HIV infection
Persons with HIV and BV should receive the same treatment as persons without
HIV.
Trichomoniasis
Trichomoniasis is caused by the protozoan T. vaginalis. The majority of men in-
fected with T. vaginalis  are asymptomatic, but many women are symptomatic.
Among women, T. vaginalis  typically causes a diffuse, malodorous, yellow-green
discharge with vulvar irritation. There is recent evidence of a possible relationship
between vaginal trichomoniasis and adverse pregnancy outcomes, particularly pre-
mature rupture of the membranes and preterm delivery.
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Recommended Regimen
Metronidazole 2 g orally in a single dose.
Alternative Regimen
Metronidazole 500 mg twice daily for 7 days.
Only metronidazole is available in the United States for the treatment of trichomo-
niasis. In randomized clinical trials, both of the recommended metronidazole
regimens have resulted in cure rates of approximately 95%. Treatment of the patient
and sex partner results in relief of symptoms, microbiologic cure, and reduction of
transmission. Metronidazole gel has been approved for the treatment of BV but it has
not been studied for the treatment of trichomoniasis. Earlier preparations of metroni-
dazole for topical vaginal therapy demonstrated low efficacy against trichomoniasis.
Follow-Up
Follow-up is unnecessary for men and for women who become asymptomatic after
treatment. 
Infections by strains of T. vaginalis  with diminished susceptibility to metronidazole
occur. However, most of these organisms respond to higher doses of metronidazole.
If failure occurs with either regimen, the patient should be retreated with metronida-
zole 500 mg 2 times a day for 7 days. If repeated failure occurs, the patient should be
treated with a single 2 g dose of metronidazole once daily for 3–5 days. 
Patients with culture-documented infection who do not respond to the regimens
described in this report and in whom reinfection has been excluded, should be man-
aged in consultation with an expert. Evaluation of such cases should include
determination of the susceptibility of T. vaginalis  to metronidazole. 
Management of Sex Partners
Sex partners should be treated. Patients should be instructed to avoid sex until
patient and partner(s) are cured. In the absence of microbiologic test-of-cure, this
means when therapy has been completed and patient and partner(s) are without
symptoms.
Special Considerations
Allergy, Intolerance, or Adverse Reactions
Effective alternatives to therapy with metronidazole are not available.
Pregnancy
The use of metronidazole is contraindicated in the first trimester of pregnancy. Pa-
tients may be treated after the first trimester with 2 g of metronidazole in a single
dose.
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HIV Infection
Persons with HIV infection and trichomoniasis should receive the same treatment
as persons without HIV.
Vulvovaginal Candidiasis
Vulvovaginal candidiasis (VVC) is caused by C. albicans  or, occasionally, by other
Candida  spp, Torulopsis  sp, or other yeasts. An estimated 75% of women will experi-
ence at least one episode of VVC during their lifetime, and 40%–45% will experience
two or more episodes. A small percentage of women (probably <5%) experience re-
current VVC (RVVC). Typical symptoms of VVC include pruritus and vaginal discharge.
Other symptoms may include vaginal soreness, vulvar burning, dyspareunia, and ex-
ternal dysuria. None of these symptoms is specific for VVC. VVC usually is not
sexually acquired or transmitted.
Diagnostic Considerations
A diagnosis of Candida  vaginitis is suggested clinically by pruritus in the vulvar
area together with erythema of the vagina or vulva; a white discharge may occur. The
diagnosis can be made when a woman has signs and symptoms of vaginitis, and
when a wet preparation or Gram stain of vaginal discharge demonstrates yeasts or
pseudohyphae, or when a culture or other test yields a positive result for a yeast spe-
cies. Vaginitis solely because of Candida  infection is associated with a normal vaginal
pH (≤4.5). Use of 10% KOH in wet preparations improves the visualization of yeast and
mycelia by disrupting cellular material that may obscure the yeast or pseudohyphae.
Identifying Candida  in the absence of symptoms should not lead to treatment, be-
cause approximately 10%–20% of women normally harbor Candida  spp and other
yeasts in the vagina. VVC may be present concurrently with STDs.
Treatment
Topical formulations provide effective treatment for VVC. The topically applied
azole drugs are more effective than nystatin. Treatment with azoles results in relief of
symptoms and negative cultures among 80%–90% of patients after therapy is com-
pleted.
Recommended Regimens
The following intravaginal formulations are recommended for the treatment of
VVC.
Butoconazole 2% cream 5 g intravaginally for 3 days;*
or
Clotrimazole 1% cream 5 g intravaginally for 7–14 days;†
or
*These creams and suppositories are oil-based and may weaken latex condoms and dia-
phragms. Refer to product labeling for further information.
†Over-the-counter (OTC) preparations.
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Clotrimazole 100 mg vaginal tablet for 7 days;†
or
Clotrimazole 100 mg vaginal tablet, two tablets for 3 days;
or
Clotrimazole 500 mg vaginal tablet, one tablet single applica-
tion;
or
Miconazole 2% cream 5 g intravaginally for 7 days;*†
or
Miconazole 200 mg vaginal suppository, one suppository for
3 days;*
or
Miconazole 100 mg vaginal suppository, one suppository for
7 days;*†
or
Tioconazole 6.5% ointment 5 g intravaginally in a single appli-
cation;*
or
Terconazole 0.4% cream 5 g intravaginally for 7 days;
or
Terconazole 0.8% cream 5 g intravaginally for 3 days;
or
Terconazole 80 mg suppository, 1 suppository for 3 days.*
Although information is not conclusive, single-dose treatments should probably be
reserved for cases of uncomplicated mild-to-moderate VVC. Multi-day regimens
(3- and 7-day) are the preferred treatment for severe or complicated VVC.
Preparations for intravaginal administration of both miconazole and clotrimazole
are now available over-the-counter (OTC [nonprescription]), and women with VVC can
choose one of those preparations. The duration for treatment with either preparation
is 7 days. Self-medication with OTC preparations should be advised only for women
who have been diagnosed previously with VVC and who experience a recurrence of
the same symptoms. Any woman whose symptoms persist after using an OTC
preparation or who experiences a recurrence of symptoms within 2 months should
seek medical care.
*These creams and suppositories are oil-based and may weaken latex condoms and dia-
phragms. Refer to product labeling for further information.
†Over-the-counter (OTC) preparations.
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Alternative Regimens
Several trials have demonstrated that oral azole agents such as fluconazole, keto-
conazole, and itraconazole may be as effective as topical agents. The optimum dose
and duration of oral therapy have not been established, but a range of 1–5 days of
treatment, depending on the agent, has been effective in clinical trials. The ease of
administration of oral agents is an advantage over topical therapies. However, the
potential for toxicity associated with using a systemic drug, particularly ketoconazole,
must be considered. No oral agent is approved currently by the FDA for the treatment
of acute VVC.
Follow-Up
Patients should be instructed to return for follow-up visits only if symptoms persist
or recur. Women who experience three or more episodes of VVC per year should be
evaluated for predisposing conditions (see Recurrent Vulvovaginal Candidiasis).
Management of Sex Partners
VVC is not acquired through sexual intercourse; treatment of sex partners has not
been demonstrated to reduce the frequency of recurrences. Therefore, routine notifi-
cation or treatment of sex partners is not warranted. A minority of male sex partners
may have balanitis, which is characterized by erythematous areas on the glans in con-
junction with pruritus or irritation. These partners may benefit from treatment with
topical antifungal agents to relieve symptoms.
Special Considerations
Allergy or Intolerance to the Recommended Therapy
Topical agents are usually free of systemic side effects, although local burning or
irritation may occur. Oral agents occasionally cause nausea, abdominal pain, and
headaches. Therapy with the oral azoles has been associated rarely with abnormal
elevations of liver enzymes. Hepatotoxicity secondary to ketoconazole therapy has
been estimated to appear in 1:10,000 to 1:15,000 exposed persons. Clinically impor-
tant interactions may occur when these oral agents are administered with other drugs,
including terfenadine, rifampin, astemizole, phenytoin, cyclosporin A, coumarin-like
agents, or oral hypoglycemic agents.
Pregnancy
VVC is common during pregnancy. Only topical azole therapies should be used for
the treatment of pregnant women. The most effective treatments that have been stud-
ied for pregnant women are clotrimazole, miconazole, butoconazole, and terconazole.
Many experts recommend 7 days of therapy during pregnancy.
HIV Infection
Acute VVC occurs frequently among women with HIV infection and may be more
severe for these women than for other women. However, insufficient information ex-
ists to determine the optimal management of VVC in HIV-infected women. Until such
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information becomes available, women with HIV infection and acute VVC should be
treated following the same regimens as for women without HIV infection.
Recurrent Vulvovaginal Candidiasis
RVVC, usually defined as three or more episodes of symptomatic VVC annually,
affects a small proportion of women (probably <5%). The natural history and patho-
genesis of RVVC are poorly understood. Risk factors for RVVC include diabetes
mellitus, immunosuppression, broad spectrum antibiotic use, corticosteroid use, and
HIV infection, although the majority of women with RVVC have no apparent predis-
posing conditions. Clinical trials addressing the management of RVVC have involved
continuing therapy between episodes.
Treatment
The optimal treatment for RVVC has not been established. Ketoconazole 100 mg
orally, once daily for up to 6 months reduces the frequency of episodes of RVVC. Cur-
rent studies are evaluating weekly intravaginal administration of clotrimazole, as well
as oral therapy with itraconazole and fluconazole, in the treatment of RVVC. All cases
of RVVC should be confirmed by culture before maintenance therapy is initiated.
Although patients with RVVC should be evaluated for predisposing conditions, rou-
tinely performing HIV testing for women with RVVC who do not have HIV risk factors
is unwarranted.
Follow-Up
Patients who are receiving treatment for RVVC should receive regular follow-up to
monitor the effectiveness of therapy and the occurrence of side effects.
Management of Sex Partners
Treatment of sex partners does not prevent recurrences, and routine therapy is not
warranted. However, partners with symptomatic balanitis or penile dermatitis should
be treated with a topical agent.
Special Considerations
HIV Infection
Insufficient information exists to determine the optimal management of RVVC
among HIV-infected women. Until such information becomes available, management
should be the same as for other women with RVVC.
PELVIC INFLAMMATORY DISEASE
PID comprises a spectrum of inflammatory disorders of the upper genital tract
among women and may include any combination of endometritis, salpingitis, tubo-
ovarian abscess, and pelvic peritonitis. Sexually transmitted organisms, especially
N. gonorrhoeae  and C. trachomatis, are implicated in the majority of cases; however,
microorganisms that can be part of the vaginal flora, such as anaerobes, G. vaginalis,
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H. influenzae, enteric Gram-negative rods, and Streptococcus agalactiae  also can
cause PID. Some experts also believe that M. hominis and U. urealyticum  are  etio-
logic agents of PID.
Diagnostic Considerations
Because of the wide variation in many symptoms and signs among women with
this condition, a clinical diagnosis of acute PID is difficult. Many women with PID ex-
hibit subtle or mild symptoms that are not readily recognized as PID. Consequently,
delay in diagnosis and effective treatment probably contributes to inflammatory se-
quelae in the upper reproductive tract. Laparoscopy can be used to obtain a more
accurate diagnosis of salpingitis and a more complete bacteriologic diagnosis. How-
ever, this diagnostic tool is often neither readily available for acute cases nor easily
justifiable when symptoms are mild or vague. Moreover, laparoscopy will not detect
endometritis and may not detect subtle inflammation of the fallopian tubes. Conse-
quently, the diagnosis of PID is usually made on the basis of clinical findings.
The clinical diagnosis of acute PID is also imprecise. Data indicate that a clinical
diagnosis of symptomatic PID has a positive predictive value (PPV) for salpingitis of
65%–90% when compared with laparoscopy as the standard. The PPV of a clinical
diagnosis of acute PID varies depending on epidemiologic characteristics and the
clinical setting, with higher PPV among sexually active young (especially teenage)
women and among patients attending STD clinics or from settings with high rates of
gonorrhea or chlamydia. In all settings, however, no single historical, physical, or
laboratory finding is both sensitive and specific for the diagnosis of acute PID (i.e., can
be used both to detect all cases of PID and to exclude all women without PID). Combi-
nations of diagnostic findings that improve either sensitivity (detect more women
who have PID) or specificity (exclude more women who do not have PID) do so only at
the expense of the other. For example, requiring two or more findings excludes more
women without PID but also reduces the number of women with PID who are de-
tected.
Many episodes of PID go unrecognized. Although some women may have asymp-
tomatic PID, others are undiagnosed because the patient or the health-care provider
fails to recognize the implications of mild or nonspecific symptoms or signs, such as
abnormal bleeding, dyspareunia, or vaginal discharge (“atypical PID”). Because of the
difficulty of diagnosis and the potential for damage to the reproductive health of
women even by apparently mild or atypical PID, experts recommend that providers
maintain a low threshold of diagnosis for PID. Even so, the long-term outcome of early
treatment of women with asymptomatic or atypical PID on important clinical out-
comes is unknown. The following recommendations for diagnosing PID are intended
to help health-care providers recognize when PID should be suspected and when they
need to obtain additional information to increase diagnostic certainty. These
recommendations are based in part on the fact that diagnosis and management of
other common causes of lower abdominal pain (e.g., ectopic pregnancy, acute appen-
dicitis, and functional pain) are unlikely to be impaired by initiating empiric
antimicrobial therapy for PID.
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Minimum Criteria
Empiric treatment of PID should be instituted on the basis of the presence of all of
the following three minimum clinical criteria for pelvic inflammation and in the ab-
sence of an established cause other than PID:
• Lower abdominal tenderness,
• Adnexal tenderness, and
• Cervical motion tenderness.
Additional Criteria
For women with severe clinical signs, more elaborate diagnostic evaluation is war-
ranted because incorrect diagnosis and management may cause unnecessary
morbidity. These additional criteria may be used to increase the specificity of the diag-
nosis. 
Listed below are the routine criteria for diagnosing PID:
• Oral temperature >38.3 C, 
• Abnormal cervical or vaginal discharge,
• Elevated erythrocyte sedimentation rate,
• Elevated C-reactive protein,
• Laboratory documentation of cervical infection with N. gonorrhoeae  or
C. trachomatis.
Listed below are the elaborate criteria for diagnosing PID:
• Histopathologic evidence of endometritis on endometrial biopsy,
• Tubo-ovarian abscess on sonography or other radiologic tests,
• Laparoscopic abnormalities consistent with PID.
Although initial treatment decisions can be made before bacteriologic diagnosis of
C. trachomatis  or N. gonorrhoeae  infection, such a diagnosis emphasizes the need to
treat sex partners.
Treatment
PID therapy regimens must provide empiric, broad-spectrum coverage of likely
pathogens. Antimicrobial coverage should include N. gonorrhoeae, C. trachomatis,
Gram-negative facultative bacteria, anaerobes, and streptococci. Although several
antimicrobial regimens have proven effective in achieving clinical and microbiologic
cure in randomized clinical trials with short-term follow-up, few studies have been
done to assess and compare elimination of infection of the endometrium and fallopian
tubes, or the incidence of long-term complications such as tubal infertility and ectopic
pregnancy.
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No single therapeutic regimen has been established for persons with PID. When
selecting a treatment regimen, health-care providers should consider availability, cost,
patient acceptance, and regional differences in antimicrobial susceptibility of the likely
pathogens. 
Many experts recommend that all patients with PID be hospitalized so that super-
vised treatment with parenteral antibiotics can be initiated. Hospitalization is
especially recommended when the following criteria are met:
• The diagnosis is uncertain, and surgical emergencies such as appendicitis and
ectopic pregnancy cannot be excluded,
• Pelvic abscess is suspected,
• The patient is pregnant,
• The patient is an adolescent (among adolescents, compliance with therapy is un-
predictable),
• The patient has HIV infection,
• Severe illness or nausea and vomiting preclude outpatient management,
• The patient is unable to follow or tolerate an outpatient regimen,
• The patient has failed to respond clinically to outpatient therapy,
• Clinical follow-up within 72 hours of starting antibiotic treatment cannot be ar-
ranged.
Inpatient Treatment
Experts have experience with both of the following regimens. Also, there are mul-
tiple randomized trials demonstrating the efficacy of each regimen.
Regimen A
Cefoxitin 2 g IV every 6 hours or cefotetan 2 g IV every 12
hours,
PLUS
Doxycycline 100 mg IV or orally every 12 hours.
NOTE: This regimen should be continued for at least 48 hours after the patient dem-
onstrates substantial clinical improvement, after which doxycycline 100 mg orally
2 times a day should be continued for a total of 14 days. Doxycycline administered
orally has bioavailability similar to that of the IV formulation and may be administered
if normal gastrointestinal function is present. 
Clinical data are limited for other second- or third-generation cephalosporins (e.g.,
ceftizoxime, cefotaxime, and ceftriaxone), which might replace cefoxitin or cefotetan,
although many authorities believe they also are effective therapy for PID. However,
they are less active than cefoxitin or cefotetan against anaerobic bacteria.
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Regimen B
Clindamycin 900 mg IV every 8 hours,
PLUS
Gentamicin loading dose IV or IM (2 mg/kg of body weight) fol-
lowed by a maintenance dose (1.5 mg/kg) every 8 hours.
NOTE:This regimen should be continued for at least 48 hours after the patient demon-
strates substantial clinical improvement, then followed with doxycycline 100 mg
orally 2 times a day or clindamycin 450 mg orally 4 times a day to complete a total of
14 days of therapy. When tubo-ovarian abscess is present, many health-care providers
use clindamycin for continued therapy rather than doxycycline, because it provides
more effective anaerobic coverage. Clindamycin administered intravenously appears
to be effective against C. trachomatis  infection; however, the effectiveness of oral clin-
damycin against C. trachomatis  has not been determined.
Alternative Inpatient Regimens. Limited data support the use of other inpatient
regimens, but two regimens have undergone at least one clinical trial and have broad-
spectrum coverage. Ampicillin/sulbactam plus doxycycline has good anaerobic
coverage and appears to be effective for patients with a tubo-ovarian abscess. Intrave-
nous ofloxacin has been studied as a single agent. A regimen of ofloxacin plus either
clindamycin or metronidazole provides broad-spectrum coverage. Evidence is insuffi-
cient to support the use of any single agent regimen for inpatient treatment of PID.
Outpatient Treatment
Clinical trials of outpatient regimens have provided little information regarding in-
termediate and long-term outcomes. The following regimens provide coverage
against the common etiologic agents of PID, but evidence from clinical trials
supporting their use is limited. The second regimen provides broader coverage
against anaerobic organisms but costs substantially more than the other regimen.
Patients who do not respond to outpatient therapy within 72 hours should be hospital-
ized to confirm the diagnosis and to receive parenteral therapy.
Regimen A
Cefoxitin 2 g IM plus probenecid, 1 g orally in a single dose
concurrently, or ceftriaxone 250 mg IM or other parenteral
third-generation cephalosporin (e.g., ceftizoxime or cefo-
taxime),
PLUS
Doxycycline 100 mg orally 2 times a day for 14 days.
Vol. 42 / No. RR-14 MMWR 79
Regimen B
Ofloxacin 400 mg orally 2 times a day for 14 days,
PLUS
Either clindamycin 450 mg orally 4 times a day, or metronida-
zole 500 mg orally 2 times a day for 14 days.
Clinical trials have demonstrated that the cefoxitin regimen is effective in obtaining
short-term clinical response. Fewer data support the use of ceftriaxone or other third-
generation cephalosporins, but, based on their similarities to cefoxitin, they also are
considered effective. No data exist regarding the use of oral cephalosporins for the
treatment of PID.
Ofloxacin is effective against both N. gonorrhoeae  and C. trachomatis. One clinical
trial demonstrated the effectiveness of oral ofloxacin in obtaining short-term clinical
response with PID. Despite results of this trial, there is concern related to ofloxacin’s
lack of anaerobic coverage; the addition of clindamycin or metronidazole provides this
coverage. Clindamycin, but not metronidazole, further enhances the Gram-positive
coverage of the regimen.
Alternative Outpatient Regimens. Information regarding other outpatient regi-
mens is limited. The combination of amoxicillin/clavulanic acid plus doxycycline was
effective in obtaining short-term clinical response in one clinical trial, but many of the
patients had to discontinue the regimen because of gastrointestinal symptoms.
Follow-Up
Hospitalized patients receiving IV therapy should show substantial clinical im-
provement (e.g., defervescence, reduction in direct or rebound abdominal tenderness,
and reduction in uterine, adnexal, and cervical motion tenderness) within 3–5 days of
initiation of therapy. Patients who do not demonstrate improvement within this time
period usually require further diagnostic workup or surgical intervention, or both.
If the provider elects to prescribe outpatient therapy, follow-up examination should
be performed within 72 hours, using the criteria for clinical improvement previously
described.
Because of the risk for persistent infection, particularly with C. trachomatis, pa-
tients should have a microbiologic re-examination 7–10 days after completing
therapy. Some experts also recommend rescreening for C. trachomatis  and N. gonor-
rhoeae 4–6 weeks after completing therapy.
Management of Sex Partners
Evaluation and treatment of sex partners of women who have PID is imperative
because of the risk for re-infection and the high likelihood of urethral gonococcal or
chlamydial infection of the partner.
Since nonculture, and perhaps culture, tests for C. trachomatis  and N. gonor-
rhoeae  are thought to be insensitive among asymptomatic men, sex partners should
be treated empirically with regimens effective against both of these infections—
regardless of the apparent etiology of PID or pathogens isolated from the infected
woman.
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Even in clinical settings in which only women are seen, special arrangements
should be made to provide care for male sex partners of women with PID. When this
is not feasible, health-care providers should ensure that sex partners are appropriately
referred for treatment.
Special Considerations
Pregnancy
Pregnant women with suspected PID should be hospitalized and treated with par-
enteral antibiotics.
HIV Infection
Differences in the clinical manifestations of PID between HIV-infected women and
noninfected women have not been described clearly. However, in one study,
HIV-infected women with PID tended to have a leukopenia or a lesser leukocytosis
than women who were not HIV-infected, and they were more likely to require surgical
intervention. HIV-infected women who develop PID should be managed aggressively.
Hospitalization and inpatient therapy with one of the IV antimicrobial regimens de-
scribed in this report is recommended.
EPIDIDYMITIS
Among men <35 years of age, epididymitis is most often caused by N. gonorrhoeae
or C. trachomatis. Epididymitis caused by sexually transmitted Escherichia coli  infec-
tion also occurs among homosexual men who are the insertive partners during anal
intercourse. Sexually transmitted epididymitis is usually accompanied by urethritis,
which is often asymptomatic. Nonsexually transmitted epididymitis associated with
urinary tract infections caused by Gram-negative enteric organisms is more common
among men >35 years of age, and among men who have recently undergone urinary
tract instrumentation or surgery.
Diagnostic Considerations
Men with epididymitis typically have unilateral testicular pain and tenderness; pal-
pable swelling of the epididymis is usually present. Testicular torsion, a surgical
emergency, should be considered in all cases but is more frequent among adoles-
cents. Emergency testing for torsion may be indicated when the onset of pain is
sudden, pain is severe, or test results available during the initial visit do not permit a
diagnosis of urethritis or urinary tract infection. The evaluation of men for epididymi-
tis should include the following procedures:
• A Gram-stained smear of urethral exudate or intraurethral swab specimen for
N. gonorrhoeae  and for NGU (≥5 polymorphonuclear leukocytes per oil immer-
sion field),
• A culture of urethral exudate or intraurethral swab specimen for N. gonorrhoeae,
• A test of an intraurethral swab specimen for C. trachomatis,
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• Culture and Gram-stained smear of uncentrifuged urine for Gram-negative
bacteria.
Treatment
Empiric therapy is indicated before culture results are available. Treatment of
epididymitis caused by C. trachomatis  or N. gonorrhoeae  will result in microbiologic
cure of infection, improve signs and symptoms, and prevent transmission to others.
Patients with suspected sexually transmitted epididymitis should be treated with
an antimicrobial regimen effective against C. trachomatis  and N. gonorrhoeae; confir-
mation of these agents by testing will assist in partner notification efforts, but current
tests for C. trachomatis  are not sufficiently sensitive to exclude infection with that
agent.
Recommended Regimen
Ceftriaxone 250 mg IM in a single dose
and
Doxycycline 100 mg orally 2 times a day for 10 days.
The effect of substituting the 125 mg dose of ceftriaxone recommended for treat-
ment of uncomplicated N. gonorrhoeae, or the azithromycin regimen recommended
for treatment of C. trachomatis, is unknown.
As an adjunct to therapy, bed rest and scrotal elevation are recommended until
fever and local inflammation have subsided.
Alternative Regimen
Ofloxacin 300 mg orally 2 times a day for 10 days.
NOTE: Ofloxacin is contraindicated for persons ≤17 years of age.
Follow-Up
Failure to improve within 3 days requires re-evaluation of both the diagnosis and
therapy, and consideration of hospitalization. Swelling and tenderness that persist
after completing antimicrobial therapy should be evaluated for testicular cancer and
tuberculous or fungal epididymitis.
Management of Sex Partners
Patients with epididymitis that is known or suspected to be caused by N. gonor-
rhoeae  or C. trachomatis  should be instructed to refer sex partners for evaluation and
treatment. Sex partners of these patients should be referred if their contact with the
index patient was within 30 days of onset of symptoms.
Patients should be instructed to avoid sexual intercourse until patient and part-
ner(s) are cured. In the absence of microbiologic test-of-cure, this means until therapy
is completed and patient and partner(s) are without symptoms.
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Special Considerations
HIV Infection
Persons with HIV infection and uncomplicated epididymitis should receive the
same treatment as persons without HIV. Fungal and mycobacterial causes of
epididymitis are more common, however, among patients who are immunocom-
promised.
HUMAN PAPILLOMAVIRUS INFECTION
Genital Warts
Exophytic genital and anal warts are benign growths most commonly caused by
HPV types 6 or 11. Other types that may be present in the anogenital region (e.g., types
16, 18, 31, 33, and 35) have been strongly associated with genital dysplasia and carci-
noma. These types are usually associated with subclinical infection, but occasionally
are found in exophytic warts.
Treatment
The goal of treatment is removal of exophytic warts and the amelioration of signs
and symptoms—not the eradication of HPV. No therapy has been shown to eradicate
HPV. HPV has been identified in adjacent tissue after laser treatment of HPV-
associated cervical intraepithelial neoplasia and after attempts to eliminate subclinical
HPV by extensive laser vaporization of the anogenital area.
Genital warts are generally benign growths that cause minor or no symptoms aside
from their cosmetic appearance. Treatment of external genital warts is not likely to
influence the development of cervical cancer. A multitude of randomized clinical trials
and other treatment studies have demonstrated that currently available therapeutic
methods are 22%–94% effective in clearing external exophytic genital warts, and that
recurrence rates are high (usually at least 25% within 3 months) with all modalities.
Several well-designed studies have indicated that treatment is more successful for
genital warts that are small and that have been present <1 year. No studies have
assessed if treatment of exophytic warts reduces transmission of HPV. Many experts
speculate that exophytic warts may be more infectious than subclinical infection, and
therefore, the risk for transmission might be reduced by “debulking” genital warts.
Most experts agree that recurrences of genital warts more commonly result from re-
activation of subclinical infection than reinfection by a sex partner. The effect of
treatment on the natural history of HPV is unknown. If left untreated, genital warts
may resolve on their own, remain unchanged, or grow. In placebo-controlled studies,
genital warts have cleared spontaneously without treatment in 20%–30% of patients
within 3 months.
Regimens
Treatment of genital warts should be guided by the preference of the patient. Ex-
pensive therapies, toxic therapies, and procedures that result in scarring should be
avoided. A specific treatment regimen should be chosen with consideration given to
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anatomic site, size, and number of warts as well as the expense, efficacy, convenience,
and potential for adverse effects. Extensive or refractory disease should be referred to
an expert.
Carbon dioxide laser and conventional surgery are useful in the management of
extensive warts, particularly for those patients who have not responded to other regi-
mens; these alternatives are not appropriate for treatment of limited lesions. One
randomized trial of laser therapy indicated efficacy of 43%, with recurrence among
95% of patients. A randomized trial of surgical excision demonstrated efficacy of 93%,
with recurrences among 29% of patients. These therapies and more cost-effective
treatments do not eliminate HPV infection.
Interferon therapy is not recommended because of its cost and its association with
a high frequency of adverse side effects, and efficacy is no greater than that of other
available therapies. Two randomized trials established systemic interferon alpha to be
no more effective than placebo. Efficacy of interferon injected directly into genital
warts (intralesional therapy) during two randomized trials was 44%–61%, with recur-
rences among none to 67% of patients.
Therapy with 5-fluorouracil cream has not been evaluated in controlled studies,
frequently causes local irritation, and is not recommended for the treatment of genital
warts.
External Genital/Perianal Warts
Cryotherapy with liquid nitrogen or cryoprobe.
or
Podofilox 0.5% solution for self-treatment (genital warts only ).
Patients may apply podofilox with a cotton swab to warts twice
daily for 3 days, followed by 4 days of no therapy. This cycle
may be repeated as necessary for a total of 4 cycles. Total wart
area treated should not exceed 10 cm2, and total volume of
podofilox should not exceed 0.5 mL per day. The health-care
provider should demonstrate the proper application technique
and identify which warts should be treated. If possible, the
health-care provider should apply the initial treatment to dem-
onstrate the proper application technique and identify which
warts should be treated. The use of podofilox is contraindi-
cated during pregnancy .
or
Podophyllin 10%–25%, in compound tincture of benzoin. To
avoid the possibility of problems with systemic absorption and
toxicity, some experts recommend that application be limited
to ≤0.5 mL or ≤10 cm2 per session. Thoroughly wash off in
1–4 hours. Repeat weekly if necessary. If warts persist after
six applications, other therapeutic methods should be consid-
ered. The use of podophyllin is contraindicated during
pregnancy.
or
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Trichloroacetic acid (TCA) 80%–90%. Apply only to warts; pow-
der with talc or sodium bicarbonate (baking soda) to remove
unreacted acid. Repeat weekly if necessary. If warts persist af-
ter six applications, other therapies should be considered.
or
Electrodesiccation or electrocautery. Electrodesiccation and
electrocautery are contraindicated for patients with cardiac
pacemakers or for lesions proximal to the anal verge.
Cryotherapy is relatively inexpensive, does not require anesthesia, and does not
result in scarring if performed properly. Special equipment is required, and most pa-
tients experience moderate pain during and after the procedure. Efficacy during four
randomized trials was 63%–88%, with recurrences among 21%–39% of patients.
Therapy with 0.5% podofilox solution is relatively inexpensive, simple to use, safe,
and is self-applied by patients at home. Unlike podophyllin, podofilox is a pure com-
pound with a stable shelf-life and does not need to be washed off. Most patients
experience mild/moderate pain or local irritation after treatment. Heavily keratinized
warts may not respond as well as those on moist mucosal surfaces. To apply the
podofilox solution safely and effectively, the patient must be able to see and reach the
warts easily. Efficacy during five recent randomized trials was 45%–88%, with recur-
rences among 33%–60% of patients.
Podophyllin therapy is relatively inexpensive, simple to use, and safe. Compared
with other available therapies, a larger number of treatments may be required. Most
patients experience mild to moderate pain or local irritation after treatment. Heavily
keratinized warts may not respond as well as those on moist mucosal surfaces. Effi-
cacy in four recent randomized trials was 32%–79%, with recurrences among
27%–65% of patients.
Few data on the efficacy of TCA are available. One randomized trial among men
demonstrated 81% efficacy and recurrence among 36% of patients; the frequency of
adverse reactions was similar to that seen with the use of cryotherapy. One study
among women showed efficacy and frequency of patient discomfort to be similar to
podophyllin. No data on the efficacy of bichloroacetic acid are available.
Few data on the efficacy of electrodesiccation are available. One randomized trial of
electrodesiccation demonstrated an efficacy of 94%, with recurrences among 22% of
patients; another randomized trial of diathermocoagulation demonstrated an efficacy
of 35%. Local anesthesia is required, and patient discomfort is usually moderate.
Cervical Warts
For women with (exophytic) cervical warts, dysplasia must be excluded before
treatment is begun. Management should be carried out in consultation with an expert.
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Vaginal Warts
Cryotherapy with liquid nitrogen. The use of a cryoprobe in the
vagina is not recommended because of the risk for vaginal per-
foration and fistula formation.
or
TCA 80%–90%. Apply only to warts; powder with talc or so-
dium bicarbonate (baking soda) to remove unreacted acid.
Repeat weekly as necessary. If warts persist after six applica-
tions, other therapeutic methods should be considered.
or
Podophyllin 10%–25% in compound tincture of benzoin. Apply
to the treatment area, which must be dry before removing the
speculum. Treat ≤2 cm2 per session. Repeat application at
weekly intervals. Because of concern about potential systemic
absorption, some experts caution against vaginal application
of podophyllin. The use of podophyllin is contraindicated dur-
ing pregnancy .
Urethral Meatus Warts
Cryotherapy with liquid nitrogen.
or
Podophyllin 10%–25% in compound tincture of benzoin. The
treatment area must be dry before contact with normal mu-
cosa. Podophyllin must be washed off in 1–2 hours. Repeat
weekly if necessary. If warts persist after six applications, other
therapeutic methods should be considered. The use of podo-
phyllin is contraindicated during pregnancy.
Anal Warts
 Cryotherapy with liquid nitrogen.
or
TCA 80%–90%. Apply only to warts; powder with talc or so-
dium bicarbonate (baking soda) to remove unreacted acid.
Repeat weekly if necessary. If warts persist after six applica-
tions, other therapeutic methods should be considered.
or
Surgical removal.
NOTE: Management of warts on rectal mucosa should be referred to an expert.
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Oral Warts
Cryotherapy with liquid nitrogen
or
Electrodesiccation or electrocautery
or
Surgical removal.
Follow-Up
After warts have responded to therapy, follow-up is not necessary. Annual cy-
tologic screening is recommended for women with or without genital warts. The
presence of genital warts is not an indication for colposcopy.
Management of Sex Partners
Examination of sex partners is not necessary for management of genital warts be-
cause the role of reinfection is probably minimal. Many sex partners have obvious
exophytic warts and may desire treatment; also, partners may benefit from counsel-
ing. Patients with exophytic anogenital warts should be made aware that they are
contagious to uninfected sex partners. The majority of partners, however, are prob-
ably already subclinically infected with HPV, even if they do not have visible warts. No
practical screening tests for subclinical infection are available. Even after removal of
warts, patients may harbor HPV in surrounding normal tissue, as may persons with-
out exophytic warts. The use of condoms may reduce transmission to partners likely
to be uninfected, such as new partners; however, the period of communicability is
unknown. Experts speculate that HPV infection may persist throughout a patient’s life-
time in a dormant state and become infectious intermittently. Whether patients with
subclinical HPV infection are as contagious as patients with exophytic warts is un-
known.
Special Considerations
Pregnancy
The use of podophyllin and podofilox are contraindicated during pregnancy. Geni-
tal papillary lesions have a tendency to proliferate and to become friable during
pregnancy. Many experts advocate removal of visible warts during pregnancy.
HPV types 6 and 11 can cause laryngeal papillomatosis among infants. The route of
transmission (transplacental, birth canal, or postnatal) is unknown, and laryngeal
papillomatosis has occurred among infants delivered by caesarean section. Hence,
the preventive value of caesarean delivery is unknown. Caesarean delivery must not
be performed solely to prevent transmission of HPV infection to the newborn. How-
ever, in rare instances, caesarean delivery may be indicated for women with genital
warts if the pelvic outlet is obstructed or if vaginal delivery would result in excessive
bleeding.
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HIV Infection
Persons infected with HIV may not respond to therapy for HPV as well as persons
without HIV.
Subclinical Genital HPV Infection (Without Exophytic Warts)
Subclinical genital HPV infection is much more common than exophytic warts
among both men and women. Infection is often indirectly diagnosed on the cervix by
Pap smear, colposcopy, or biopsy and on the penis, vulva, and other genital skin by the
appearance of white areas after application of acetic acid. Acetowhitening is not a
specific test for HPV infection, and false-positive tests are common. Definitive
diagnosis of HPV infection relies on detection of viral nucleic acid (DNA or RNA) or
capsid proteins. Pap smear diagnosis of HPV generally does not correlate well with
detection of HPV DNA in cervical cells. Cell changes attributed to HPV in the cervix are
similar to those of mild dysplasia and often regress spontaneously without treatment.
Tests for the detection of several types of HPV DNA in cells scraped from the cervix are
now widely available, but the clinical utility of these tests for managing patients is not
known. Management decisions should not be made on the basis of HPV DNA tests.
Screening for subclinical genital HPV infection using DNA tests or acetic acid is not
recommended.
Treatment
In the absence of coexistent dysplasia, treatment is not recommended for subclini-
cal genital HPV infection diagnosed by Pap smear, colposcopy, biopsy, acetic acid
soaking of genital skin or mucous membranes, or the detection of HPV nucleic acids
(DNA or RNA) or capsid antigen, because diagnosis often is questionable and no ther-
apy has been demonstrated to eradicate infection. HPV has been demonstrated in
adjacent tissue after laser treatment of HPV-associated dysplasia and after attempts to
eliminate subclinical HPV by extensive laser vaporization of the anogenital area of
men and women.
In the presence of coexistent dysplasia, management should be based on the grade
of dysplasia.
Management of Sex Partners
Examination of sex partners is not necessary. The majority of partners are probably
already infected subclinically with HPV. No practical screening tests for subclinical in-
fection are available. The use of condoms may reduce transmission to partners likely
to be uninfected, such as new partners; however, the period of communicability is
unknown. Experts speculate that HPV infection may persist throughout a patient’s life-
time in a dormant state and become infectious intermittently. Whether patients with
subclinical HPV infection are as contagious as patients with exophytic warts is un-
known.
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CERVICAL CANCER SCREENING FOR WOMEN WHO ATTEND
STD CLINICS OR WHO HAVE A HISTORY OF STDs
Women who have a history of STDs are at increased risk for cervical cancer, and
women attending STD clinics may have additional characteristics that place them at
even higher risk. Prevalence studies have found that precursor lesions for cervical
cancer occur approximately five times more often among women attending STD clin-
ics than among women attending family planning clinics. 
The Pap smear (cervical smear) is an effective and relatively low-cost screening test
for invasive cervical cancer and squamous intraepithelial lesions (SIL)*, the precur-
sors of cervical cancer. The screening guidelines of both the American College of
Obstetricians and Gynecologists and the American Cancer Society recommend an-
nual Pap smears for sexually active women. Although these guidelines take the
position that Pap smears can be obtained less frequently in some situations, women
who attend STD clinics or who have a history of STDs should be screened annually
because of their increased risk for cervical cancer. Moreover, reports from STD clinics
indicate that many women do not understand the purpose or importance of Pap
smears, and many women who have had a pelvic examination believe they have had
a Pap smear when they actually have not.
Recommendations
Whenever a woman has a pelvic examination for STD screening, the health-care
provider should inquire about the result of her last Pap smear and should discuss the
following information with the patient:
• Purpose and importance of the Pap smear,
• Whether a Pap smear was obtained during the clinic visit,
• Need for a Pap smear each year,
• Names of local providers or referral clinics that can obtain Pap smears and ade-
quately follow up results (if a Pap smear was not obtained during this
examination).
If a woman has not  had a Pap smear during the previous 12 months, a Pap smear
should be obtained as part of the routine pelvic examination in most situations.
Health-care providers should be aware that, after a pelvic examination, many women
may believe they have had a Pap smear when they actually have not, and therefore
may report they have had a recent Pap smear.
In STD clinics, a Pap smear should be obtained during the routine clinical evalu-
ation of women who have not had a documented normal smear within the past
12 months.
*The 1988 Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses introduced the
new terms low-grade squamous intraepithelial lesion  (SIL) and high-grade SIL. Low-grade SIL
encompasses cellular changes associated with HPV and mild dysplasia/cervical intraepithelial
neoplasia 1 (CIN 1). High-grade SIL includes moderate dysplasia/CIN 2, severe dysplasia/CIN
3, and carcinoma in situ (CIS)/CIN 3 (16 ).
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A woman may benefit from receiving printed information about Pap smears and a
report containing a statement that a Pap smear was obtained during her clinic visit.
Whenever possible, a copy of the Pap smear result should be sent to the patient for
her records.
Follow-Up
If a Pap smear shows severe inflammation with reactive cellular changes, the
woman should be advised to have another Pap smear within 3 months. If possible,
underlying infection should be treated before the repeat Pap smear is obtained.
If a Pap smear shows either SIL (or equivalent) or atypical squamous cells of unde-
termined significance (ASCUS), the woman should be notified promptly and
appropriate follow-up initiated.
Appropriate follow-up of Pap smears showing a high-grade SIL (or equivalent) on
Pap smears should always include referral to a health-care provider who has the ca-
pacity to provide a colposcopic examination of the lower genital tract and, if indicated,
colposcopically directed biopsies. Because clinical follow-up of abnormal Pap smears
with colposcopy and biopsy is beyond the scope of many public clinics, including
most STD clinics, in most situations women with Pap smears demonstrating these
abnormalities will need to be referred to other local providers or clinics. Women with
either a low-grade SIL or ASCUS also need similar follow-up, although some experts
believe that, in some situations, a repeat Pap smear may be a satisfactory alternative
to referral for colposcopy and biopsy.
Other Management Considerations
Other considerations in performing Pap smears are the following:
• The Pap smear is not an effective screening test for STDs;
• If a woman is menstruating, a Pap smear should be postponed and the woman
should be advised to have a Pap smear at the earliest opportunity;
• If a woman has an obvious severe cervicitis, the Pap smear may be deferred until
after antibiotic therapy has been completed to obtain an optimum smear; 
• A woman with external genital warts does not require Pap smears more fre-
quently than a woman without warts, unless otherwise indicated.
Special Considerations
Pregnancy
Women who are pregnant should have a Pap smear as part of routine prenatal care.
A cytobrush may be used for obtaining Pap smears from pregnant women, although
care should be taken not to disrupt the mucous plug.
HIV Infection
Recent studies have documented an increased prevalence of SIL among women
infected with HIV. Also, HIV may hasten the progression of precursor lesions to inva-
sive cervical cancer; however, evidence supporting such a progression is limited. The
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following provisional recommendations for Pap smear screening among HIV-infected
women are based partially on consultation with experts in the care and management
of cervical cancer and HIV infection among women. 
These provisional recommendations may be altered in the future as more informa-
tion regarding cervical disease among HIV-infected women becomes available:
• Women who are HIV-infected should be advised to have a comprehensive gyne-
cologic examination, including a Pap smear, as part of their initial medical
evaluation. 
• If initial Pap smear results are within normal limits, at least one additional Pap
smear should be obtained in approximately 6 months to rule out the possibility
of false-negative results on the initial Pap smear. If the repeat Pap smear is nor-
mal, HIV-infected women should be advised to have a Pap smear obtained
annually.
• If the initial or follow-up Pap smear shows severe inflammation with reactive
squamous cellular changes, another Pap smear should be collected within
3 months. 
• If the initial or follow-up Pap smear shows SIL (or equivalent) or ASCUS, the
woman should be referred for a colposcopic examination of the lower genital
tract and, if indicated, colposcopically directed biopsies. 
HIV infection is not an indication for colposcopy among women with normal Pap
smears.
HEPATITIS B
Hepatitis B is a common STD. Sexual transmission accounts for an estimated one-
third to two-thirds of the estimated 200,000 to 300,000 new HBV infections that
occurred annually in the United States during the past 10 years. Of persons infected as
adults, 6%–10% become chronic HBV carriers. These persons are capable of transmit-
ting HBV to others and are at risk for developing fatal complications. HBV leads to an
estimated 5,000 deaths annually in the United States from cirrhosis of the liver and
hepatocellular carcinoma.
The risk of perinatal HBV infection among infants born to HBV-infected mothers
ranges from 10% to 85%, depending on the mother’s hepatitis B e antigen status. In-
fected newborns usually become HBV carriers and are at high risk for developing
chronic liver disease.
Prevention
Infection of both adults and neonates can be readily prevented with a safe and
effective vaccine that has been used in the United States for more than 10 years. Uni-
versal vaccination of newborns is now recommended (17 ). The use of hepatitis B
immune globulin (HBIG) combined with vaccination can prevent infection among per-
sons exposed sexually to HBV if administered within 14 days of exposure.
Vol. 42 / No. RR-14 MMWR 91
 Vaccination Eligibility
Persons known to be at high risk for acquiring HBV (e.g., persons with multiple sex
partners, sex partners of HBV carriers, or injecting drug users) should be advised of
their risk for HBV infection (as well as HIV infection) and the means to reduce their risk
(i.e., exclusivity in sexual relationships, use of condoms, avoidance of nonsterile drug
injection equipment, and HBV vaccination).
Selected high-risk groups for which HBV vaccination is recommended by the ACIP
include the following persons:
• Sexually active homosexual and bisexual men,
• Men and women diagnosed as having recently acquired another STD,
• Persons who have had more than one sex partner in the preceding 6 months.
Such persons should be vaccinated unless they are immune to HBV as a result of
past infection or vaccination. Refer to Hepatitis B Virus: A Comprehensive Strategy for
Eliminating Transmission in the United States Through Universal Child Vaccination,
Recommendations of the Advisory Committee on Immunization Practices (ACIP) (17 ).
Screening for Antibody Versus Vaccination Without Screening
The prevalence of past HBV infection among sexually active homosexual men and
among injecting drug users is high. Serologic screening for evidence of past infection
before vaccinating members of these groups may be cost-effective, depending on the
relative costs of laboratory testing and vaccine. Among those attending STD clinics, it
may be cost-effective to screen older persons for past infection. During a recent study
of 2,000 STD clinic patients who accepted HBV vaccination, 28% of those ≥25 years of
age had evidence of past infection, whereas only 7% of persons <25 years of age had
evidence of past infection. Past infection with HBV can be detected with a serologic
test for antibody to the hepatitis B core antigen (anti-HBc). Immunity can be demon-
strated by a test for antibody to the hepatitis B surface antigen (anti-HBs). The HBV
carrier state can be detected by a test for HBsAg. If only a test for anti-HBc is used to
screen for susceptibility to infection, persons immune because of prior vaccination
will be falsely classified as susceptible. If only a test for anti-HBs is used, carriers will
be falsely classified as susceptible.
Vaccination Schedules
The usual vaccination schedule is three doses of vaccine at 0, 1, and 6 months. An
alternative schedule of 0, 1, 2, and 12 months also has been approved for one vaccine.
The dose is 1 mL for adults, which must be administered IM in the deltoid—not in a
buttock. For persons 11–19 years of age, the dose is either 0.5 or 1 mL, depending on
the manufacturer of the vaccine.
Management of Persons Exposed to HBV
Susceptible persons exposed to HBV through sexual contact with a person who has
acute or chronic HBV infection should receive postexposure prophylaxis with 0.06
mL/kg of HBIG in a single IM dose within 14 days of their last exposure; early admini-
stration may be more effective. HBIG administration should be followed by the
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standard three-dose immunization series with HBV vaccine beginning at the time of
HBIG administration.
Special Considerations
Pregnancy
Pregnancy is not a contraindication to HBV or HBIG vaccine administration.
HIV Infection
Among HIV-infected persons, HBV infection is more likely to lead to chronic HBV
carriage. HIV infection also impairs the response to HBV vaccine. Therefore, HIV-
infected persons who are vaccinated should be tested for anti-HBs 1–2 months after
the third vaccine dose. Revaccination with one or more doses should be considered
for those who do not respond to vaccination initially. Those who do not respond to
additional doses should be advised that they may remain susceptible.
PROCTITIS, PROCTOCOLITIS, AND ENTERITIS
Sexually transmitted gastrointestinal syndromes include proctitis, proctocolitis,
and enteritis. Proctitis occurs predominantly among persons who participate in anal
intercourse, and enteritis occurs among those whose sexual practices include
oral-fecal contact. Proctocolitis may be acquired by either route depending on the
pathogen. Evaluation should include appropriate diagnostic procedures, such as
anoscopy or sigmoidoscopy, stool examination, and culture.
Proctitis is an inflammation limited to the rectum (the distal 10 cm–12 cm) that is
associated with anorectal pain, tenesmus, and rectal discharge. N. gonorrhoeae,
C. trachomatis  (including LGV serovars), T. pallidum, and HSV are the most common
sexually transmitted pathogens involved. Among patients coinfected with HIV, herpes
proctitis may be especially severe.
Proctocolitis is associated with symptoms of proctitis plus diarrhea and/or abdomi-
nal cramps and inflammation of the colonic mucosa extending to 12 cm. Pathogenic
organisms include Campylobacter  spp, Shigella  spp, Entamoeba histolytica, and,
rarely, C. trachomatis  (LGV serovars). CMV or other opportunistic agents may be in-
volved among immunosuppressed patients with HIV infection.
Enteritis usually results in diarrhea and abdominal cramping without signs of proc-
titis or proctocolitis. In otherwise healthy patients, Giardia lamblia  is most commonly
implicated. Among patients with HIV infection, other infections that are not generally
sexually transmitted may occur, including CMV, Mycobacterium avium-intracellulare,
Salmonella  spp, Cryptosporidium, Microsporidium, and Isospora. Multiple stool ex-
aminations may be necessary to detect Giardia, and special stool preparations are
required to diagnose cryptosporidiosis and microsporidiosis. Additionally, enteritis
may be a primary effect of HIV infection.
When laboratory diagnostic capabilities are available, treatment should be based
on the specific diagnosis. Diagnostic and treatment recommendations for all enteric
infections are beyond the scope of these guidelines.
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Treatment
Acute proctitis of recent onset among persons who have recently practiced recep-
tive anal intercourse is most often sexually transmitted. Such patients should be
examined by anoscopy and should be evaluated for infection with HSV, N. gonor-
rhoeae, C. trachomatis, and T. pallidum. If anorectal pus is found on examination, or if
polymorphonuclear leukocytes are found on a Gram-stained smear of anorectal secre-
tions, the following therapy may be prescribed pending results of further laboratory
tests.
Recommended Regimen
Ceftriaxone 125 mg IM (or another agent effective against anal
and genital gonorrhea)
and
Doxycycline 100 mg orally 2 times a day for 7 days.
NOTE: For patients with herpes proctitis, refer to Genital Herpes Simplex Virus Infec-
tions.
Follow-Up
Follow-up should be based on specific etiology and severity of clinical symptoms.
Reinfection may be difficult to distinguish from treatment failure.
Management of Sex Partners
Partners of patients with sexually transmitted enteric infections should be evalu-
ated for any diseases diagnosed in the index patient.
ECTOPARASITIC INFECTIONS
Pediculosis Pubis
Patients with pediculosis pubis (pubic lice) usually seek medical attention because
of pruritus. Commonly, they also notice lice on pubic hair.
Recommended Regimens
Lindane 1% shampoo applied for 4 minutes and then thor-
oughly washed off (not recommended for pregnant or lactating
women or for children <2 years of age)
or
Permethrin 1% creme rinse applied to affected areas and
washed off after 10 minutes
or
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Pyrethrins with piperonyl butoxide applied to the affected area
and washed off after 10 minutes.
The lindane regimen remains the least expensive therapy; toxicity (as indicated by
seizure and aplastic anemia) has not been reported when treatment is limited to the
recommended 4-minute period. Permethrin has less potential for toxicity in the event
of inappropriate use.
Other Management Considerations
The recommended regimens should not  be applied to the eyes. Pediculosis of the
eyelashes should be treated by applying occlusive ophthalmic ointment to the eyelid
margins two times a day for 10 days.
Bedding and clothing should be decontaminated (machine washed or machine
dried using heat cycle or dry-cleaned) or removed from body contact for at least
72 hours. Fumigation of living areas is not necessary.
Follow-Up
Patients should be evaluated after 1 week if symptoms persist. Re-treatment may
be necessary if lice are found or if eggs are observed at the hair-skin junction. Patients
who are not responding to one of the recommended regimens should be retreated
with an alternative regimen.
Management of Sex Partners
Sex partners within the last month should be treated.
Special Considerations
Pregnancy
Pregnant and lactating women should be treated with permethrin or pyrethrins
with piperonyl butoxide.
HIV Infection
Persons with HIV infection and pediculosis pubis should receive the same treat-
ment as those without HIV infection.
Scabies
The predominant symptom of scabies is pruritus. For pruritus to occur, sensitiza-
tion to Sarcoptes scabiei must occur. Among persons with their first infection,
sensitization takes several weeks to develop, while pruritus may occur within 24 hours
after reinfestation. Scabies among adults may be sexually transmitted, although sca-
bies among children is usually not sexually transmitted.
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Recommended Regimen
Permethrin cream (5%) applied to all areas of the body from
the neck down and washed off after 8–14 hours,
or
Lindane (1%) 1 oz. of lotion or 30 g of cream applied thinly to all
areas of the body from the neck down and washed off thor-
oughly after 8 hours. 
NOTE: Lindane should not be used following a bath, and it should not be used
by persons with extensive dermatitis, pregnant or lactating women, and children
<2 years of age.
Alternative Regimen
Crotamiton (10%) applied to the entire body from the neck
down, nightly for 2 consecutive nights, and washed off
24 hours after the second application.
Permethrin is effective and safe but costs more than lindane. Lindane is effective in
most areas of the country, but lindane resistance has been reported in some areas of
the world, including parts of the United States. Seizures have occurred when lindane
was applied after a bath or used by patients with extensive dermatitis. Aplastic ane-
mia following lindane use also has been reported.
Other Management Considerations
Bedding and clothing should be decontaminated (machine washed or machine
dried using hot cycle or dry-cleaned) or removed from body contact for at least
72 hours. Fumigation of living areas is not necessary.
Follow-Up
Pruritus may persist for several weeks. Some experts recommend re-treatment
after 1 week for patients who are still symptomatic; other experts recommend re-
treatment only if live mites can be observed. Patients who are not responding to the
recommended treatment should be retreated with an alternative regimen.
Management of Sex Partners
Both sexual and close personal or household contacts within the last month should
be examined and treated.
Special Considerations
Pregnant Women, Infants, and Young Children
Infants, young children, and pregnant and lactating women should not be treated
with lindane. They may be treated with permethrin or crotamiton regimens.
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HIV Infection
Persons with HIV infection and uncomplicated scabies should receive the same
treatment as persons without HIV infection. Persons with HIV infection and others
who are immunosuppressed are at increased risk for Norwegian scabies, a dissemi-
nated dermatologic infection. Such patients should be managed in consultation with
an expert.
SEXUAL ASSAULT AND STDs
Adults and Adolescents
Recommendations in this report are limited to the identification and treatment of
sexually transmitted infections and conditions commonly identified in the manage-
ment of such infections. The documentation of findings and collection of specimens
for forensic purposes and the management of potential pregnancy or physical and
psychological trauma are beyond the scope of these recommendations. Among sexu-
ally active adults, the identification of sexually transmitted infections following assault
is usually more important for the psychological and medical management of the
patient than for legal purposes, if the infection could have been acquired before the
assault.
Trichomoniasis, chlamydia, gonorrhea, and BV appear to be the infections most
commonly diagnosed among women following sexual assault. Since the prevalence
of these conditions is substantial among sexually active women, their presence (post-
assault) does not necessarily signify acquisition during the assault. Chlamydial and
gonococcal infection among females are of special concern because of the possibility
of ascending infection.
Evaluation for Sexually Transmitted Infections
Initial Examination
An initial examination should include the following procedures:
• Cultures for N. gonorrhoeae  and C. trachomatis  from specimens collected from
any sites of penetration or attempted penetration.
If chlamydial culture is not available, nonculture tests for chlamydia are an accept-
able substitute, although false-negative test results are more common with
nonculture tests and false-positive test results may occur. If a nonculture test is used,
a positive test result should be verified with a second test based on a different diag-
nostic principle or with a blocking antibody or competitive probe procedure.
• Wet mount and culture of a vaginal swab specimen for T. vaginalis  infection. If
vaginal discharge or malodor is evident, the wet mount should also be examined
for evidence of BV and yeast infection.
• Collection of a serum sample to be preserved for subsequent analysis if follow-
up serologic tests are positive (see Follow-up Examination 12 Weeks After
Assault).
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Follow-Up Examination 2 Weeks After Assault
Examination for sexually transmitted infections should be repeated 2 weeks after
the assault. Because infectious agents acquired through assault may not have pro-
duced sufficient concentrations of organisms to result in positive tests at the initial
examination, culture and wet mount tests should be repeated at the 2-week visit un-
less prophylactic treatment has already been provided.
Follow-Up Examination 12 Weeks After Assault
Serologic tests for syphilis and HIV infection should be performed 12 weeks after
the assault. If positive, testing of the sera collected at the initial examination will assist
in determining whether the infection antedated the assault.
Prophylaxis
Although not all experts agree, most patients probably benefit from prophylaxis
because a) follow-up of patients who have been sexually assaulted can be difficult,
and b) patients may be reassured if offered treatment or prophylaxis for possible
infection. The following prophylactic measures address the more common micro-
organisms:
• HBV vaccination (see HEPATITIS B).
• Antimicrobial therapy: empiric regimen for chlamydial, gonococcal, and tricho-
monal infections and for BV.
Recommended Regimen
Ceftriaxone 125 mg IM in a single dose
PLUS
Metronidazole 2 g orally in a single dose
PLUS
Doxycycline 100 mg orally 2 times a day for 7 days.
NOTE: For patients requiring alternative treatments, see the appropriate sections of
this report addressing those agents.
Other Management Considerations
At the initial examination and, as indicated, at follow-up examinations, patients
should be counseled regarding the following:
• Symptoms of STDs and the need for immediate examination if symptoms occur,
and
• Use of condoms for sexual intercourse until STD prophylactic treatment is com-
pleted.
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Risk for Acquiring HIV Infection
Although HIV-antibody seroconversion has been reported among persons whose
only known risk factor was sexual assault or sexual abuse, the risk for acquiring HIV
infection through sexual assault is minimal in most instances. Although the overall
rate of transmission of HIV from an HIV-infected person during a single act of hetero-
sexual intercourse is thought to be low (<1%), this risk depends on many factors.
Prophylactic treatment for HIV is not known to be effective and is not generally recom-
mended in this situation. However, all persons should be offered HIV counseling and
testing after the assault.
Raising the issue of the potential for HIV infection during the initial medical evalu-
ation may add to the acute psychological stress the patient may be experiencing
because of the assault. An alternative is to address the issue at the 2-week follow-up
appointment when the patient may be better able to receive this information and give
informed consent for HIV testing. All persons electing to be tested for HIV should re-
ceive pretest and posttest counseling.
Sexual Assault or Abuse of Children
Recommendations in this report are limited to the identification and treatment of
sexually transmitted infections. Management of the psychosocial and legal aspects of
the sexual assault or abuse of children are important, but are beyond the scope of
these recommendations.
The identification of sexually transmissible agents among children beyond the neo-
natal period suggests sexual abuse. However, there are exceptions; for example,
rectal or genital infection with C. trachomatis  among young children may be the re-
sult of perinatally acquired infection and may persist for as long as 3 years. In addition,
BV and genital mycoplasmas have been identified among children who have been
abused and among those who have not been abused. A finding of genital warts, al-
though suggestive of assault, is not specific for sexual abuse without other evidence.
When the only evidence of sexual abuse is the isolation of an organism or the detec-
tion of antibodies to a sexually transmissible agent, findings should be confirmed and
the implications carefully considered.
Evaluation for Sexually Transmitted Infections
Examinations of children for sexual assault or abuse should be conducted so as to
minimize trauma to the child. The decision to evaluate the child for STDs must be
made on an individual basis. Situations involving a high risk for STDs and a strong
indication for testing include the following:
• A suspected offender is known to have an STD or to be at high risk for STDs (e.g.,
multiple partners or past history of STD),
• The child has symptoms or signs of an STD,
• There is a high STD prevalence in the community.
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Obtaining the indicated specimens requires skill to avoid psychological and physi-
cal trauma to the child. The clinical manifestations of some sexually transmitted
infections are different among children when compared with adults. Examinations
and specimen collection should be conducted by practitioners who have experience
and training in the evaluation of abused or assaulted children.
A principal purpose of the examination is to obtain evidence of an infection that is
likely to have been sexually transmitted. However, because of the legal and psychoso-
cial consequences of a false-positive diagnosis, only tests with high specificities
should be used. Additional cost and time are justified to obtain such tests.
The scheduling of examinations should depend on the history of assault or abuse.
If initial exposure is recent, infectious agents acquired through the exposure may not
have produced sufficient concentrations of organisms to result in positive tests. A
follow-up visit approximately 2 weeks after the last sexual exposure should include a
repeat physical examination and collection of additional specimens. To allow suffi-
cient time for antibody to develop, another follow-up visit approximately 12 weeks
after the last sexual exposure also is necessary to collect sera. A single examination
may be sufficient if the child was abused for an extended period of time, or if the last
suspected episode of abuse took place some time before the child received the medi-
cal evaluation.
The following recommendation for scheduling examinations is a general guide.
The exact timing and nature of follow-up contacts should be determined on an individ-
ual basis and should be considerate of the patient’s psychological and social needs.
Compliance with follow-up appointments may be improved when law enforcement
personnel or child protective services are involved.
Initial and 2-Week Examinations
During the initial examination and 2-week follow-up examination (if indicated), the
following should be performed:
• Cultures for N. gonorrhoeae  specimens collected from the pharynx and anus in
both sexes, the vagina in girls, and the urethra in boys. Cervical specimens are
not recommended for prepubertal girls. For boys, a meatal specimen of urethral
discharge is an adequate substitute for an intraurethral swab specimen when
discharge is present. Only standard culture systems for the isolation of N. gonor-
rhoeae  should be used. All presumptive isolates of N. gonorrhoeae  should be
confirmed by at least two tests that involve different principles (e.g., biochemical,
enzyme substrate, or serologic methods). Isolates should be preserved in case
additional or repeated testing is needed.
• Cultures for C. trachomatis  from specimens collected from the anus in both
sexes and from the vagina in girls. Limited information suggests that the likeli-
hood of recovering chlamydia from the urethra of prepubertal boys is too low to
justify the trauma involved in obtaining an intraurethral specimen. A urethral
specimen should be obtained if urethral discharge is present. Pharyngeal
specimens for C. trachomatis  also are not recommended for either sex because
the yield is low, perinatally acquired infection may persist beyond infancy, and
culture systems in some laboratories do not distinguish between C. trachomatis
and C. pneumoniae.
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Only standard culture systems for the isolation of C. trachomatis  should be
used. The isolation of C. trachomatis  should be confirmed by microscopic iden-
tification of inclusions by staining with fluorescein-conjugated monoclonal
antibody specific for C. trachomatis. Isolates should be preserved. Nonculture
tests for chlamydia are not sufficiently specific for use in circumstances involv-
ing possible child abuse or assault. 
• Culture and wet mount of a vaginal swab specimen for T. vaginalis  infection. The
presence of clue cells in the wet mount suggests BV among children with vaginal
discharge. The significance of clue cells or other indicators of BV as an indicator
of sexual exposure is unclear. The clinical significance of clue cells or other indi-
cators of BV in the absence of vaginal discharge also is not clear.
• Collection of a serum sample to be preserved for subsequent analysis if follow-
up serologic tests are positive. If the last sexual exposure occurred >8 weeks
before the initial examination, sera should be tested immediately for antibody to
sexually transmitted agents. Agents for which suitable tests are available include
T. pallidum, HIV, and HBV. The choice of agents for serologic tests should be
made on a case-by-case basis (see Examination 12 Weeks After Assault).
Examination 12 Weeks After Assault
An examination approximately 12 weeks after the last suspected sexual exposure
is recommended to allow time for antibodies to infectious agents to develop. Sero-
logic tests for the agents listed below should be considered: 
• T. pallidum,
• HIV,
• HBV.
The prevalence of these infections varies greatly among communities, and de-
pends upon whether risk factors are known to be present in the abuser or assailant.
Also, results of HBV tests must be interpreted carefully, because HBV may be transmit-
ted by nonsexual modes as well as sexually. The choice of tests must be made on a
case-by-case basis.
Presumptive Treatment
There are few data upon which to establish the risk of a child’s acquiring a sexually
transmitted infection as a result of sexual abuse. The risk is believed to be low in most
circumstances, although documentation to support this position is inadequate.
Presumptive treatment for children who have been sexually assaulted or abused is
not widely recommended because girls appear to be at lower risk for ascending infec-
tion than adolescent or adult women, and regular follow-up can usually be assured.
However, some children or their parents or guardians may be very concerned about
the possibility of contracting an STD, even if the risk is perceived by the health-care
practitioner to be low. Addressing patient concerns may be an appropriate indication
for presumptive treatment in some settings.
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Reporting
Every state, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, and
American Samoa have laws that require the reporting of child abuse. The exact re-
quirements vary from state to state but, generally, if there is reasonable cause to
suspect child abuse, it must be reported. Health-care providers should contact their
state or local child protective service agency about child abuse reporting requirements
in their areas.
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